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ANS Autonomic nervous system
ApEn Approximate entropy
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G
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H
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LABA Long acting beta agonists
LAMA Long acting muscarinic antagonist
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LFnu Low frequency power normalized units
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P
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PP Drop Pulse pressure drop
PRISMA Preferred reporting items for systematic reviews and meta analyses
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PSD Power spectral density
Q
QoL Quality of life
R
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RMSSD Root mean square successive differences
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RV Residual volume
S
SAD Small airway disease
SampEn Sample entropy
SBP Systolic blood pressure
SD1 Dispersion of points (standard deviation) perpendicular to the axis of line-of-identity
SD2 Dispersion of points (standard deviation) along the axis of line-of-identity
SDANN Standard deviation of the averages of N-N
SDNN Standard deviation of NN intervals
SDNNi Standard deviation of NN intervals for 5 minutes segments
SF-36 36-Item short form questionnaire
SI3 Sympathetic index
sNN50 Sum of N-N, differing more than 50 milliseconds
SSR Sympathetic skin response
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T 
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TNF Tumor necrosis factor
U
ULF Ultra low frequency 
V
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W
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Outline and scope of the dissertation
This dissertation comprises 7 chapters divided in 3 parts, and a general discussion. 
Part I is the general introduction, which consists of 3 chapters. The first chapter 
offers a general overview (definition, burden, features, pathogenesis, assessment, 
classification and management options) of COPD (Chapter 1). This chapter is written 
to show COPD as a complicated, under-diagnosed and under-recognized disorder 
that affects a significant proportion of the global population. The second chapter 
is dedicated to the autonomic nervous system (ANS). The introducing aspects 
presented a physiological overview of the ANS: divisions, structure and function. 
Thereafter, a detailed account of various means of assessing the integrity and/or 
anomalies in the ANS was presented (Chapter 2). These assessment techniques 
included both subjective (symptoms assessment) and objective measures (autonomic 
function test parameters) that are capable of evaluating autonomic dysfunction 
or dysautonomia. The third and concluding chapter of the general introduction 
describes the link between autonomic function and the disease of COPD by means 
of a systematic review (Chapter 3). The major aim of this chapter is to establish the 
evidence to support the impairment of the autonomic function, and it’s major 
influencing factors, in patients with COPD in the existing literature. 
 PART II presents the original research studies in this dissertation. These studies 
were aimed at assesses dysautonomia in COPD using different means with the 
objective of answering two research questions: 
(i) what is the profile of autonomic symptoms that are present in patients 
with stable COPD, and what are the contributing factors? 
(ii) are autonomic function and autonomic reactivity test parameters 
impaired among physically active patients with COPD? 
To answer these questions, two separate studies were conducted. The first study 
reports on autonomic symptoms in COPD. In this study, the 31-item composite 
autonomic symptoms score (COMPASS-31) questionnaire along with other important 
patient outcomes were examined to provide an overview of autonomic symptoms 
in COPD (Chapter 4). The second original research is a laboratory study that reports 
on the autonomic function and autonomic reactivity tests in a subgroup of COPD 
patients in rehabilitation (Chapter 5). 
 In the third and final part of this dissertation (Part III), we sought to answer 
the question, “is there evidence to support the effect of non-pharmacological 
interventions on the autonomic function in COPD?”. To achieve this, we systematically 
reviewed the available studies in literature that have reported on diverse non- 
pharmacological interventions for autonomic function modulation in COPD. 
Here, two systematic reviews were conducted. The first systematic review focused 
on the effect of respiratory rehabilitation techniques such as oxygen therapy, 
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noninvasive ventilation (NIV) and controlled breathing on the autonomic function 
in COPD (Chapter 6).  The second systematic review investigated the efficacy of 
aerobic exercise training in modulating autonomic function indices in COPD 
(Chapter 7).  
 In the concluding segments of this dissertation, a general discussion comprising 
the main findings, validation of the Dutch COMPASS-31 in COPD, clinical implications, 
strengths and limitations, directions for future research, is provided. Thereafter, 
a general conclusion based on the results of the entire research ensued.

“The complexities of life situations are really not as complicated 
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1.  Definition and description
Chronic obstructive pulmonary disease (COPD) refers to a diverse clinical disorder 
of the pulmonary system that ranges from chronic bronchitis to lung emphysema 
(1, 2). The disease is mainly characterized by an airflow limitation that is usually 
progressive, and associated with abnormal chronic airway inflammatory responses 
of the lungs to noxious particles or gases (3-5). COPD is complex, heterogeneous, and 
it is a significant contributor to the morbidity and mortality rates in the world (6, 7). 
 A recent definition of COPD describes it as a preventable and treatable disease 
that is characterized by persistent respiratory symptoms such as dyspnea, chronic 
cough and excessive sputum production, as well as an airflow limitation that is 
due to airway and/or alveolar abnormalities usually caused by significant exposure 
to noxious particles or gases (8). COPD also has a multi-component aspect that is 
characterized by structural and functional changes, both within and outside the 
lungs. These components operate in a complex and interdependent manner that 
has been described as a ‘vicious cycle’, typically involving factors such as mucus 
hypersecretion and accumulation in the airways, bacterial colonization, ciliary 
damage, neutrophil activation, release of inflammatory mediators, tissue damage 
and systemic effects [Figure 1] (9).    
2.  Burden 
COPD continually induce a substantial economic and social burden worldwide. 
The prevalence, morbidity and mortality of COPD is also known to vary across 
countries and even across different groups within countries (8). The data regarding 


























the prevalence of COPD has a wide variation due to differences in survey methods. 
Nevertheless, the lowest estimates from these surveys (spirometry alone) puts the 
prevalence rate of COPD among adults at about <6%. However, higher prevalence 
(up to 11.6 %) are often reported among older adults that are 55 years and above 
(10). With over 3 million deaths per year, COPD is currently the third leading cause 
of death worldwide, and it remains a significant global health problem (11-13).
 COPD is projected to cause over 4.5 million deaths per year by the year 2030, 
partly due to the increasing prevalence of cigarette smoking, and also the high 
proportion of an ageing population across the world (8, 14). Currently, COPD accounts 
for about 10% of all hospitalizations, thereby causing a significant socioeconomic 
burden to individuals and health systems (15). The progression of COPD is further 
complicated by individual variation from patient-to-patient, which makes identification 
and treatment challenging (16, 17). Consequently, there are no accurate data for 
some aspects of COPD such as incidence and mortality, as current estimates are 
mainly based upon  administrative health data or hospital records (18).  
 According to the 2017 report of the global strategy for the diagnosis, management, 
and prevention of COPD, the total direct costs associated with COPD in the 
European Union (EU) is estimated to be around 38.6 billion Euros. This represents 
about 6% of the total health care budget of the EU (8). More importantly, these costs 
were mainly incurred from hospitalizations following COPD exacerbations, and 
the use of devices such as ambulatory oxygen (8). In addition, the management of 
coexisting COPD comorbidities such as hypertension and diabetes mellitus equally 
accounts for a significant proportion of these costs.
3.  Common features and risk factors 
Most COPD patients are elderly (19) and those with severe COPD have low quality 
of life (QoL), and a limited life expectancy compared to their healthy counterparts 
(20). Consequently, it is not unusual to find COPD patients presenting with high 
rates of depression (21-23), anxiety (21-23), fatigue (24, 25), dyspnea (26) and a 
largely poor health status. COPD patients have poor muscle function especially in 
the lower limbs, which is also implicated in the exercise intolerance and poor 
exercise capacity in these patients (27). In the majority of COPD patients, there is a 
decrease in muscle strength of about 20-30% and a concomitant decrease in muscle 
mass in some patients, due to disuse-related muscle atrophy (27). 
 The major risk factors for COPD are cigarette  (tobacco) smoking, outdoor and 
indoor pollution and physical inactivity (28). Cigarette (tobacco) smoking is 
primarily an important etiological factor in COPD because it constitutes over 90% 
of COPD etiology (8, 29). Tobacco smoking is associated with the decline of the 
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pulmonary function, and it is implicated in the majority of the inflammatory 
changes that occur in the airways of patients with COPD (30). Smoking is also 
associated with an increase in sympathetic activity through its action in (i) 
reducing the baseline levels of the vagal-cardiac nerve activity, and (ii) altering the 
vagally mediated arterial baroreceptor-cardiac reflex responses (31). Adequate 
understanding of the functioning of the ANS in COPD may help to further predict 
and identify important aspects to COPD prognostication and management. 
Presently, a host of diverse factors such as disease severity (32), exacerbations (33), 
lung function and respiratory parameters (34-38), physical activity levels (39) and 
presence or absence of disease comorbidities have been documented to influence 
important patient outcomes in COPD. 
4. Pathophysiology 
COPD is a consequence of a complex interplay of several factors including genetic 
features (α1- antitrypsin deficiency), environmental predisposition and impaired 
lung development. Several genetic predisposing factors have been identified to 
play an important role in the pathogenesis of COPD (40). The best investigated 
among these are the genetic variants in the alpha‐1 antitrypsin (AAT) gene serpin 
peptidase inhibitor, clade A, member 1 (SERPINA1), which is responsible for about 
1-2% of COPD prevalence (40, 41). 
 Systemic inflammation and chronic airway hyper inflammation are the most 
important aspects to the pathogenesis of COPD. Inflammation persists throughout 
the course of COPD, is also associated with the level of airway obstruction and 
prognosis to therapy (42). COPD is referred to as a, “chronic systemic inflammatory 
syndrome” because of the numerous inflammatory biomarkers that have been 
found to be prevalent in persons with the disease (43). Some of the circulating 
inflammatory biomarkers that are often increased and frequently used for 
establishing a diagnosis of COPD include white blood cells, fibrinogen, C-reactive 
protein (CRP), interleukin 6 (IL-6) and tumor necrosis factor alpha (TNF-α) (44, 45). 
The amount of these inflammatory biomarkers is affected during exacerbations, 
exercise training and use of medication (46).
 Abnormal inflammatory responses in COPD are a consequence of the interplay 
between several mechanisms that occur during the pathogenesis of the disease. 
Fabbri et al., (2008) described how these inflammatory markers are associated with 
the severity of COPD and are a major contributor in the development of disease 
comorbidities such as cardiovascular diseases, diabetes mellitus, muscular 
dysfunction and osteoporosis (43, 47) [Figure 2]. 
22
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Figure 2   A schematic representation of the inflammatory processes in COPD and 
how it relates to other organs (43).
Table 1   Inflammatory markers in COPD and non-COPD individuals.  
Adapted from (29).
CD45 CD3 Neutr EOS Mast CD25 CD68 ELAM-1 CD8 TGF-b NK CD4 CCR5-CD3 NF-kB
(P65)





Notes: , significantly increased values in comparison with that indicated by ; , basal values or 
values non-significantly changed; , significantly decreased values in comparison with that indicated 
by . Similar numbers indicate results from the same study comparisons. ELAM-1, endothelial 
adhesion molecule-1; NK, natural killer; NF-κB, nuclear factor-kappa B; STAT-4, signal transducer and 
activators of transcription; MPO, myeloperoxidase; NT, nitro tyrosine.
Muscle weakness/wasting 
Cigarette smoke pollutants  
Cardiovascular events 
osteoporosis Local and systemic inflammation  
C - Reactive Protein 
Metabolic syndrome 
Type 2 diabetes  
TNF-α – IL6 
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4.1  Cellular and molecular aspects
A number of cells (both inflammatory and structural) play a significant role as 
inflammatory agents or mediators in COPD pathogenesis (48). They include 
macrophages, epithelial cells, dendritic cells, neutrophils, eosinophils and T and B 
lymphocytes. Precisely, these cells along with other genetic and epigenetic factors 
contribute to the amplification of inflammation in COPD. 
 Furthermore, they are also implicated in the marked proliferation in oxidant 
and antioxidant imbalance in patients with COPD, consequently leading to 
oxidative stress (49, 50). Oxidative stress in turn causes DNA damage and generation 
of antibodies, which often results in an increased ageing process, formation of 
cancerous cells, steroid resistance, emphysema and fibrosis in addition to the 
amplified inflammation in COPD (48). 
 In a review, Di Stefano et al. in 2005 provided a profile of inflammatory cells in 
the submucosa of three different COPD stages (mild, moderate & severe) and two 
control groups (smokers and non-smokers) [Table 1]. They found COPD to be 
associated with an increase in several inflammatory cells in the blood.
4.2  Pathogenesis 
The pathogenesis of COPD usually starts from exposure to noxious substances such 
as tobacco smoke. The inhalation of these noxious particles causes inflammation, 
which results in the release of chemical mediators like TNF-alpha, interleukin 8, and 
leukotriene B4. The continuous release of these mediators (abnormal inflammatory 
response) leads to a damage of the airways, pulmonary vasculature and lung 
Table 1   Inflammatory markers in COPD and non-COPD individuals.  
Adapted from (29).
CD45 CD3 Neutr EOS Mast CD25 CD68 ELAM-1 CD8 TGF-b NK CD4 CCR5-CD3 NF-kB
(P65)





Notes: , significantly increased values in comparison with that indicated by ; , basal values or 
values non-significantly changed; , significantly decreased values in comparison with that indicated 
by . Similar numbers indicate results from the same study comparisons. ELAM-1, endothelial 
adhesion molecule-1; NK, natural killer; NF-κB, nuclear factor-kappa B; STAT-4, signal transducer and 
activators of transcription; MPO, myeloperoxidase; NT, nitro tyrosine.
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parenchyma (emphysema). The progression of COPD is also accelerated by the 
presence of underlying genetic or age-related decline in lung function (17). 
 The pathology of COPD can be broadly classified into two parts; (i) a structural 
damage to the small airways, also known as small airway disease, and (ii) a damage 
to the lung parenchyma including the alveolar (especially the ducts). Irrespective 
of whether the disease is characterized by either small airway disease or damage 
to the lung parenchyma, chronic inflammation remains a key factor in the progression 
of COPD. Additionally, other conditions such as the development of oxidative stress 
as mentioned earlier, and proteases/anti-proteases imbalance are also known to 
play a role in confounding COPD through an exaggeration of the inflammatory 
response to elements such as cigarette smoke, environmental pollutants, or bacterial 
infections (50, 51). Lastly, bacterial infections in the respiratory mucosa is another 
factor contributing to the pathogenesis of COPD. Specifically, bacterial colonization 
of the lower airway is associated with the rate of COPD inflammation and 
exacerbations (52). 
5.  Diagnosis and assessment 
COPD is associated with several systemic manifestations such as muscle dys- 
function, systemic inflammation and metabolic dysfunction. Consequently, making 
a single disease diagnosis somewhat rare.  According to the 2017 global strategy 
for the diagnosis, management and prevention of COPD, assessment is carried out 
to determine the level of airflow limitation, health status, risk of undesirable events 
such as exacerbation, hospitalization and to support treatment prognosis. To achieve 
this goal, a set of assessment techniques including spirometry, anamnesis, and 
several forms of examination techniques are used. Nevertheless, COPD is primarily 
diagnosed by spirometry (1). However, with more understanding of the disease as 
a multifactorial entity, current assessment and classification techniques are based 
on several assessment variables that take into account symptoms, arterial oxygen 
and carbon dioxide tension, the degree of spirometric abnormality, the exacerbation 
risk, and the presence of comorbidities.  
5.1  Pulmonary function tests (spirometry)
Pulmonary function tests or spirometry is one of the most useful techniques for 
diagnosing and monitoring the progression of COPD. Spirometry comprises several 
parameters that provide different information regarding the lung function status 
of individuals with respiratory diseases. The forced expiratory volume in the first 
second (FEV1), forced vital capacity (FVC) and the Tiffeneau index (FEV1/FVC) are 
three important parameters of spirometry that are utilized for assessing and 
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diagnosing COPD in the clinic. The FEV1  in particular is highly reproducible and 
it forms a major part of the COPD classification system (Table 2) (53). The FEV1 has 
been used and is capable of predicting an age-related decline in the lung function 
that may even predict future COPD disease, as presented in Figure 3. 
Other parameters of pulmonary function tests (lung function and volumes), that 
are useful in COPD assessment and monitoring, include peak expiratory flow rate (PEF), 
forced inspiratory flow (FIF), force expiratory flow (FEF), vital capacity (VC), residual 
volume (RV), functional residual capacity (FRC) and total lung capacity (TLC) [Figure 4].
 Clinically, a diagnosis of COPD is made after the administration of at least one 
short acting inhaled bronchodilator, which does not lead to a reversal of airway 
obstruction. Specific spirometric cut-off points are utilized in staging the disease 
as shown in Table 2. In the past, COPD was graded using a single measurement 
such as FEV1, but improvements in the identification of the disease has led to 
better staging systems that are able to monitor disease progression and predict 
morbidity and mortality. This is achieved through the incorporation of variables 
such as age, arterial blood gases, dyspnea, body mass index (BMI), and distance 
walked during a six minute walk test in addition to assessing the FEV1 (55). 
Figure 3   Progression of the FEV1 in four different trajectories and how two leads 
to COPD, while the other two did not lead to COPD (17).
26
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5.2  Symptoms assessment in COPD
The most common COPD symptoms include chronic cough, sputum production 
and dyspnea. While symptoms such as chronic cough and excessive sputum 
production are usually asked during the initial (or subsequent) hospital visit, the 
other symptoms such as dyspnea can be measured using questionnaires. The 
Modified British Medical Research Council (mMRC) dyspnea scale is a questionnaire 
that has been proven to be useful in assessing the dyspnea symptoms in  patients 
with COPD (56). This 5-item scale accurately measures the perceived respiratory 
distress, which is also a frequently occurring feature of patients with COPD. 
Figure 4   Flow volumes of different disease scenarios. Adapted from (54).
– – –: predicted flow–volume curves; ––––: observed inspiratory and expiratory flow–volume curves.
(a) Obstructive defects with a low FEV1, 38%; FEV1/VC, 46%; PEF, 48%; TLC, 101% or normal 
(b) Obstructive defects with a FEV1, 57%; FEV1/VC, 73%; PEF, 43%; TLC, 96%  ratio of FEV1/VC. In both 
(a) and (b), TLC is normal, and flows are less than expected over the entire volume range. 
(c) Example of a typical restrictive defect (FEV1 66%; FEV1/VC 80%; PEF 79%; TLC 62%). The TLC is low and 
flow is higher than expected at a given lung volume. 
(d) Example of a typical mixed defect characterized by a low TLC and a low FEV1/VC ratio (FEV1 64%; 
FEV1/VC 64%; PEF 82%; TLC 72%).
(a) (b) (c) (d)
Table 2  Spirometric GOLD grading system
Severity Post-bronchodilator FEV1/FVC FEV1 %  Predicted
Mild COPD ≤0.7 ≥80
Moderate COPD ≤0.7 50-80
Severe COPD ≤0.7 30-50
Very severe COPD ≤0.7 <30
27
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5.3  Health status of patients with COPD
Psychological issues, particularly anxiety and depression, are among the important 
variables affecting the quality of life (QoL) in patients with COPD (57). The hospital 
anxiety and depression scale (HADS) has been often used for this purpose. The COPD 
assessment test (CAT) questionnaire is another instrument that can be utilized to 
assess the QoL of patients with COPD (58, 59). These questionnaires along with 
other instruments are an important part of assessing the health status of patients 
with COPD. In general the health status of patients with COPD is affected by 
several parameters including disease symptoms, depression, fatigue, especially 
during exacerbation (60). While, the clinical control of COPD symptoms is 
measureable with the clinical COPD questionnaire (CCQ) (59), the rates of 
exacerbation in COPD, which provides valuable insight to the progression and 
prognosis of COPD may requires hospitalization especially in severe cases. Burge 
and Wedzicha recently defined exacerbation as a sustained worsening of the 
patient’s condition, from the stable state and beyond normal day-to-day variations 
that is acute in onset and may warrant additional treatment in a patient with 
underlying COPD (61).  Patients with COPD often present with a high rate of 
fatigue, which is associated with the severity of the disease (62). Fatigue in COPD 
has been measured in the past using subjective instruments like the CRQ (fatigue 
subscale), multidimensional fatigue inventory (MFI), the identity-consequences fatigue 
scale (ICFS), functional assessment of chronic Illness therapy-fatigue scale (FACIT-
Fatigue) and the checklist individual strength (CIS) scale (63-66).    
5.4  The BODE index
The BODE (Body mass index, airflow Obstruction, Dyspnea, and Exercise capacity) 
index is a multidimensional grading system that was developed to enhance the 
prognosis of several outcomes in patients with COPD such as hospitalization, 
morbidity and mortality (67). The BODE index is currently summarized as a 
10-point scale, in which higher scores indicate an increased severity of the disease 
and higher risk of mortality of the individual patient (12) [Table 3]. Moreover, the 
use of the BODE index has helped decision makers to allocate scarce health 
resources such as diagnostic or therapeutic interventions in a more systematic and 
efficacious way to patients in need. 
5.5  The ABCD classification system of patients with COPD
The ABCD system of COPD classification was initially developed in 2011 as a form 
of revision of the global obstructive lung disease (GOLD) strategy document with 
the aim of increasing the understanding of the impact of COPD on an individual 
patient level (68). This system of grading combines the symptoms burden, 
exacerbation in the last year along with the spirometric scores [Figure 5].
28
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5.6  Phenotypic heterogeneity 
Generally, the goal of phenotyping is to recognize various sub-groups with 
distinctive prognostic or therapeutic features. In COPD, a number of studies have 
attempted to provide different forms of classification with the aim of optimizing 
therapy in patient care (clinical use) as well as for research purposes (improving 
the quality of clinical trials). For example, about 20% to 35% of COPD patients have 
been reported to have nutritional depletion that predisposes them to metabolic 
problems manifesting as disease phenotypes (69). 
Metabolic phenotypes range from cachexia, which refers to unintentional weight 
loss of >5% in 6 months and fat free mass index (FFMI) ≤16 kg/m2 (males) and ≤15 
kg/m2 (females) (70, 71), to sarcopenia (skeletal muscle index <2; BMI >21 kg/m2 and 
FFMI ≤16 kg/m2 (men) or ≤15 kg/m2 (women) (71), to obesity (BMI of 30-35 kg/m2) 
Table 3  BODE index
BODE score 0 1 2 3
FEV1 ≥65% 50–64% 36–49% ≤35%
6 min walk test >350meters 250–349 meters 150–249 meters <149 meters
Dyspnea scale 0–1 2 3 4
BMI >21kg/m2 <21 kg/m2   




(exacerbation = not leading to hospital admission; 




(exacerbation = not leading to hospital admission; 




(exacerbation =  2 or  1 leading to hospital admission; 




(exacerbation =  2 or  1 leading to hospital admission; 
symptoms = CAT≥ 10; breathlessness= mMRC ≥ 2)
Figure 5  The ABCD system of COPD classification. Adapted from (8).
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[Figure 6]. Other classifications include additional subdivisions of morbid obesity, 
sarcopenia obesity and pre-cachexia (72). These phenotypes are often associated with 
increased cardiovascular and mortality risk and/or impaired physical performance. 
There is also a loss of skeletal muscle mass combined with muscle fiber atrophy that is 
characterized by a shift of type I to type II fibers, thereby leading to a decrease in the 
skeletal muscle mass and function (72). Other characteristics include osteoporosis 
and low-fat mass. Cachexia is usually associated with emphysema and hyper- 
inflation, and muscle wasting (72). Cachexia in COPD has been attributed to factors 
such as energy imbalance,  disuse atrophy, tissue hypoxia from arterial hypoxemia, 
systemic inflammation and anabolic hormonal insufficiency (73). 
The obesity phenotype is usually associated with chronic bronchitis, increased 
subcutaneous and visceral adipose tissue, decreased thoracic compliance, increased 
airway resistance, increased work of breathing, worsened dyspnea and wheezing 
and arterial stiffness (72, 74). Patients with COPD who are obese or overweight 
have decreased QoL, increased physical limitations, increased dyspnea, reduced 
functional capacity, poor prognosis and reduced health status(75). The sarcopenia is 
mainly characterized by loss of skeletal muscle mass and muscle fiber atrophy, 
which then leads to reduced exercise performance, decreased muscle strength and 
poor health status (75-77). Here, there is preservation of fat mass, but it is 
redistributed in favor of increased visceral adipose tissue.
Figure 6   Abnormal metabolic phenotypes in COPD: (a) Cachexia, (b) Obesity, and 




6.  Management of stable patients
6.1  Smoking cessation 
Cigarette smokers have a higher prevalence of symptoms and problems with lung 
function (FEV1 decline), and a greater COPD mortality than nonsmokers (78). 
Unfortunately, a significant proportion of COPD patients have been reported to 
have not only smoked for a long time, but still smoke during the course of the 
disease (79). Smoking cessation has been reported to be the single most effective 
and sensible way to reduce exposure to COPD risk factors (8). Ideally, all COPD 
smokers should be offered the most intensive smoking cessation intervention 
feasible, and a smoking cessation plan should be first line of approach for managing 
these patients (8). 
 Presently, smoking cessation programmes have been reported to be an 
effective intervention for stopping the progression of COPD and reducing morbidity 
(78). The major component of a smoking cessation plan is counselling (no matter 
how brief), in addition, a number of agents or interventions like varenicline and 
bupropion SR or nicotine replacement therapy (NRT) can be added to help 
counselling (80). Long term NRT-use has been reported to be efficacious for 
cessation among the general population of COPD smokers, regardless of daily 
cigarette consumption (81). Several other options have been proposed in addition 
to those earlier mentioned with successful results: counter nicotine gum, 
transdermal patches, lozenges, and electronic cigarettes. The use of electronic 
cigarettes in particular, has been reported to ameliorate subjective and objective 
disease-related outcomes and exacerbation rates as well as improving success in 
abstaining from smoking in the long term (82). However, the evidence to support 
these claims are scanty. Moreover, the European Respiratory Society (ERS) recently 
(14th Feb. 2018) reacted strongly to an article citing beneficial uses of electronic 
cigarettes, “Human lungs are made to breath clean air and any substance inhaled 
long term may be detrimental”.
6.2  Pharmacological options
Generally, the most commonly used pharmacological options for COPD symptoms/
events are bronchodilators, glucocorticoids and antibiotics. However, because of 
the complexity in the pathogenesis of COPD, current therapies are not only 
challenging, but remain inadequate and have numerous adverse effects (13, 83). 
Consequently, a host of other medications are consumed on a case by case basis as 
the need arises.
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6.2.1  Bronchodilators
Inhaled bronchodilators are prescribed to treat symptomatic COPD. Bronchodila-
tors (84) are either short-acting or long-acting. Long acting bronchodilators such as 
long acting beta agonists (LABA) and Long acting muscarinic antagonists (LAMAs) 
have been referred to as the cornerstone of pharmacotherapy for patients with 
COPD who are stable (85).  More recently, novel approaches that are aimed at 
improving adherence, compliance and the overall clinical outcomes in COPD have 
been reported (86). Adherence to bronchodilators such as SAMAs (ipratropium) 
and SABAs (salbutamol) and theophylline (using different administration forms) 
have been associated with a reduced risk of death and admission to hospital due to 
exacerbations in COPD (87). The focus of new therapies involving the administration 
of bronchodilator medications, is to increase adherence and treatment efficacy 
either through reduction of dose frequency and/or a combination of several classes 
of bronchodilators. Specifically, the use of long acting bronchodilators is associated 
with improvement of QoL, exercise tolerance, and exacerbation in COPD patients 
(88).
6.2.2  Glucocorticoids 
The use of glucocorticoids offers an effective therapy means for treating 
inflammation in patients with COPD. Glucocorticoids are administered either 
orally (89) or by inhalation (8). The administration of glucocorticoids by inhalation 
(inhaled corticosteroids [ICS]), especially when used in combination with other 
inhalation therapies have been reported to be highly efficacious (90). Glucocorti-
coids are indicated in COPD patients with an FEV1 of <50% or a history of severe 
and frequent exacerbations (91, 92). On the one hand, the use of ICS in COPD is 
associated with optimal improvement of QoL and, in some patients, reduce 
exacerbation rate. In addition, ICS has been associated with slowing down the rate 
of lung function decline in COPD when used over a long duration of ≥2 years (93). 
On the contrary, there are also reports of poor/absent responses, resistance, 
insensitivity and even adverse reactions with ICS use in some patients, and 
withdrawal of ICS use is also associated with lung function (significant dose- and 
time-dependent FEV1) decline (92, 94) and poor health status (92). 
6.2.3  Antibiotics 
About 50% (or less) of COPD exacerbations are caused by bacterial infections (52). 
This phenomenon warrants the use of antibiotics in order to improve the patient’s 
condition and reduce symptoms. Antibiotics are also prescribed in patients who 
cough, have dyspnea and produce purulent sputum (95). In addition, a variety of 
antibiotic medication such as macrolides (azithromycin) (8) may be administered 
for COPD patients, even though the use of these antibiotic therapy in acute 
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exacerbations of COPD still remains controversial (resistant organisms) (96). For 
example, azithromycin administered over 1 year in COPD patients who are at an 
increased risk of acute exacerbations, but have no hearing impairment, resting 
tachycardia, or apparent risk of QTc prolongation, have been found to have a 
decreased  frequency of acute exacerbations and an improved QoL (97). 
6.2.4  Other medication options
A number of medications are prescribed for COPD patients on a case by case bases 
depending on the diagnosis and presentation: (i) alpha-1 antitrypsin augmentation 
therapy can be given in patients with severe hereditary alpha-1 antitrypsin with 
an associated decline in FEV1, (ii) anti-oxidant mucolytics are also given to selected 
patients especially those who respond less well to inhaled steroids (low reversibility 
and heavy smoking) (98), (iii) theophylline may be given in the absence of LABA due 
to its anti-inflammatory effects (side effects) (99), and (iv) low dose long acting 
opioids can be used for severe COPD patients with dyspnea. The medication 
compositions for COPD can also be based on the ABCD classification system and 
staging as described earlier. Generally, polypharmacy is common due to the 
complex nature of the disease. Unfortunately, combining different groups of 
medications comes with significant risks (8). Figure 7 highlights the medication 
pattern using this classification system.
 Generally, COPD is associated with a wide variety of systemic consequences, 
most notably is systemic inflammation. Therefore, there is need for a better 
understanding of its origin, consequences and most importantly, the potential 
therapy to enhance care (43). Another method of pharmacological intervention for 
COPD according to clinical phenotypes based on the ABCD classification system is 
available and popular [Figure 8]. Here, it can be seen that bronchodilators are the 
basis of treatment of COPD irrespective of the clinical phenotype, while glucocor-
ticoids such as inhaled corticosteroids (ICS) are only indicated when there are 
frequent exacerbations or in case of COPD-asthma overlap. Miravitlles et al. 
reported that in the event of a severe case of chronic bronchitis and frequent 
exacerbation in spite of optimal therapy, a treatment with long-term antibiotics 
under close follow-up should be utilized (5).
 Another important medication that has been used for a long time with 
beneficial outcomes in patients with COPD is phosphodiesterase-4 (PDE4) inhibitors 
(100). PDE4 is associated with a modest improvements of the lung function, while 
maintaining exacerbation rate and health status, as well as considerably reducing 
the sputum neutrophil and eosinophil concentration (100, 101). 
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6.3  Non-pharmacological options
Pulmonary rehabilitation (PR) is one of the main non-pharmacological options in 
the management of COPD. PR has become an important component in the 
management of COPD because it has demonstrated physiological, symptom-reduc-
ing, psychosocial, and health economic benefits for patients with chronic 
respiratory diseases. One of the most comprehensive description of PR is provided 
in the joint official statement of the American Thoracic Society/ European 
Respiratory Society (ATS/ERS) in 2013. Here, PR is defined as a, “comprehensive 
intervention based on a thorough patient assessment followed by patient-tailored 
therapies that include, but are not limited to, exercise training, education, and 
behavior change, designed to improve the physical and psychological condition of 
people with chronic respiratory disease and to promote the long-term adherence 
to health-enhancing behaviors” (102)  [Figure 9]. 
Figure 7   Pharmacologic treatment algorithms by Global Initiative for Chronic 
Obstructive Lung Disease (GOLD)/ABCD grading system (8).
Green boxes and arrows indicate preferred treatment pathways. ICS = inhaled corticosteroid; LABA = long-acting 
β-agonist; LAMA = long-acting muscarinic antagonist.
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Figure 8   An example of pharmacological intervention in accordance to clinical 
phenotypes PDE4: phosphodiesterase-4 (5).
Figure 9   Components and goals of pulmonary rehabilitation. Adapted from (103).
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The first ATS/ERS joint official statement on the use of PR for chronic respiratory 
diseases was in the year 2006 (104). Ever since, there has been a significant growth 
in our knowledge of its effectiveness and scope of PR. Moreover, this can be seen in 
recent  Cochrane reviews and high quality randomized controlled trials (RCT) studies 
that have provided evidence for large and clinically significant improvements in 
dyspnea, fatigue, emotional function and sense of control in COPD patients 
following PR (105, 106). Consequently, comprehensive PR is an important 
component in the clinical management of patients with COPD (103), providing 
both short and long term treatment benefits even among patients with severe 
stage disease (106-108).
6.3.1  Exercise training 
Exercise training can be defined as an activity lasting at least 20 minutes in which 
the heart rate is elevated above 60% of the maximal heart rate (MHR). Exercise 
training has been shown to reverse functional impairments (109), improve exercise 
capacity, muscle function and QoL. Exercise training interventions also have a 
positive effect on the ANS control of the heart, by increasing the parasympathetic 
nervous activity influence over the heart, and concurrently lowering the 
sympathetic nervous activity (110). The use of supervised and structured exercise 
(endurance/aerobic) training is considered to be a cornerstone of effective PR.
 Exercise training is the main component of PR that leads to the significant 
improvements for several parameters such as in maximal exercise capacity, 
walking distance and endurance capacity (111). The general recommendation for 
exercise training in COPD is that it should take the form of constant load or 
interval training combined with strength training (8). It is important to note that 
COPD patients vary from one another, whilst some respond well to exercise 
training, others do not (112). Therefore, exercise training parameters should be 
chosen with care depending on treatment goals. Exercise training parameters 
vary depending on whether a include sub-maximal (113) or maximal (37, 113) 
training intensity is desired. Exercise training can also be applied in a continuous 
or interval training modes. Interval training refers to repeated short periods of 
exercise alternated with rest or high vs low intensity, which is variable and 
depends on the duration of the work phase (114). Lastly, the use of exercise training, 
protocols such as one legged (partitioning) exercise training which uses less 
amount of active muscle mass and equally less demand on the cardiorespiratory 
system offers a different approach to COPD rehabilitation (115).   
6.3.2  Resistance training
In clinical practice, most COPD patients may not be able to perform high intensity 
aerobic or endurance exercises due to cardiopulmonary limitations or disease 
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symptoms such as dyspnea and leg fatigue (116).  Therefore, other means of 
exercises, such as resistance training, that can generate high muscle force becomes 
a treatment option. Resistance training uses a principle of loading whereby 
selected muscles are engaged in repetitive lifting of weights. Resistance training 
improves peripheral muscle force and endurance (109), functional capacity, and 
other outcomes (117). Resistance exercises can offer help in carrying out simple 
tasks such as pulling, pushing, and lifting (which require skeletal muscle mass 
and the strength of both upper and lower limbs).
 Additionally, an improved muscular function from resistance training allows 
patients to perform submaximal physical tasks at a lower percentage of maximal 
voluntary contraction, which in turn results in a lower cardiovascular load (118). 
Also, the poor muscle function in COPD patients is implicated in the lowered 
autonomic function indices (119). 
6.3.3  Inspiratory muscle training
Inspiratory muscle training (IMT) is an intervention that is designed to increase 
strength and/or endurance of inspiratory muscles(120). COPD patients are known 
to have a diminished maximal inspiratory pressure (MIP) as well as a diminished 
maximal expiratory pressure (MEP). Consequently, IMTs have been utilized to 
offer improvement in both strength and endurance of the respiratory muscles in 
COPD. The use of IMT also has a significant effect on important COPD parameters 
such as dyspnea at rest and during exercise, functional exercise capacity, adaptive 
changes in the structure of external intercostal muscles and the overall muscle 
function (121-123). Moreover, respiratory muscle dysfunction in COPD is associated 
with a number of negative consequences such as comorbid conditions, hypoxia, 
hypercapnia, nutritional status, medication, inflammation, and oxidative stress 
(116, 124, 125) .
6.3.4  Nutritional intervention
Nutritional supplementation is recommended for patients with COPD because of 
the negative impact of the disease on the overall nutritional status of some patients 
(obesity or cachexia) (72).  The main parameters of interest are body weight, fat 
mass and fat free mass. Patients who received nutritional supplementation have 
been reported to show significantly improve clinical, physiological and functional 
outcomes (8). However, there is only limited evidence to support this claim. 
6.3.5  Education and self-management 
According to the 2017 report of the global strategy for the management and 
prevention of COPD, self-management and education (i.e. coaching by healthcare 
professionals) are major components of chronic care in the non-pharmacological 
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approaches to improve COPD management (8). Patients with COPD often present 
with high rates of depression, anxiety and cognitive disorders (psychiatric 
morbidities) (21, 23). The use of a self-management programme is reported to 
improve the health status and reduce hospital admission in COPD (126). 
 Generally, the goal of self-management is to stimulate and engage COPD 
patients into adapting their lifestyles and health behavior in order to be able to 
manage and cope with the disease. Education and self-management takes into 
account individual patient’s needs, preferences and goals to form a self-manage-
ment education plan (126, 127). Some of the features of self-management include 
education on smoking cessation, nutrition, sleep, how to deal with breathlessness, 
energy conservation techniques, stress management, avoiding triggers/aggravating 
factors, social interaction, disease monitoring and advanced care strategies 
depending on the COPD stage (8, 128).
6.3.6  Oxygen therapy
Hypoxemia at rest is an important complication in patients with COPD, and it is 
often associated with premature death. Therefore, oxygen therapy (supplementation) is 
generally recommended for patients with low oxygen tension (PaO2) at or below 7.3kPa/ 
55mmHg or oxygen saturation (SaO2) at or below 88% with or without hypercapnia 
(39). The use of  oxygen therapy in combination with other non-pharmacological 
options such as noninvasive ventilation (NIV) is also common. Oxygen therapy is 
associated with improved admission free survival rates following life threatening 
COPD exacerbations (129). Long term oxygen therapy is usually given for at least 
16 hours/day in chronic hypoxemic patients. Hypoxemia should be re-evaluated after 
every 3 months (8). Oxygen therapy has been associated with improved patient 
outcomes including pulmonary hypertension (130) and autonomic function (131-134).
6.3.7  Mobile health (mHealth) or tele monitoring 
More recently, there has been a focus on new possibilities that mHealth offers in 
view of the latest advances in mobile communications and technologies (135). 
Generally, mHealth involves an integration of mobile computing, medical sensor, 
and communications technologies for mobile health-care applications that can be 
used as wearables or electrodes to provide feedback for monitoring (for example in 
a remote control center) (136).  Mobile health (mobile technology) can help to 
recognize early symptoms of disease deterioration, support patients in self-man-
agement, and it has the potential to increase adherence, reach a wider audience, 
and even increase quality of life, patient satisfaction outcomes and compliance to 
rehabilitation intervention (137, 138).  
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6.3.8  Mechanical ventilation 
The use of assisted mechanical ventilation, in the form of either NIV or invasive 
mechanical ventilation (IMV), to improve gas-exchange and reduce symptoms in 
COPD patients with unstable condition is common and effective (129, 139). 
Specifically, NIV is a supportive technique that is applied in the event of severe 
respiratory failure in COPD, that is either due to mechanical disturbances, central 
depression  or respiratory muscle fatigue in COPD (140, 141). The use of long term 
NIV as a complementary therapy (such as positive pressure ventilation), has been 
reported to improve the survival rates of hypercapnic stable COPD patients (142).  
NIMV is delivered using a nasal or full face mask for which different pressure 
parameters have been used (143, 144). NIV is effective for improving several patient 
outcomes (141). Even though IMV is usually utilized upon NIV failure, which is 
common in high risk COPD patients that are admitted in the intensive care unit 
(ICU), or those with respiratory failure associated with acute exacerbation of COPD 
(AECOPD), it has become an intervention of choice during exacerbations (15). 
 Although a small group of stable COPD may benefit from NIV, the current 
evidence only supports its use for COPD exacerbation and patients with unstable 
condition. Hence, it is not usually administered as a long term maintenance 
therapy. Nevertheless, some studies have even reported that NIV enhances 
autonomic function of patients with COPD (145, 146). 
Table 4  Definitions of COPD exacerbations. Adapted from (95).
Type Symptoms Additional minor symptoms 
1 An increase in sputum volume
An increase in sputum purulence
2 Any two from
     An increase in sputum volume
     An increase in sputum purulence
     An increase in sputum dyspnea
3 A single symptom from 
     An increase in sputum volume Sore throat or nasal discharge within last 5 days
     An increase in sputum purulence Fever without cause
     An increase in sputum dyspnea
Plus at least one minor symptom
Increased wheezing 
Increased respiratory rate (>20% above baseline)
Increased heart rate  (>20% above baseline)
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7.  Exacerbation
Exacerbations are a significant cause of morbidity and mortality in COPD (147). It 
refers to a sustained worsening of the patient’s condition, from the stable state and 
beyond normal day-to-day variations, that is acute in onset and may warrant 
additional treatment in a patient with underlying COPD (95). It is also defined as 
worsening of respiratory symptoms requiring treatment with oral or parenteral 
corticosteroids or antibiotic or both. It is reported to be more common in those 
patients with moderate-to-severe disease. Table 4 presents the 3 types of COPD 
exacerbation. 
 The etiology of COPD exacerbations include bacterial and viral infections, cold 
weather, pollution, and interruption of regular treatment  (95).  
8.  Comorbidities
A significant proportion of COPD patients often suffer from extra pulmonary 
abnormalities that include nutritional-body composition abnormalities, skeletal 
muscle dysfunction, osteoporosis, psychiatric morbidity, gastro-esophageal reflux 
disease, metabolic syndrome, obstructive sleep apnea, renal dysfunction, and hormonal 
dysregulation (8, 23, 46, 148). Cardiovascular diseases (CVDs) are the most frequently 
occurring comorbidities that are associated with high morbidity and hospitalization 
rates in COPD. Five separate disease entities within have been reported in COPD: 
heart failure, ischemic heart diseases, arrhythmias, peripheral vascular diseases 
and hypertension (8). The onset and progression of CVD in COPD involve the 
affectation of many organs and tissues. For example, in the arteries, there is 
unusual thickening, stiffening, remodeling and endothelial dysfunction, while in 
the veins thromboembolism may occur [Figure 10] (83). Other manifestations of 
COPD that can put an individual at risk of CVDs include increased arterial carbon 
dioxide tension (PaCO2), decreased oxygen tension (PaO2) and increased respiratory 
rates (149).
 The TOward a Revolution in the treatment of CHronic obstruction (TORCH) 
trial also attributed about 26% of COPD deaths to cardiovascular causes, 21% to 
cancer and only 35% to COPD (150). Consequently, cases of cardiovascular mortality, 
including sudden cardiac death is often reported among individuals with COPD 
(151). In the existing literature, a number of studies have reported an unusually 
heightened presence of CVD risk factors in COPD (1, 6, 34, 35, 152-156). Patients 
with COPD also have higher prevalence of cerebral cortical dysfunction as a result of 
an increased cortical inhibition levels compared to their healthy counterparts (157). 
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Occasionally, COPD coexists with other chronic diseases such as asthma, namely 
asthma-COPD overlap syndrome (ACOS), which is a condition in which an 
individual has clinical features of both asthma and COPD (158) [Figure 10]. Heart 
failure and left ventricular systolic dysfunction (LVSD) also coexist with COPD 
especially among the elderly dyspneic COPD types (159). These complexities often 
present a therapeutic challenge because COPD medications are also associated 
with some adverse and deleterious effect on a coexisting condition.
 Another aspect to the cardiovascular-related morbidity and mortality in COPD 
is the impairment in the autonomic nervous system (ANS) (160). Patients with 
COPD have been reported to have cardiac sympathetic activation, systemic 
neurohumoral activation and peripheral sympathetic activation as a result of 
impaired autonomic control (161). Cardiac sympathetic activation is reflected by a 
significantly reduced heart rate variability (HRV) and baroreceptor reflex sensitivity 
(BRS) indices, also demonstrating poor cardiac autonomic control. 
 Neurohumoral activation is represented as an abnormally increased concentration 
of organic chemicals such as plasma norepinephrine and plasma renin or aldosterone 
Figure 10   The interaction between COPD and the pathogenesis of CVD (83).
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activities, all of which in the long run augment the sympathetic nerve traffic, have 
been widely reported in COPD (161-163). Similarly, peripheral sympathetic activation 
has been reported in a number of studies assessing the muscle sympathetic nerve 
activity (MSNA) in COPD compared to healthy controls (164-166). Other measures 
of the ANS integrity in COPD such as heart rate recovery (HRR) following exercise 
training and sympathetic skin response test have also revealed similar outcome 
(167-169). More information regarding these autonomic function parameters and 
more are described in detail in Chapter 2.  
 The use of certain classes of COPD medication have been reported to have an 
effect on the HRV values in COPD (170). More specifically, the following two classes 
of drugs have been associated with adverse effects on the cardiovascular autonomic 
system: (i) long acting β2 agonists, which are typically administered to improve 
lung function and health status in symptomatic COPD, and (ii) inhaled corticoste-
roids (ICS), which are given to reduce the frequency of acute episodes of symptoms 
exacerbation and also delay deterioration of the health status (171). Moreover, 
polypharmacy, which is common in COPD, has a negative influence on the 
autonomic function. 
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1.   General description of the autonomic nervous system 
(ANS)
The autonomic nervous system (ANS) consists of a set of nerves (cells and axons) 
that provides innervation to several organs of the body such as blood vessels, glands, 
smooth muscles of viscera, heart, lungs (airways) and urogenital organs (1, 2). 
The ANS represents a crossing point between the central nervous system (CNS) and 
the body (3). It is responsible for regulating and coordinating certain bodily 
functions mainly comprising secretory activity of glands, contraction and 
relaxation of smooth muscles, cardiovascular adaptation and functioning relating 
to the body physiology, responses to stimulus and homeostasis (4-6). The ANS 
relays impulses that are initiated in visceral receptors via the afferent autonomic 
pathways to the CNS for processing. Subsequently, the CNS transmits responses to 
the target organs via efferent pathways to the respective visceral effectors (7).   
 The ANS is responsible for the continuous adaptation of the human body to 
both internal and external changes by regulating bodily functions such as blood 
pressure, respiratory rate, blood circulation, body temperature and digestion, without 
a conscious effort. The ANS also regulates the caliber of the airways, secretion 
production, modulates the inflammatory response and modulates airway responses 
to inflammation (8). The ANS is referred to as the visceral nervous system or the 
vegetative nervous system. Combined with the somatic nervous system, it forms 
the efferent (i.e. outgoing) division of the peripheral nervous system [Figure 1]. 
The a regulates 
 The ANS consists of a central and a peripheral part. The central part of the 
ANS is located in the brain, brainstem and spinal cord, while the peripheral part 
comprises nerve axons that originate from the spinal cord to various target organs 
or glands. Generally, the ANS is made up of two major divisions: sympathetic and 
parasympathetic. However, a third division, known as the enteric nervous systems, 
encompasses a complex set of neurons (both parasympathetic and sympathetic) 
lining the wall of the gut especially the small and large intestines (4, 9).  Our focus 
in this section of the dissertation is to provide a general description, anatomical 
structure, functions and interactions of the ANS. 
1.1  Sympathetic nervous system
The sympathetic nervous system originates from the preganglionic neurons 
located in the inter-medio-lateral cell column (lateral horn) of the thoracic and 
upper lumbar (thoracolumbar) region, specifically, between T1 and L3 segments of 
the spinal column [Figure 2] (4, 10). The preganglionic cells of the neurons of the 
sympathetic nervous system receive inputs from the vasomotor center in the brain 
stem. The preganglionic neurons leave the spinal column via the ventral root, and 
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then through the white rami, in a segmentally organized manner to pass through 
the para-vertebral sympathetic chain ganglia. Thereafter, a different subgroup of 
neurons arising from the sympathetic chain ganglia further converge to form 
the celiac, mesenteric (superior and inferior) and cervical (superior sympathetic) 
ganglia [Figure 2]. The sympathetic ganglia allows for mass activation of the 
sympathetic chain as a large unit through a phenomenon known as ‘divergence’, 
which results when a preganglionic fiber synapses with many post ganglionic 
neurons. Divergence is useful in situations that require a more global response 
such as during danger, exercise hypoglycemia, dehydration and exposure to extreme 
temperature conditions (11). The sympathetic nervous system is also capable 
of acting in a localized fashion to create selective regional effects in organs, 
a phenomenon known as ‘convergence’.
 The sympathetic effects in the ANS last longer compared to the parasympa-
thetic effect due to the nature of the neurotransmitter released at the post 
ganglionic fibers, the norepinephrine (NE) (Table 6). The NE is activated slowly and 
its action lasts for several minutes before it is finally metabolized by the liver (11). 
During sympathetic stimulation, there is an increase in the firing rate of the 
pacemaker cells in the SA node, which in turn increases the heart rate (12). 
 Physiologically, this occurs as a result of a positive inotropic effect of NE on heart 
muscle, when it is binding to beta-1 adrenergic receptors of the heart, resulting in 
an increased cardiac output. NE also decreases the basal pulmonary vascular tone 
and elevates the pulmonary blood flow through the activation of α2-adrenoceptors 
and NE release, also causing a pulmonary vasodilator response (13). Peripheral 
circulatory effects of NE include increasing blood flow to the skeletal muscles and 
reducing blood flow to the gastrointestinal system.
Figure 1   An illustration of the functional division of the nervous system.
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The role of the sympathetic nervous system on the heart and peripheral circulation 
is mainly coordinated by intrinsic mechanisms comprising cardiopulmonary 
mechanoreceptors, baroreceptors in the carotid sinus and aortic arch, cardio- 
vascular low threshold poly-modal receptors, and arterial chemoreceptors (14).
1.2  Parasympathetic nervous system
The parasympathetic nervous system is part of the efferent neurons that originate 
from the brain stem and sacral regions of the spinal cord. Their pre-ganglionic 
fibers, which originate from medial medullary sites (nucleus ambiguous, nucleus 




tractus solitarius, and dorsal motor nucleus) of the spinal cord, travel over a long 
distance to reach a ganglion that is located near or inside a target organ. Consequently, 
only short post-ganglionic axons make a connection with the target organ or 
gland. The neurotransmission in the parasympathetic nervous system is mainly 
modulated by nicotinic and muscarinic receptors (10, 15). The parasympathetic 
nervous system is controlled by the hypothalamus in the brain stem, and majority 
of its preganglionic innervation comes  from the vagus nerve, which is one of the 
major cranial nerves.  
 The parasympathetic nervous system functions in a very localized manner 
and its effects are mostly for a short-term and often localized because of the ratio 
of pre-to-post-ganglionic neurons [Figure 2]. Furthermore, the neurotransmitter 
released by the post ganglionic neurons in the parasympathetic nervous system is 
acetylcholine (Ach), which is metabolized quickly by circulating acetylcholinesterase 
thereby reducing the effect of parasympathetic stimulation. The parasympathetic 
branch acts mainly by decreasing the firing rate of the pacemaker cells in the 
SA node (12). Examples of the effects of parasympathetic stimulation include 
inhibition of the heart, constriction of the bronchi, constriction of the pupils and 
stimulation of the salivary gland.
1.3  Enteric nervous system
The enteric nervous system is the third division of the ANS that is mainly associated 
with the gastrointestinal system (7, 16). Unlike the sympathetic and parasympa-
thetic nervous systems, the enteric nervous system performs many of its functions 
independent of CNS contribution. It comprises two main ganglionated plexuses 
(the myenteric and submucosa), and the nerve fibers which arise from the plexuses 
and supply the muscle, blood vessels and mucosa of the gastrointestinal (GI) tract. 
The enteric nervous system contains a large number of neurons, approximately 
107 to 108 (17). Its major functions are GI peristalsis and secretion. 
1.4  Parasympathetic vs sympathetic interactions
Even though the role of the sympathetic and parasympathetic divisions of the ANS 
tend to be antagonistic to one another, especially when they innervate the same 
organ. However, the two branches do not oppose one another per se. Instead, both 
systems interact in a complex and dynamic manner that includes either co- 
activation or reciprocal activation with a view to maintaining a desirable autonomic 
tone in the nervous system (3). Generally, there is a predominance of vagal “tone” 
(parasympathetic activation) over sympathetic tone (sympathetic activation) at rest. 
Additionally, unexpected parasympathetic stimulation (accentuated antagonism) 
occurs in order to inhibit tonic sympathetic activation during rest and strenuous 
conditions through a strong vagus nerve discharge. 
57
AUTONOMIC NERVOUS SYSTEM (ANS): PHYSIOLOGICAL OVERVIEW AND ASSESSMENT MEANS
2
1.5  Chemical divisions of the autonomic nervous system
The chemical division of the ANS, also referred to as neurotransmitter division, is 
based on the chemical mediators that are released to enable the ANS function (7). 
Neurotransmitters are synthesized and stored in the axons before they are 
released. The major neurotransmitters that are released by neurons of the ANS are 
Ach and NE, representing the cholinergic and noradrenergic divisions, respectively 
(19). The cholinergic nerve fibers include all preganglionic fibers of the ANS in 
both sympathetic and parasympathetic nervous systems, all postganglionic fibers 
of the parasympathetic system, and the sympathetic postganglionic fibers 
innervating sweat glands. On the other hand, all other sympathetic postganglionic 
fibers release NE and are adrenergic fibers. Table 1 describes the respective 
receptors, location and effect of binding of the chemical divisions of the ANS. 
2.  Indicators of altered ANS functioning 
A diagnosis of autonomic failure is sometimes an indication of a problem in the 
CNS function. However, for this to be established, isolated peripheral autonomic 
nerve disorders have to be ruled out (20). In many autonomic laboratories, the 
assessment of altered ANS function assessment is only possible in a systematic and 
segmental fashion. This is because of the absence of a distinctive test or assessment 
protocol that assesses all the components of the nervous system at once. Besides, it 
is still practically impossible to assess the function of deeply sited unmyelinated 
nerve axons accurately. 
 Consequently, a number of studies have proposed several means of assessing 
the integrity of the ANS. Several parameters are now being used to identify 
abnormal or altered ANS functioning. In the past, the use of  plasma and urinary 
catecholamine levels provided one of the few ways to assess the level of sympathetic 
activity (3, 21, 22). However, several parameters now exist that reflect ANS 
functioning accurately, with an added advantage of being non-invasive (23).  
 The analysis of the autonomic control of the heart, by means of indirect 
markers, represents a valuable approach for identifying patients at higher risk 
for sudden cardiovascular events (24). Several stimuli (internal and external) 
continuously act by balancing the tone between the two branches of the ANS (25). 
Problems with  the ANS can be screened subjectively, by means of questionnaires 
collecting information regarding autonomic symptoms (26), in addition to objective 
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2.1  Subjective assessment of the ANS
Subjective assessment of the signs of ANS dysfunction takes the form of 
questionnaire administration or anamnesis that are usually performed in clinical 
settings. The subjective assessment of the ANS to determine the level of autonomic 
symptoms has been simplified for various purposes. The autonomic symptoms 
profile (ASP), which is valid and reliable (29) has been used for various patient 
populations (30, 31). The most recent and simplified version of the ASP is the 
composite autonomic symptoms scores (COMPASS-31), which delineate the severity 
and distribution of autonomic symptoms across six domains; orthostatic 
intolerance, vasomotor, secretomotor, gastrointestinal, urinary and pupillomotor 
function (26). The psychometric properties of the most recent COMPASS-31 
including the Cronbach α coefficient values range from moderate to good (0.40 to 
0.90), and with 4 domains (orthostatic intolerance, vasomotor, gastrointestinal 
and pupillomotor) reaching a Cronbach α coefficient greater than 0.70 (32). 
Additionally, the total score COMPASS-31 score has a moderately good rank 
correlation (r= 0.67) with the composite autonomic symptom scale (CASS), 
indicating a good criterion validity (29). In addition to being valid and reliable, 
this instrument is easy to use and it has a good diagnostic accuracy (33). 
 For autonomic symptom assessment using the COMPASS-31 questionnaire, 
a score between 0 and 100 is achievable. The higher the score, the unhealthier 
the subject or patient is. For the six COMPASS-31 domains (orthostatic intolerance, 
gastro intestinal, vasomotor, secretomotor, urinary and pupillomotor) different 
sympathovagal interpretations can be suggested. For example, higher orthostatic 
intolerance score is a reflection of increased sympathetic activity (34), while higher 
gastro-intestinal score (especially the constipation subgroup) indicates problems 
with parasympathetic function (35). The vasomotor scores are reflective of 
sympathetic dysfunction (36). For secretomotor symptoms, tears and sweat formation, 
and dryness of the mouth indicate parasympathetic dysfunction (37), while 
problems with sweating have to do with sympathetic function (38). Lastly, low 
scores for bladder and pupillomotor domains are associated with impairments in 
the parasympathetic function (37, 39). 
2.2  Objective assessment tests of autonomic function
The objective assessment of the ANS uses indirect recordings of parameters such 
as the heart rate variability (HRV), which has gained acceptance. Conversely, direct 
tests of sympathetic post ganglionic nerves in the tests of muscle sympathetic 
nerve activity (MSNA) and skin sympathetic response (SSR) are limited by lack of 
generalizability. As a result, current efforts and guidelines have increasingly 
recommended that several autonomic function tests should be performed in order to 
gain insight into the overall autonomic activity of organs of individual subject (40). 
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Thereafter, all this information can be combined in a complementary manner to 
provide information about the state of the ANS.
3.  Selected autonomic function parameters
3.1  Heart rate variability analyses
The HRV is a sensitive and noninvasive electrocardiographic method of measuring 
the functioning of the autonomic input to the heart (41, 42). It reflects the 
beat-to-beat changes of the heart known as R-R intervals [Figure 3], which is related 
to the ongoing interplay between the sympathetic and parasympathetic systems of 
the ANS, and the ability of the cardiovascular system to adapt to both external and 
internal changes (25, 43). According to the report of the Task Force of the European 
Society of Cardiology (1996), the HRV is one of the recognized parameters for the 
estimation of cardiac autonomic modulations(33). The HRV has been extensively 
used for the autonomic modulation of the sinus node due to its improved standards of 
measurements, physiological interpretation and clinical implications (40, 44, 45). 
The HRV is particularly useful when evaluating the balance between sympathetic 
and parasympathetic activities (46). The HRV is an analysis of the fluctuations in 
the heart rate, which are mediated by the sympatho-vagal activities.  Furthermore, 
the HRV index is a widely accepted and frequently reported physiological marker 
of autonomic function in COPD (23, 47, 48). 
Figure 3   Representation of the normal sinus rhythm of the heart and R to R 
wave interval (RRi) (49).
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Presently, the HRV has become an important tool for assessing, prognosticating 
and detecting autonomic impairments in several neurological and even in 
non-neurological disorders. It remains an invaluable tool for both clinical practice 
and physiological research (50). The HRV responses can indicate alterations and 
abnormalities in cardiac autonomic control as earlier stated (51). A decrease in 
the overall index of HRV analyses is in turn associated with the development of 
several cardiovascular disorders including myocardial infarction, alcoholic cardio- 
myopathy, chronic heart failure and ventricular arrhythmia (43). 
 The HRV analysis consist of several individual parameters categorized as 
either linear or nonlinear HRV analyses. The linear HRV analysis is further 
subdivided into time and frequency domain. In general, the linear analyses are 
measured in terms of inter-beat intervals of normal beats, while the nonlinear 
analyses is based on interpretations of the degree of the HRV in less stable 
circumstances.
3.1.1  Time domain linear HRV analyses 
The time domain analysis refers to measures and quantification of the HRV in 
terms of heart rate at the intervals between successive beats (R-R intervals), 
measured in units of time (milliseconds) (40). These inter-beat intervals of the 
heart rate time series vary (shorter or longer) over a course of time. The indices 
derived from the time domain HRV analysis largely depend on vagal modulation, 
and a reduction in the values of these indices is interpreted as a sign of heightened 
sympathetic modulation of the sinus node (45). One of the major indices of time 
domain HRV is the standard deviation of the N-N interval (SDNN), which depicts 
variability of the heart beats in a particular time series. The SDNN also depends on 
the length of the time series, making it unsuitable to use for comparison, if 
different time series lengths are used. The standard deviation of the average NN 
interval (SDANN), is another index of time domain parameters that is computed 
over short periods (typically 5 mins), and is used for estimating the changes in 
heart rate over longer periods of time (Table 2). 
 The next three important indices of HRV analysis follows computations that 
are based on the variations in successive NN intervals. These measures include the 
square root of the mean squared differences of successive NN intervals (RMSSD) 
(52), the number of interval differences of successive NN intervals greater than 
50ms (NN50), and (iii) the proportion derived by dividing NN50 by the total number of 
NN intervals (pNN50). All these parameters show variations in the high frequency 
band of the power and they are mainly reflective of parasympathetic activity.
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3.1.2  Frequency domain analyses of HRV
The frequency domain HRV analysis measures the index of the variability in the 
fluctuations at various frequencies in a specified R-R time series with a correlation 
to neural discharge (45). The frequency domain analysis of HRV also provides 
significant assessment of the cardiac autonomic control (53)W. The frequency- 
domain analyses approach is based on a spectral technique, which analyzes the RR 
interval series as a complex sum of waveforms. Thereafter, it is decomposed with 
either fast Fourier transformation (FFT) or autoregressive approach (AR) algorithms 
(54), each having its advantage and disadvantages (55). The power spectrum of a 
time series refers to the frequency content within a time series (and the power 
contained in every frequency). For example, if a set of R-R series has a significantly 
high variability, there would be a greater contribution at higher frequencies, 
while RR series with low variability are associated with lower frequencies. Usually, 
the R-R interval data are converted to power spectral density (PSD), which enables 
the determination of the amount of variance or power as a function of frequency 
ranges. 
 The frequency domain comprises different indices (Table 6), which are 
classified according to their frequency bands. The indices include high frequency 
(HF)  band (.15 and .4 Hz), low frequency (LF) band (.04 to .15Hz), very low frequency 
(VLF) band (.0033 and .04Hz) and the ultra-low frequency band (ULF) (.0000115 and 
.0033Hz) as illustrated in Figure 11 (56). A minimum period of at least 1 min, 2 min, 
5 min and 24 h recording is required to assess the HF, LF, VLF and ULF band, 
respectively (57). 
Figure 4   Power spectral density of the HRV signal indicating the difference 
frequency bands. Adapted from (58).
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The HF power, also called respiratory band, indicative of the changes in the heart 
rate that is primarily prompted during respiratory cycle, mainly comprise 
activation during expiration and inhibition during inspiration. For this reason, 
most frequency domain analyses reflect parasympathetic activity. This effect of 
respiration on heart rate is a phenomenon that is referred to as, ‘respiratory sinus 
arrhythmia (RSA)’(53). The LF band has been reported to also characterize both 
sympathetic and parasympathetic activities (43).  The LF has been earlier referred 
to as the baroreceptor range because it mainly reflects activity during resting 
conditions (57). In addition, its sympathetic tone feature is thought to be more 
dominant (59). This interpretation forms the basis of using the LF as an index to 
estimate sympathovagal balance. For example, during Orthostatic tilt, there is an 
increase in LF and a decrease in HF fluctuations, which corresponds to activation 
of sympathetic and withdrawal of vagal activity as a response to tilting. Moreover, 
the LF represents oscillations related to regulation of blood pressure and vasomotor 
tone (53).
 Past studies have even proposed the use of the ratio of LF to HF (LF/HF) for 
quantifying the changing relationship between sympathetic and parasympathetic 
activities. The use of LF/HF ratio has gained wide acceptance mainly because it is 
easy to interpret. An increased ratio of LF/HF is interpreted to represent a shift 
towards a “sympathetic dominance” (>2), while the opposite corresponds to a 
“parasympathetic dominance”(15). This was based on the postulation that HF and 
LF represents cardiac parasympathetic tone and sympathetic outflow, respectively 
(53, 60). The LF and HF indices are also expressed in normalized values, which is 
a second step measure after the initial estimation of the power in the LF and HF 
bands. The normalized units (nu) indices are based on the following formula (61). 
LFnu = LF/(LF + HF)
HFnu = HF/(LF + HF)
The normalization of the spectral HRV measures of LF and HF makes it easier to 
understand the proportion of the quantities expressed, and even exchange values 
across different laboratories. Normalization also ensures removal of within and 
across subject variability in the total HRV spectral power (61).  The VLF is generally 
believed to be a factor that is related to thermoregulation and kidney function. 
However, it occurs less frequently during short term recording just like the ULF. 
Their effects on the ANS are computed mainly during long term HRV recordings 
(24hours).
 In summary, the parameters of the HRV analyses expressed in ms2 have 
clinical application unlike those expressed in hertz. All HRV analysis parameters 
(Table 2) give information about the sympathetic and parasympathetic tone to the 
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SDNN ms Standard deviation of all normal R-R intervals 
(same as SDRR)
SDANN ms Standard deviation of the mean of all 5-min 
segment of normal R-R intervals
RMSSD ms The root mean square of differences of successive 
RR intervals
NN50(count) Number of consecutive RR intervals that differ 
more than 50 ms
pNN50 % The percentage value of consecutive RR intervals 
that differ more than 50 ms
Mean-RR ms
Geometric measures
RR triangular index The integral of the RR interval histogram 
divided by the maximum of the histogram
TINN ms Baseline width of the RR interval histogram
Differential index Difference between the widths of the histogram 
of differences between adjacent NN intervals (in 
heights) 
Logarithmic index Coefficient of the negative exponential 
curve which is the best approximation of the 
histogram of absolute differences between 
adjacent NN intervals 
Frequency domain analysis
Spectra measures (parametric and non-parametric)
Total power ms2 Peak frequencies of the power spectral density 
estimate for VLF, LF, and HF frequency bands (Hz)
ULF ms2 The powers for ultra-low frequency bands in ms2 
and in percentage value. 
VLF ms2 The powers for very low frequency bands in ms2 
and in percentage value. 
LF [LFnu] ms2 The power in the low frequency bands in ms2 
, in percentage value [and also represented in 
normalized units (n.u)].
HF [HFnu] ms2 The power in the High frequency bands in ms2 
, in percentage value and [also represented in 
normalized units (n.u)]. 
LF/HF ratio Ratio of LF and HF frequency band powers
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heart (64). The VLF power is only applicable to long terms (typically 24 hrs.) and 
cannot be interpreted from short-term measurements. The LF power reflects both 
sympathetic and parasympathetic changes in heart rate largely due to the effect of 
the baroreflex system. Therefore, higher LF scores indicate optimum functioning 
of the autonomic control of the heart.  The HF power reflects parasympathetic 
influence - changes in heart rate largely caused by breathing (vagus control), while 
the LF / HF ratio reflects balance between sympathetic and parasympathetic (43). 
The higher the ratio, the more sympathetic dominance. 
3.1.3  Nonlinear analyses of the HRV 
The nonlinear analysis of the HRV offers a robust interpretation of the HRV in less 
stable conditions. It uses a symbolic analysis of 3-beats sequences to distinguish 
between both branches of the ANS (3). Due to the likelihood that the neural 
modulation of cycle length (CL) of the SA node is not linear, hence, the complete 
reliance on the use of linear HRV analysis may be limited in its interpretation or 
scope (45).  The nonlinear HRV analysis fills this gap by providing us with innovative 
indices that are capable of increasing the understanding of the correlation 
properties and even characteristics of heart rate behavior (Table 3). 
Poincaré plots 
The Poincaré plots (also called return map) of HRV is one of the recent means of 
HRV analysis that presents the nonlinear dynamics of both randomness of heart 
rate and autonomic modulation (50, 65), and it shows  the nature of fluctuations in 
the heart rate (66). The plot itself is a graph of every RR interval plotted against the 
prior interval, thereby creating a scatter plot (57). More importantly, Poincaré plot 
is a quantitative-visual tool that shows the shape of the plot as well as the summary 
of the beat-to-beat information on the behavior of the heart that can be categorized 
into functional classes that reflect the degree of problems in the heart function 
(Figure 5) . Poincaré analysis allows researchers to visually observe patterns buried 
within a time series. 
 Additionally, the ‘width’ of the Poincaré plot is reported to be a measure of 
parasympathetic nervous system activity (67). Generally, the shape of the plot is 
quantified by fitting an ellipse into the data points oriented along the line-of-iden-
tity (LOI). The width and length of the ellipse are determined by the standard 
deviations of the points perpendicular to and along the LOI and they are denoted 
by SD1 and SD2, respectively. The SD1 index measures short-term HRV variability, 
whereas SD2 index measures the long-term HRV variability (68) [Figure 5].
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Table 3  Nonlinear heart rate variability parameters.
Variable Units Description
Poincare plot
SD1 ms The standard deviation of the Poincaré plot perpendicular  
to the line-of-identity
SD2 ms The standard deviation of the Poincaré plot along  
the line-of-identity
Recurrence plot
Lmean beats Mean line length
Lmax beats Max line length








Figure 5   Poincaré plots (66). 
The figure on  the left shows the ellipse fitting process in a normal plot. The coordinate system x1 and x2 
is established at 45° to the normal axis. The standard deviation of the distance of the points from each 
axis determines the width ( SD1 ) and length ( SD2 ) of the ellipse. 
The figure in the middle is that of a subject who has intermittent ventricular premature contractions. 
The Poincaré plot clearly separates the activity caused by the ectopic and the activity caused by sinus 
rhythm.
The figure on the right is that of a subject with prominent RSA. The oscillation caused by respiration 
causes a gradual increase in heart rate during inspiration, followed by a rapid decrease during expiration. 
This causes the plot to appear asymmetrical.
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Recurrence plot
Several parameters including mean line length (Lmean), maximum line length 
(Lmax), recurrence rate (REC), determinism (DET) and Shannon entropy of line 
length distribution (ShanEn) comprise the recurrence plot, which helps in 
analyzing the complexity of the nonlinear HRV data. The recurrence plot uses 
variables such as the embedding dimension (m) and threshold (r) values as such as 
the D2 (the minimum number of dynamic variables needed to model the underlying 
system) to produce a binary square matrix consisting of values of either 0 and 
1 point (68). Higher D2 values indicate greater degree of complexity.
Other nonlinear HRV analyses variables 
Other nonlinear parameters include the sample entropy (SampEn), which provides 
a reliable measure signal regularity and complexity especially for data from short 
time series. The approximate entropy (ApEn) also measures the complexity or 
irregularity of the HRV based on two parameters; the embedding dimension (m) 
and tolerance (r). ApEn values indicate low predictability of fluctuations in 
successive RR intervals, and small ApEn values is indicative of a regular and 
predictable signal, i.e. the smaller the ApEn values, the better the cardiovascular 
autonomic functioning of the heart (57). Other nonlinear HRV analysis are: (i) 
detrended fluctuations analyses (DFA), which is the extracts of the correlations 
between successive RR intervals over different time scales. These DFA correlation 
results in two slopes; (i) α1, which describes brief fluctuations and also reflects the 
baroreceptor reflex, while (ii) the α2 describes the long-term fluctuations and that 
reflects the regulatory mechanisms that limit fluctuations in a beat cycle. The DFA 
is decreased in cardiovascular disorders such as myocardial infarction (57, 69); and 
(ii)) the D2, which refers to the minimum number of dynamic variables needed to 
model the underlying system (68). Higher D2 values indicate greater complexity, 
and hence better cardiac autonomic functioning (57).
3.2  Baroreceptor sensitivity
The baroreceptor system comprises a cardiovascular and a CNS aspect. It is one of 
the most important systems responsible for cardiovascular autonomic control (70), 
as well as a significant prognostic variable in cardiovascular medicine (71). 
The baroreflex system adjusts the heart rate and sympathetic output to blood 
vessel intermittently, thereby, preventing wide fluctuations in the blood pressure 
at the same time maintaining blood flow to the brain (72). The baroreceptor 
functions in a linear relationship (between the systolic blood pressure and R-R 
interval)  model that is referred to as the sigmoidal stimulus (73). 
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Baroreceptors are located in the aortic arch and carotid sinus anatomically, 
making them well positioned to relay information regarding blood pressure 
changes to the CNS [Figure 6]. 
 Even though the BRS remains continuously active both in rest by inhibiting 
sympathetic activity, it mainly functions upon external or internal stimulation such as 
valsalva maneuver, exercise, stress and food intake. Expectedly, the impairments 
in the functioning of the baroreflex are associated with cardiovascular disease.
 In the laboratory or clinical setting, the BRS can be assessed with the aid of 
devices that monitors the fluctuations in the heart rate per unit blood pressure 
changes (expressed in ms/mmHg). Two major techniques have been widely used in 
the assessment of BRS; (i) the first technique measures the reflex response to 
external stimuli such as Valsalva maneuver (VM) and head up tilt (HUT) when the 
focus is on sympathetic stimulation (75), (ii) the second and more advanced 
technique with clinical relevance and does not require external intervention even 
by subject. Here the resting cardiovascular parameters are continuously evaluated 
for the fluctuations in heart rate and blood pressure correlation (regression) in 
mostly a standard laboratory (71, 76).  The second method provides a more accurate 
and reliable estimate of the BRS (71) compared to the first, which has some 
limitations (76). Figure 7 illustrates both normal and abnormal BRS and cardio- 
vascular responses to VM. Finally, the BRS index is a parameter that reflects the 
rate of parasympathetic function. Higher BRS values reflects better function of 
the autonomic functioning of the heart.
Figure 6   Baroreceptor reflex innervation (sympathetic and parasympathetic). 
Adapted from (74).
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3.3  Muscle/skin sympathetic nerve activity (MSNA/SSNA)
The MSNA and SSNA represents the measure of the peripheral sympathetic activation 
that is generally increased in COPD. The MSNA can be determined in using micro-
neurography, a process whereby the nerve activity is recorded directly from intra- 
neural microelectrodes inserted percutaneously into a peripheral nerve. Presently, 
the quantification of the MSNA is limited to measures of burst frequency (bursts/
minute) and burst incidence (bursts/100 heart beats) (77). Another major constraint 
is the difficultly in applying microneurography in routine clinical settings is that 
it is invasive, assesses only a localized segment of the nervous system (sympathetic 
tone in the peripheral nerves), and requires a high level of expertise and is time 
consuming. 
3.4  Heart rate recovery 
The heart rate recovery (HRR) is a simple-to-measure vagal mediated recovery of 
the heart to pre-exercise levels following an exercise training. Specifically, HRR, 
which is measured in beats per minute, refers to the fall in the heart rate during 
Figure 7   Examples of a normal (top) and abnormal (bottom) BRS response (82).




the first minute after peak exercise ( HRR = heart rate peak − heart rate1 minute 
recovery) (78, 79). Abnormal HRR after symptom-limited exercise predicts mortality 
(78, 79). The HRR has been used as an outcome for assessing the effect of exercise 
intervention on the autonomic control even in COPD patients populations (80, 81). 
3.5  Metaiodobenzylguanidine (MIBG) scintigraphy/imaging 
The MIBG imaging is a direct, noninvasive and quantitative method of assessing 
cardiac (adrenergic) autonomic dysfunction. The test is based on the principle that 
impaired MIGB uptake by the myocardial muscle is associated with sympathetic 
denervation (83), specifically impairments in the NE reuptake function (84). The 
test is performed by injecting iodine-123 (I-123) MIBG, a norepinephrine analog 
that shares the same uptake-I mechanism into sympathetic nerve terminals, and 
scintigraphically assessing MIBG uptake and release measurements on the planar 
images obtained at different time intervals (prior and after injection) (84).
 The MIBG test has a long-term prognostic capacity to predict cardiac death, 
and for identifying threshold levels for patients at risk of cardiovascular diseases 
(85, 86). Currently, it is more utilized in cardiology for conditions such as cardio- 
myopathy, myocardial infarction, heart failure and long QT syndrome (83, 85). 
Nevertheless, a few studies have adopted the test for other patient populations 
especially those with established autonomic neuropathy (87, 88). 
4.   Assessment of the ANS function using autonomic 
reactivity tests 
In the past, a group of tests reflecting either cardiac parasympathetic or sympathetic 
damage was developed for assessing diabetic autonomic neuropathy (27). These tests, 
mainly comprise an evaluation of abnormal responses of the heart rate to VM, 
HUT or standing, and the heart rate variation during deep breathing, to assess 
parasympathetic damage. The other two tests are blood pressure response to standing 
and hand grip tests to assess sympathetic damage. All these tests are popular in 
assessing the ANS integrity. And have been utilized commonly to provide clinically 
important information regarding the distribution, location and even severity of 
the ANS deficits. For this reason, the autonomic reflex test battery, which assesses 
the reaction of the ANS to stimuli such as deep breathing, VM and HUT, is considered 
as a standard measure (40, 89-91).  
 Several other tests including evaluation of resting values of HRV and the 
baroreflex receptor sensitivity, which connotes the rate of fluctuations in blood 
pressure, have also been used in several patient and non- patient populations 
(92-95). The subsequent sections will provide a detailed description of the 3 notable 
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autonomic reactivity tests, namely heart rate during deep breathing HRDB, VM and 
HUT tests. 
4.1  Deep breathing
The deep breathing is a widely utilized and popular test (89, 96, 97) that is based 
on the principle of respiratory sinus arrhythmia (RSA) maneuver. The RSA connotes 
the modulation of cardiac vagal efferent activity by the central respiratory drive 
(98) via the premotor cardio inhibitory parasympathetic neuron activity and the 
lung inflation reflex. With healthy individuals, the heart rate increases during 
inspiration and decreases during expiration (99). The deep breathing test is 
conducted by performing 8 consecutive breathing cycles at a rate of 6 breaths/
minute. The average value of the differences between the maximum and minimum 
heart rate of 5 consecutive and largest responses is then calculated as the heart 
rate during deep breathing (HRDB) (28). The HRDB, which is also referred to as expi-
ratory-inspiratory ratio [IE ratio], is a parasympathetic parameter. Higher values 
represent better autonomic control of the heart. The normative/reference values 
are presented in Table 4.
4.2  Valsalva maneuver 
The VM represents a natural challenge for the baroreceptors (82). It is a test with 
both respiratory and circulatory implications. When VM is evoked, it incites a 
sequence of rapid changes in preload and afterload stress on the cardiovascular 
system. During the strain, venous return to the heart is decreased and peripheral 
venous pressures become increased (100). Thereafter, systolic and pulse pressures 
begin to fall, while mean arterial pressure remains stable. In the laboratory, the 
test is evoked by blowing at a pressure of between 40 and 50 mmHg through a 
mouthpiece + plastic tube (with a small air leak) connected to a manometer usually 
in a supine position except conditions warrant some degree of tilting (101). 
 Under normal conditions and under continuous recording of beat-to-beat 
finger plethysmography and blood pressure monitoring, the blood pressure goes 
through 4 phases during VM. The first phase (I) is when the test is initiated, and it 
is characterized by intra-thoracic and intra-abdominal pressure surges causing 
mechanical compression of the aorta, which leads to an increase in blood pressure. 
The early second phase (II_E) of the VM kicks in when the cardiac output and blood 
pressure starts to drop due to the effect of the already increased intra-thoraco -
abdominal pressure on the venous return (venous preload), thereby prompting a 
sympathetic response (vasoconstriction in the extremities thereby increasing 
peripheral resistance). The late second phase (II_L) occurs as a consequence of 
sympathetic activation aimed at restoring blood pressure back to normal levels. 
The next phase (third) launches after the VM is stopped. Here, the intrathoracic 
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pressure drops suddenly causing the blood pressure to fall quickly. A mild sympathetic 
activation occurs for about 1 or 2 seconds to restore the blood pressure back to 
normal levels again. Finally, the fourth phase(IV) comprises a rise in the blood 
pressure rises again leading to an overshooting above the resting levels due to a 
persisting vasoconstriction in the extremities even after CO and venous return are 
back to normal levels (102).
 The response to VM depends on the integrity of the BRS pathway. Blunting of the 
HR is an indication of impairment in vagal component of the BRS, while adrenergic 
failure is manifested as loss of normal phase II_L and phase IV pattern. Both the 
function of the sympathetic and parasympathetic components of the ANS can be 
assessed using the responses of the blood pressure (103) and heart rate(104) to VM, 
respectively. Figure 8 illustrates a normal and abnormal cardiovascular responses 
to VM. 
 A number of parameters can be derived from the VM test (28). These include: 
(i) Vasalva ratio (VR), which is a parasympathetic variable that is calculated as the 
ratio of the maximum HR (HRmax) during VM and the maximum HR within 
30 seconds from the HRmax; (ii) Valsalva index (VI) is calculated as the ratio 
between the longest RRi during VM recovery (phase 4) and the shortest RRi during 
the peak of VM. A VI of less than 1.4 is considered abnormal (104); (iii) blood 
pressure drop is a sympathetic nervous system variable that is expressed as the 
value of the BP during the phase II minus baseline value (negative values are 
referred to as BP drops, while positive values are blood pressure rise); (iv) insufficient 
recovery is when the blood pressure parameters fail to rise up to baseline in phase 
II L; (v) pressure recovery time (PRT) is the time (in seconds) between the lowest 
point of phase III and the return of the blood pressure to the baseline. the longer 
this time, the more abnormal and it is reflective of sympathetic abnormality; (vi) 
Figure 8   Cardiovascular (heart rate and beat to beat blood pressure) responses  
to VM test (103). (A) normal subject, and (B) subject with  
diabetic autonomic neuropathy. All the VM phases are also indicated  
(I, ll_E, II_L, lll, IV). HR is the line in green.
A B
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pulse pressure (pp) drop during VM is the difference between the baseline pulse 
pressure and the pulse pressure during the VM. The deeper the PP falls during 
valsalva, the more this indicates sympathetic failure. The normative/reference 
values of some VM indices are presented in Table 4.
 A number of parameters are also calculated from the VM parameters. They 
include the adrenergic BRS (BRS_a), which is a sympathetic measure. Lower BRS_a 
values are indicative of abnormal sympathetic functioning. The next is the vagal 
BRS (BRS_v), which is a parasympathetic measure. Here, lower, values reflect 
abnormal parasympathetic functioning. The last is the global BRS (BRS_g), which 
is a product of BRS_a and BRS_v. Lower BRS_g values are abnormal. 
4.3  Head up (passive) tilt
The HUT is a passive tilt of at least 60° angle from a supine position on a tilt table 
or couch. The test has been used for detecting vasovagal syncope and other 
orthostatic symptoms (105, 106). Head-up tilt is utilized for as a valuable research 
tool by physiologists and/or physicians to study the hemodynamic and endocrine 
adaptation to changes in position. During tilting, there is activation of the sympathetic 
nervous system and withdrawal of the parasympathetic nervous system activity (67). 
These lead to changes in the body, which include blood redistribution from thorax 
to the extremities, significant fall in stroke volume and blood pressure (107). 
Figure 9   Cardiovascular (heart rate and beat to beat blood pressure) responses 
to HUT test in normal subject (A), neurogenic OH patient indicated  
by a pronounced fall in blood pressure (B), POTS indicated as an 
increased HR without OH (C), and syncope which is characterized by 







However, these changes are minimized in healthy subjects through a number of 
compensatory mechanisms involving the ANS (early phases), renal system and 
through the action of hormones (later phases). Furthermore, the baroreceptors 
(initiating a decrease in the parasympathetic outflow and a corresponding increase 
in sympathetic outflow), veno-arteriolar reflex (by constricting arterioles in the 
muscles fat and skin), respiration and muscle pumps are also known to contribute 
to mitigate the impact of tilting on the various body systems (108).
 Individuals with compromise to either ANS or any of the above-mentioned 
systems usually exhibit abnormal responses to HUT. These abnormal responses 
may include; (i) initial orthostatic hypotension, defined as a transient drop in 
blood pressure amounting to >40 of SBP mmHg and >20mmHG of DBP within the 
first 15 seconds of head up tilt, (ii)  orthostatic hypotension, defined as a drop in 
blood pressure that is >40 of SBP mmHg and >20mmHG of DBP within 3 minutes 
of head up tilt either as a result of hypovolemia or neurogenic cause, (iii) delayed 
orthostatic hypotension is the fall blood pressure that occurs after 3 minutes of 
tilting, (iv) postural orthostatic tachycardia syndrome refers to the sustained and 
excessive increases in the heart rate of at least 30 bpm or reaching a heart rate of 
120 bpm or higher during a 10 minutes tilt, (v) vasovagal syncope (reflex syncope) 
is the loss of consciousness that follows a large and abrupt decrease in the systemic 
blood pressure, and (vi) orthostatic hypertension, which refers to an increase in 
the SBP or 20 mmHg or more. Table 4 presents selected HUT parameters reference 
values.
5.   Autonomic reflex screening (battery) tests for 
grading of autonomic failure
More recent advancement in the field of autonomic function testing has led to the 
development of a number of laboratory tests that can be used to assess the level of 
autonomic failure. In this dissertation, we will focus on the composite autonomic 
scoring scale (CASS) and the quantitative autonomic reflex and small fibers tests 
(QASAT) methods for grading autonomic failure.
5.1  Composite autonomic scoring scale (CASS)
The CASS comprises three subscales: an adrenergic, sudomotor and a cardiovagal. 
The adrenergic and cardio-vagal subscales represent cardiovascular reflex tests, 
while the sudomotor test is assessed by quantitative sudomotor axonal reflex test 
(QSART). The CASS is slightly weighted to recognize the importance of adrenergic 
function, by allocating 4 points to it, while only 3 points are assigned to 
postganglionic sudomotor and cardiovagal functions. Grading autonomic failure 
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is possible using this scores (Table 5) (109). To calculate the cardiovagal score, both 
deep breathing and Valsalva ratio are required. Adrenergic score requires both 
Valsalva maneuver and tilt test results, while sudomotor score can be calculated 
from QSART results or from the thermoregulatory sweat test (109).  
The CASS provides a quantitative estimation of autonomic failure in cardiovagal 
(score 0-3), adrenergic (score 0-4), and sudomotor (score 0-3) domains as well as total 
score (0-10). Generally, a total CASS score of 0 represents no autonomic failure, 1-3 
indicates no or mild autonomic failure, scores from 4 to 6 indicate moderate autonomic 
failure, while scores from 7 to 10 indicate severe autonomic failure (Table 6).
 The original developers of CASS have identified a number of limitations with 
the scale (111). Firstly, the CASS does not take into account the baseline heart rate 
and other mechanisms underlying changes in heart rate variability during the 
subscale of cardiovascular heart rate index also known as the HRDB test (111). 
Secondly, the adrenergic subscale, which is only defined as a combination of 
abnormal blood pressure responses to VM and the presence of orthostatic 
Table 4   Normative values for Derp breathing, Valsalva and HUT tests.  
Adapted from (109) and (110).
Test Normative value
Deep breathing
Respiratory sinus arrhythmia 50-59 years (≥9 beats per minute)
60-69 years (≥7 beats per minute)
Valsalva maneuver
Valsalva ratio [VR] 50-59 years (female, 1.47; male, 1.36) 
60-69 years (female, 1.39; male, 1.29) 
Maximal drop of the MBP during  
the early phase 2
≥20 mm Hg
MBP at phase IV (recovery) ≥ baseline (mmHg)
MBP at phase IV (overshoot) > baseline (mmHg)
Maximal pulse pressure drop >50% of baseline
Systolic pressure recovery time <4 seconds
HUT
First 15 seconds of HUT Systolic BP, <40 mmHg; diastolic BP 
<20 mmHg of baseline
Within 3 minutes of HUT Systolic BP, <20 mmHg; diastolic BP  
<10 mmHg of baseline
After 3 minutes of HUT ≥ baseline <20 mmHg 
Throughout test HR increases should be < 30 beats per minute 
or should remain <120 beats per minute
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Table 5   Laboratory grading of autonomic failure. Adapted from (109).
CASS Indices Interpretations
Sudomotor index
0 Normal (≥ normative value)
1 Single site abnormal on quantitative sudomotor axon reflex test or
Length-dependent pattern (distal sweat volume < 1/3 of proximal value) or
Persistent sweat activity at foot (on thermoregulatory sweat test, anhidro-
sis present but <25%).
2 Single site <50% of lower limit on quantitative sudomotor axon reflex test
3 Two or more sites <50% of lower limit on quantitative sudomotor axon 
reflex test (on thermoregulatory sweat test, anhidrosis present >50%)
Adrenergic 
0 Normal (≥ normative value)
1 Phase II, decrease of <40 but >20 mm Hg mean BP or
Phase II, does not return to baseline or
Decrease in pulse pressure to ≤50% of baseline 
2 Phase II, decrease of <40 but >20 mm Hg mean BP  + phase II, or IV absent
3 Phase II, decrease of <40 but >20 mm Hg mean BP  + absent phases II and IV
4 Criterion for 3+ orthostatic hypotension (systolic BP decrease of ≥30 mm 
Hg; mean BP decrease of ≥20 mm Hg
Cardio-vagal
0 Normal (≥ normative value)
1 HRDB or VR mildly decreased (≥50% of minimal normal value)
2 HRDB or VR decreased to <50% of minimal normal value
3 Both HRDB and VR decreased to <50% of minimal normal value
Table 6   Laboratory grading of autonomic failure based on the CASS.  
Adapted from (28).
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Table 7   Cardiovascular component of QASAT. Adapted from (111).
Heart rate
1. Bradycardia – Supine and/or during tilt
Results Grading Value Definition
Normal 0 HR ≥ 50 BPM
Abnormal 1 HR < 50 BPM
*HR = heart rate, BPM = beats per minute, at least 10 minutes of the rest should be obtained
2. Tachycardia- supine
Results Grading Value Definition
Normal 0 HR ≥ 100 BPM
Abnormal Mild 1 HR < 100 BPM
3. Increased heart rate response to tilt
Results Grading Value Definition
Normal 0 HR increment ≥ 10 BPM and < 30 BPM during tilt  
and HR ≤ 110 during tilt
Abnormal Mild 1 HR > 110 but ≤ 120 BPM during tilt only or
HR increment during tilt >30 BPM and HR ≤ 120 BPM 
during tilt
Moderate 2 HR > 120 BPM and < 150 BPM and HR increment  
during tilt > 30 BPM or HR > 150 BPM and HR increment 
during tilt < 30 BPM
Severe 3 HR > 150 BPM and HR increment during tilt > 30 BPM
At least 10 minutes of tilt should be obtained
4.  Reduced heart rate response to tilt
Results Grading Value Definition
Normal 0 HR increment ≥ 10 BPM and < 30 BPM during tilt
Abnormal 1 HR increment during tilt <10 BPM
5. Heart rate variability
Results Grading Value Definition
Normal 0 *Heart rate variations to deep breathing test
Abnormal Mild 1 abnormal but ≥ 50% of normal value*
Moderate 2 < 50% but ≥ 35% of normal value
Severe 3 < 35 % of normal value
Blood pressure
6. Supine hypotension
Results Grading Value Definition
Normal 0 
Abnormal 1 SBP < 90 or DBP < 60
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hypotension. The CASS lacks other components/factors like the supine hypo-/
hypertension or excessive heart rate increment to tilt which are also based on 
adrenergic functions (111). Lastly, the sudomotor component of the CASS is based 
upon the QSART which grades only the postganglionic sudomotor deficit (111). 
5.2  Quantitative autonomic reflex and small fibers tests (QASAT)
The QASAT represents the most recent improvement in the measurement of 
autonomic function across the major components of the ANS. Unlike the CASS 
that is based upon cardiovascular tests, and QSART, the QASAT also assesses small 
fiber densities obtained from skin biopsies and cerebral blood flow. The QASAT has 
Table 7   Continued.
7. Orthostatic hypotension during tilt
Results Grading Value Definition
Normal 0 *Abnormal result is defined as a systolic BP ≤ 80%  
of baseline or a mean BP ≤85% of baseline. Baseline  






8. Valsalva maneuver-blood pressure
Results Grading Value Definition
Normal 0 End of phase 2 returns to or exceeds the baseline
End of phase 2 fails to return to baseline, the reduction is:
Abnormal Mild 1 ≥ 90% of baseline
Moderate 2 < 90% but ≥ 60% of baseline
Severe 3 < 60 % of baseline
9. Supine hypertension
Results Grading Value Definition
Normal 0 SBP < 140 or DBP < 90
Abnormal Mild 1 (SBP ≥ 140 or DBP ≥ 90) and (SBP < 160 or DBP < 100)
Moderate 2 (SBP ≥ 160 or DBP ≥ 100) and (SBP < 180 or DBP < 110)
Severe 3 SBP ≥ 180 or DBP ≥ 110
10. Orthostatic hypertension during tilt
Results Grading Value Definition
Normal 0 SBP ≤ 120% of baseline
Abnormal 1 SBP > 120% of baseline
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Table 8   Cerebral blood flow component of QASAT. Adapted from (111).
11. Valsalva maneuver – cerebral blood flow
Results Grading Value Definition
Normal 0 ≥ 85 % of baseline*
Abnormal Mild 1 ≥ 80 and < 85 % of baseline
Moderate 2 ≥ 65 and < 80 % of baseline
Severe 3 < 65 % of baseline
12. Cerebral autoregulation
Results Grading Value Definition
Normal 0 
Abnormal 1 Systolic CBFV > 160 cm/s during phase 4 and  
(Systolic CBFV-Diastolic CBFV) phase 4/ (Systolic CBFV
– Diastolic CBFV)baseline ) > 140 %
13.  Supine cerebral blood flow low
Results Grading Value Definition
Normal 0 
Abnormal 1 < upper normal limit
14. Supine cerebral blood flow high
Results Grading Value Definition
Normal 0 
Abnormal 1 > upper normal limit
15. Cerebral blood flow response to tilt





Using mean CBFV. CBFV should be measured at baseline, and at 1,5 and 10 minutes of tilt. *At each 
measurement, assign the value 0 for normal results. Abnormal results are defined as CBFV less than 
normal limit. Normal limit is defined as follows: At 1.minute: normal drop of CBFV ≥ 90%. Assign 1 for 
CBFV 80 – 89% of baseline, 2 for 70 - 79% of baseline and 3 for < 70% of baseline. AT 5. minute: normal 
drop of CBFV ≥ 89%. Assign 1 for CBFV 79 – 88% of baseline, 2 for 69 -78% of baselines and 3 for < 69% of 
baseline. At 10. minute: normal drop of CBFV ≥ 86%. Assign 1 for CBFV 77 – 85% of baseline, 2 for 67 - 76% 
of baseline and 3 for < 67% of baseline. Total score is obtained by sum of all scores. For tilt, longer than10 




Table 9   Small fiber Neuropathy component of QASAT. Adapted from (111).
Sudomotor
16. QSART 
Results Grading Value Definition
Normal 0 
Abnormal Mild 1 Single site ≥ 50 % and < 100 % or Length-dependent 
pattern* or Persistent sweat activity
Moderate 2 Single site < 50% or Two or more sites < 100 % and ≥ 50 %
Severe 3 Two or more sites < 50%
*100% = normal limit. At least 3 sites should be studied. *Length dependent pattern is defined as a reduction 
of the distal sweat volume more than 1/3 of proximal value.
17. Sweat gland nerve fiber density
Results Grading Value Definition
Normal 0 
Abnormal Mild 1 Single site < 100% and ≥ 85 % of lower limit
Moderate 2 Single site < 85% and ≥ 65 % or two sites < 100 % and ≥ 85 %
Severe 3 One site < 65% or two or more sites <85% and ≥ 65 %
Marked 4 One site < 50% or two or more sites < 65%
*100% = normal limit. At least 1biopsy should be done at the distal leg (10 cm above the lateral malleolus), 
with a second site at the thigh (20 cm distal to the iliac spine).
18. Epidermal nerve fiber density
Results Grading Value Definition
Normal 0 
Abnormal Mild 1 Single site < 100%* and ≥ 70 %
Moderate 2 Single site < 70% and ≥ 40 % or two sites < 100% and ≥ 70 %
Severe 3 One site < 40% or two or more sites < 70% and ≥ 40 %
Marked 4 One site < 20% or two or more sites < 40%
100% = normal limit. At least 1biopsy should be done at the distal leg (10 cm above the lateral 
malleolus) , with a second site at the thigh (20 cm distal to the iliac spine).
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been validated recently in a large study sample and has been found to be of a 
greater advantage over the CASS. The final QASAT sections are grouped in 3 main 
categories: Cardiovascular (sections 1-10), Cerebral blood flow (sections 11-15) and 
Small fiber neuropathy (sections 16-18) as illustrated in Tables 7, 8 and 9, respectively 
(111). The total QASAT item-grade score is presented as Table 10.
6.  Application of ANS measures in disease populations 
Generally, the clinical assessment of the ANS is conducted with a view to predict 
or stratify patients that are at risk of cardiac events or sudden death after acute 
myocardial infarction and non-cardiac events such as diabetic neuropathy (25, 62). 
Current measures of the ANS either for physiological or clinical uses appear to 
differ depending on the protocol or purpose. Patients with COPD also present with 
many disease comorbidities (especially cardiovascular related), each with its 
potential influence on the autonomic function. Therefore, autonomic function 
test results ought to be interpreted carefully and viewed within specific contexts. 
For now, the overall HRV, which connotes vagal activity is able to give a clue 
regarding the sympathovagal influence of the ANS on the sinus node. A decreased 
HRV analyses is interpreted as an increase in the sympathetic dominance or a 
reduction in the vagal modulation of the sinus node.
 Time domain HRV analysis has been reported to negatively correlate with the 
ejection fraction (45). Different cutoff points have been suggested for a number of 
autonomic function parameters (82).  For example, the SDNN cut-off point of <70 
milliseconds has been reported to be able to identify patients at risk of deaths due 
to ventricular fibrillation or heart pump failure(82). Furthermore, the frequency 
domain HRV analysis such as the LF/HF ratio recorded in the short term is utilized 
extensively to provide an index of the sympathovagal balance that can be useful 
for identifying disorders in early stages of myocardial infarction and even heart 
Table 10   Laboratory grading of autonomic failure based on the QASAT.  
Adapted from (111).







failure. The nonlinear HRV analysis, which offers an outlook regarding the 
integrity of the ANS through the nonlinear behavior of the heart, also provides 
interesting results that are still being explored. Lastly, the BRS and the other 
measures of the autonomic function are potentially useful for prognostication 
and predicting cardiac related mortality various patient populations especially 
when impaired vagal reflexes are identified (82).
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Cardiovascular autonomic neuropathy is one of the factors implicated in the high 
morbidity and mortality rate in patients with COPD. Thus, several studies and 
nonsystematic reviews have increasingly reported autonomic function impairment 
in these patients. For a better understanding, this systematic review was performed 
to evaluate not only the evidence for autonomic function impairment, but also 
factors influencing it. The results of the studies reviewed revealed a strong level 
evidence to support the impairment of heart rate variability in the time domain. 
A similar evidence level was found to support the impairment in baroreceptor 
sensitivity (BRS) and muscle sympathetic nerve activity (MSNA). Furthermore, 
this review identified physical activity level, muscle function and circadian rhythm 
were identified as the major influencing factors (strong evidence) of autonomic 
function in subjects with COPD. However, no definite conclusion could be reached 
for factors such as dyspnea, anxiety, body composition, pulmonary function, age, 
respiratory rate, ventilatory effort, quality of life and disease severity due to limited, 
conflicting or lack of existing evidence. The results of this review highlight 
relevant clinical messages for clinicians and other health-care providers regarding 
the role autonomic function can play as an important physiological marker for 
 prognostication and stratification. Hence, autonomic function outcomes should be 
identified and considered during management of patients with COPD. Moreover, 
this review can serve as basis for future research aimed at assessing the inter- 
ventions for autonomic function abnormalities in these patients. 
Keywords: Nervous system disease, autonomic, sympathetic, parasympathetic, chronic obstructive, 
pulmonary disease, review.
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Introduction
COPD is a highly prevalent cause of disability and mortality characterized by airflow 
limitation that is not fully reversible (1). Patients with COPD have features that 
encompass several body systems such as inflammation of the airways, cachexia or 
obesity, structural and functional changes in the respiratory and peripheral muscles, 
arrhythmias, fatigue, dyspnea, poor quality of life (QOL), reduced exercise capacity, 
depression, anxiety and sleep disturbances (1-8).
 More recently, COPD is reported to adversely affect the autonomic nervous 
system (2, 5, 6) Consequently, the autonomic function in patients with COPD has 
received a considerable amount of attention in literature (2-7, 9-11). The autonomic 
nervous system controls and regulates the internal physiology of the body and 
plays a very important role in the pathophysiology of COPD. It consists of 2 branches 
(sympathetic and parasympathetic), both of which exert antagonistic effects on most 
bodily functions and also contribute to homeostasis in the body (12). Moreover, 
the autonomic nervous system is also responsible for maintaining involuntary vital 
parameters like blood pressure, heart rate, respiration, gastro intestinal secretions 
and temperature control. 
 Autonomic function can be directly assessed by monitoring and testing certain 
specific markers of the neurophysiologic condition of the autonomic nervous system. 
These include parameters like heart rate variability in time and/or frequency domain 
analysis, baroreceptor sensitivity, muscle sympathetic nerve activity, and sympathetic 
skin response. The heart rate variability, which is the variability in time and/or 
frequency of successive R waves of the heartbeats, reflects the integration between 
the cardiovascular system and the mechanisms it regulates. Moreover, the heart 
rate variability has been recognized as a parameter for assessing autonomic function 
and quantifying sympathovagal balance for many decades (1, 13). Additionally, 
baro-receptor sensitivity (which reflects the short-term regulation of the cardio- 
vascular system), muscle sympathetic nerve activity (which shows the degree of 
sympathetic activity in muscle nerves) and sympathetic skin response (which 
reflects the sudomotor function of the unmyelinated sympathetic nerves) are 
reported to be reliable measures of autonomic function (14-16). 
 The available data in literature suggest that autonomic function parameters 
of patients with COPD may be severely impaired (17-20). Nevertheless, for a better 
understanding, a systematic evaluation of the existing literature is necessary. 
Also, there is a need to evaluate the factors associated with autonomic function 
in patients with COPD, because this has not been clearly elucidated in literature. 
Therefore, this systematic review evaluated (1) evaluate the evidence on the autonomic 





This systematic review is reported in accordance with the preferred reporting 
items for systematic reviews and meta-analyses (PRISMA) guidelines (21).
Eligibility criteria
To be included in this systematic review, studies had to report on either the 
autonomic function (outcomes) of patients with COPD (population) versus healthy 
participants (comparator) and/or the relationship between autonomic function 
and influencing factors. Only randomized control trials or patient control or 
cohort studies were retained. 
Information sources and search strategy 
To identify relevant articles, the databases of PubMed, Embase, and Web of Science 
were searched. Only articles published between January 2004 and May 2014 were 
included. The search strategy was based on a combination of the following key 
words: autonomic function OR autonomic dysfunction OR heart rate variability 
OR baroreceptor sensitivity OR muscle sympathetic nerve activity OR sympathetic 
skin response AND chronic obstructive pulmonary disease OR COPD. For the PubMed 
database, key words were also converted to possible MeSH terms. The search 
strategy for the Web of Science was done in the topic field using the key words 
autonomic function AND COPD. For the Embase database, the search terms were: 
autonomic AND function AND COPD. The search strategy for all databases was 
also filtered based on article type (clinical trial), language (English), and species 
(human). Additionally, a secondary search of the reference list of the included 
studies was undertaken to make the review as complete as possible.  
Study selection 
To be included in the review, the following inclusion criteria had to be fulfilled 
for each article. (1) Subjects had to be clinically diagnosed with COPD (explicitly 
stated). (2) The autonomic function parameters should comprise of at least one the 
following parameters for studies comparing subjects with COPD and healthy 
controls and/or reporting relationship between any of the parameters with 
influencing factors; (a) the heart rate variability in a time and/or frequency domain. 
The time domain may consist of (i) the square root of the mean of the sum of the 
squares of differences (RMSSD), (ii) RR interval (RRi), (iii) the SD of the averages of 
NN intervals in all 5-minute segments of the entire recording (SDANN), (iv) SDs of 
all NN intervals (SDNN), (v) the total number of differences between adjacent RRi 
above 50ms (sNN50), (vi) the percentage of RRi that differ from each other by 
>50 ms (vii) the ratio between the shortest RRi around the 15th beat and longest 
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RRi around the 30th beat (30:15 ratio), (viii) the difference in heart rate during 
inspiration and expiration (ΔIE), (ix) triangular interpolation of RRi, (x) the SD of 
instantaneous beat-to-beat variability (SD1), (xi) standard deviation in long term of 
the RRi (SD2) and (xii) the Valsalva ratio (the ratio of the longest RRi after release 
from the maneuver to the shortest RRi during the maneuver), (xiii) the ratio of the 
longest RRi during the 5 beats before lying down to the shortest RRi during 10 
beats after lying down (S/L ratio), (xiv) SD of RRi (SDRR), (xv)  the variability 
triangular index, (xvi) the average NN interval, and (xvii) the coefficient of 
variation of RRi (CVRR). The frequency (the density of beat-to-beat oscillation in 
the RRi) domain were recorded either in the high (0.15 - 0.4 Hz), low (0.04 - 0.15 Hz) 
and very low (0.00 – 0.04Hz) frequency bands, and may be described using parameters 
such as; (i) total power (TP), (ii) high frequency (HF), (iii) very low frequency (VLF), 
(iv) low frequency (LF) and (v) low-high frequency ratio (LF/HF). Additionally, 
the spectral components may be expressed as normalized units (nu), which is 
the absolute power/total power-VLF power × 100 (depicted as LFnu or HFnu); 
(b) the baroreceptor sensitivity expressed as ms/mm Hg; (c) the muscle sympathetic 
nerve activity expressed in burst frequency (burst/min) and/or burst incidence 
(burst/100 heartbeats); and (d) the sympathetic skin response expressed in terms 
of latency, area and amplitude in s, mV/s, and mV, respectively. (3) The article had 
to be published in English, and (4) it had to be a full-text original research report. 
 Initially, all search results were screened based on title and abstract. Thereafter, 
the full-text articles of studies that were considered potentially eligible and relevant 
were retrieved. All full-text articles were evaluated to ascertain whether they fulfilled 
the inclusion criteria. If an article did not fulfill all 4 criteria, it was excluded from 
the review.
Qualification of searchers
Literature was searched and screened by JM and PC (who has published systematic 
reviews) (12, 22-24).
Data items and collection 
Information extracted from each of the included studies are presented in Table 1. 
This table provides: (1) author and year, (2) sample size and characteristics of 
participants, (3) inclusion and exclusion criteria, (4) results of autonomic function 
parameter comparison with controls, and (5) results of influencing factors. 
Risk of bias in individual studies
To establish the validity of the selected articles, the risk of bias (methodological 
quality) in the articles was determined using specific checklists per design provided 
by the Dutch Cochrane Centre. The methodological quality was determined by 
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asking 7, 9 and 10 questions for the patients control, cohort and RCT studies, 
respectively, from the checklists as shown in Table 2. Methodological quality was 
assessed by 2 researchers (JM and HDS) who were not acquainted with each other’s 
evaluation at first. We scored each question as either + (for informative description of 
the issue and study meets the criterion), or - (the study does not meet the criterion). 
 After rating the selected articles, the results of both researchers were 
compared, and the differences were analyzed. In case of disagreement, the 
reviewers screened the manuscript a second time, and each point of differences 
were discussed. Both reviewers also had the opportunity to argue and to convince 
one another to obtain a consensus. When consensus could not be reached a third 
and final opinion was provided by PC. Each study received a total method score, 
which was the sum of all positive (+) ratings from the checklists questions. For 
uniformity across different designs, the overall method score was converted to 
percentages. A study was considered to be high quality if the methodological 
quality ≥60% and low-quality if the methodological quality was <60% (25).  
 The evidence listing for the outcomes were classified according to the methods 
used by Barker et al (25). The possible evidence levels are: strong, moderate, limited, 
conflicting evidence and no evidence. Strong evidence represents consistent 
findings in at least 2 high- quality studies. Moderate evidence connotes consistent 
findings in one high and one low quality study or at least 2 independent studies of 
low quality. Limited evidence suggests that only one study is available. Conflicting 
evidence connotes inconsistent findings in the available studies (5). 
 No evidence refers to when no study that reported any autonomic function 
outcomes was found. Additionally, findings were considered consistent only if at 
least 75% of the available studies reported the same conclusion for the outcome in 
question.
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A total of 154 studies were identified from the database and reference search. After 
the first and second screening 33 articles were included in the review for quality 
synthesis as shown in Figure1. 
Risk of bias and level of evidence 
The risk of bias and the level of evidence showed that, in most cases (263 out of 277 
items), the two researchers (JM and HDS) agreed in the quality assessment. After a 
second review, the researchers reached a consensus for 11 out of the14 items of 
which they initially disagreed. The remaining 3 questions were scored by PC. The 
evaluation criteria and final scores for the studies are presented in Table 2. After 
converting to percentages, 82% of the studies were scored as high methodological 
quality (i.e. > 60% from the checklist percent) because only 6 studies were of low 
methodological quality scores (10, 26-30).
Figure 1   Flow chart.
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Study characteristics and outcome measures 
The characteristics (study size, participants, inclusion criteria, autonomic function 
parameters and influencing factors) are presented in Table 1. Of the 20 studies that 
compared the autonomic function between patients with COPD and healthy 
controls, 15 studies reported heart rate variability as outcome, whereas 
baroreceptor sensitivity (10, 11, 19, 27, 31) and muscle sympathetic nerve activity 
(31-33) were the reported outcomes in 5 and 3 studies, respectively. Only one study 
assessed the sympathetic skin response (17). Accordingly, heart rate variability was 
expressed in ms or ms2, muscle sympathetic nerve activity was expressed as bursts/
min and/or bursts/100 heart beats, and baroreceptor sensitivity was expressed as 
ms/mmHg. Furthermore, an overview (trend) of the autonomic function outcomes 
for the and frequency domain heart rate variability, baroreceptor sensitivity and 
muscle sympathetic nerve activity of subjects with COPD in the included studies is 
illustrated in Figure 2.


































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Evidence for autonomic function in Subjects with COPD
Heart rate variability
Fifteen studies of high methodological quality investigated the differences in 
heart rate variability values between Subjects with COPD and healthy controls (3, 
10, 13, 19, 34-44). Most of these studies reported significantly lower heart rate 
variability in subjects with COPD. Specifically, the time domain parameters in 
most of the studies (12 of 15) showed that patients with COPD had lower heart rate 
variability compared to healthy controls. The studies reported that parameters 
such as  sNN50 (35), average NN interval (44), pNN50 (35, 44), SDANN (35), SDNN  (3, 
35, 38, 43, 44) SDNN index and RMSSD (3, 35, 38, 43, 44), RRi (19),  SD1(13, 43), SD2 
(13, 43), SD1/SD2(43) , triangular interpolation of RRi, and the variability of 
triangular index (13)wÿ,  were all reduced (or  negatively altered) in patients with 
COPD compared with healthy controls (p<0.05). Furthermore, other time domain 
values reported to be impaired in patients with COPD include SD of the RRi (34), 
coefficient of variation of RRi (34), Valsalva ratio (37, 42), 30:15 ratio (37), S/L ratio 
(42) and ΔIE (37). However, 3 studies reported comparable time-domain parameters 
between patients with COPD and healthy controls (36, 39, 41).
 The frequency domain values for heart rate variability showed more variation 
across the studies. Lower domain values were reported in some studies for LF (3, 34, 
36, 38, 39, 43, 44), HF (3, 34, 38, 43, 44) LF/HF ratio (39, 41), LFnu (39, 44) and TP (34, 
40, 44), whereas other investigators  reported comparable findings for the LF(10, 
41), HF (10, 36, 39, 41), LF/HF (34, 38, 40, 44), LFnu (10, 34, 38, 44) and HFnu in 
subjects with COPD compared with their healthy counterparts (10, 34, 38, 44). 
Additionally, higher values were reported in a few studies for LF (40), HF (40), LF/
HF(43) and HFnu (39) in subjects with COPD compared with healthy controls.
Based on the quality and level of evidence and the results from majority of the 
studies reviewed, there is a strong evidence to support impairment of time domain 
heart rate variability in subjects with COPD. For frequency domain heart rate 
variability, the evidence is inconsistent. 
Baroreceptor sensitivity
Five studies of low (10, 27) and high (11, 19, 31)  methodological qualities reported 
that baroreceptor sensitivity was significantly depressed among subjects with 
COPD in compared with healthy controls. Across all of the studies, the baroreceptor 
sensitivity of subjects with COPD ranged from 1.9 ± 2.92 to 8.9 ± 1.70 ms/mmHg, 
whereas that of the healthy control ranged from 6.2 ± 2.26 to 14.3 ± 2.00 ms/mmHg. 
Raupach et al (31) reported that baroreceptor sensitivity among subjects with mild 
COPD was significantly lower compared to control (5.0+0.60 vs 9.3 ± 1.10 ms/
mmHg). Similarly, significantly lower values were also reported for subjects with 
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different stages (moderate to severe) of COPD in studies by Costes et al (10) (2.7 ± 
1.50 vs 7.8 ±  4.90 ms/mmHg; p<0.01), Bartels et al (11) (1.9 ± 2.92 vs 6.2 ± 2.26 ms/
mmHg; p<0.01), and Haidar et al (19) (6.2 ± 1.05 vs. 10.7± 1.65 ms/ mmHg; p=0.03). 
Another study on subjects with mild COPD also showed baroreceptor sensitivity 
depression compared to healthy age-matched controls (8.9 ± 1.70 vs 14.3 ± 2.00  ms/
mmHg) (27). Based on the quality and level of evidence, there is a strong evidence 
to support baroreceptor sensitivity depression in subjects with COPD. 
Muscle sympathetic nerve activity
Three studies of high methodological qualities compared the muscle sympathetic 
nerve activity between subjects with COPD and healthy controls, and all concluded 
that muscle sympathetic nerve activity was impaired in subjects with COPD 
(31-33). The values in bursts/100 heartbeats ranged between 55 ± 4.7 to 86.9 ± 2.0 for 
COPD and 33 ± 6.0 to 49 ± 6.0 for healthy controls, respectively. In one study, 
subjects with COPD were reported to present with significantly elevated muscle 
sympathetic nerve activity compared to the healthy controls (burst frequency of 
62 ± 2.0 vs 29 ± 3.0 bursts/min, which  corresponds to a burst incidence of 86 ± 2.0 
vs 49 ± 6.0 bursts/100 heartbeats) (32). Furthermore, similar findings were reported 
in 2 other studies that reported baseline muscle sympathetic nerve activity to be 
significantly elevated among patients with COPD compared to healthy controls 
(p<0.05) (31, 33). Based on the quality and level of evidence, there is a strong 
evidence to support elevation of muscle sympathetic nerve activity in subjects 
with COPD.
Sympathetic skin response
Only one study of high methodological quality reported the sympathetic skin 
response of subjects with COPD (17). The outcome demonstrated that the 
sympathetic skin response was impaired in subjects with COPD compared with 
healthy controls. The evidence supporting the impairment of the sympathetic skin 
response in subject with COPD is limited
Factors influencing autonomic function in subjects 
with COPD
Disease severity (stage), duration and acute exacerbation
Four studies of low (26, 29)  and high (37, 45) methodological quality evaluated the 
influence of disease severity on autonomic function in subjects with COPD. Two of 
the studies concluded that disease severity had a significant effect on the autonomic 
function (26, 37). Chabbra and De (37) revealed that autonomic neuropathy was 
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observed more often in subjects with moderate and severe COPD compared to 
patients with mild COPD (p<0.05). Antonelli Incalzi et al (26) also reported 
significant correlations between LF/HFnu ratio with the indices of disease severity. 
Conversely, the other 2 studies reported that disease severity did not influence AF. 
Tug et al (45) found no significant difference between mild and moderate-severe 
COPD groups either for the isolated parasympathetic, sympathetic or mixed form 
(p>0.05). Similarly, Ramos et al (29) reported that different stages of COPD (Global 
Initiative for Chronic Obstructive Lung Disease [GOLD] stages I-III) had no influence 
on RMSSD. 
 Two studies (17, 45) of high methodological quality assessed the influence of 
disease duration on autonomic function in subjects with COPD, and both studies 
concluded that it had none (p>0.05). Furthermore, one study with high 
methodological quality indicated that COPD exacerbation was associated with a 
significant increase in LF, HF, LF/HF and TP (p<0.05) compared with  subjects with 
stable COPD and/or healthy controls (40).
 The evidence supporting the effect of disease severity on autonomic function 
is inconsistent. However, there is a strong evidence to support that disease duration 
has no influence on autonomic function, and there is limited evidence to support 
that exacerbation influences autonomic function in subjects with COPD. 
Pulmonary function and respiratory parameters
Eight studies of low(10, 26) and high (1, 17, 19, 34, 37, 41)  methodological qualities 
reported a relationship between spirometric indices (FEV1, percent-of-predicted 
FEV1, FEV1/FVC ratio) and autonomic function in subjects with COPD. Three of 
these studies reported that there were no significant correlations between 
pulmonary function variables and autonomic function (1, 10, 34). In contrast, the 
remaining 5 studies reported significant correlations between the lung function 
variables and autonomic function parameters (17, 19, 26, 37, 41). Weak correlations 
were found between percent-of-predicted FEV1 and Valsalva ratio (0.39) (37) and 
30:15 ratio (r=0.31) (37), between FEV1 and LF/HF (r=0.34) (41) and LF/HFnu (r=0.32) 
(26), and also between baroreceptor sensitivity and FEV1/FVC (r=0.38)(19). Haidar et 
al (19) reported a more moderate correlation between baroreceptor sensitivity and 
FEV1 (r=0.46; p<0.01) and also between RRi and FEV1 (r=0.56; p<0.01) and FEV1/FVC 
(r=0.53; p<0.01). Similarly, Bir et al (17) revealed a moderately strong relationship 
was between FEV1/FVC and latency (r=-0.468), amplitude (r=0.408) and area 
(r=0.401), as well as between %FEV1/FVC and latency (r=-0.640), amplitude (r=0.523) 
and area (r=0.519) (p<0.05). 
 Only one study with a low methodological quality reported the influence of 
respiratory rate on the autonomic function in subjects with COPD (28). The study 
results showed that both LF and HF were significantly correlated with breathing 
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frequency (r=-0.76; r=-0.70, respectively) and ventilatory effort(r=-0.52; r=-0.49, 
respectively) in subjects with COPD. 
 Seven studies of low (10, 26, 30) and high (17, 34, 37, 45) methodological 
qualities investigated the relationship between arterial blood gas parameters 
(PaO2, PaCO2, pH, SaO2) and autonomic function parameters in subjects with 
COPD. Most of these studies demonstrated that arterial blood gas parameters did 
not significantly correlate with autonomic function. Tug et al (45)  reported that 
both PaO2 and PaCO2 did not significantly correlate with SSR and RRi (p>0.05). 
Antonelli Incalzi et al (26) also reported that there was no significant correlation 
between PaO2 and LF/HFnu (except for a weak but significant relationship with 
PaCO2 at night time; r = -0.29). Furthermore, no significant relationship was 
reported between skin sympathetic response and PaCO2, PaO2 , O2 saturation and 
pH values (17), between baroreceptor sensitivity and  PaO2 (10), and between HRV 
(tri index, pNN50 and HF) and PaCO2, PaO2 and pH (37). However, 2 studies of high 
methodological quality reported significant correlations between PaO2 and HFnu 
(r =  -0.60)(34), LFnu (r = 0.44) (34) , LF/HF ratio (r=0.37) (34), Valsalva ratio (r = 0.27) 
(37) and 30:15 (r= 0.29)(37). Moreover, significant correlations were reported 
between alveolar volume transfer factor (TLCO2) and 30:15(r = 0.36) (37), and also 
between mean pulmonary artery pressure and Valsalva ratio (r = -0.33) (37). 
 Two studies assessed the influence of dyspnea on autonomic function in 
subjects with COPD. One study (high methodological quality) significant 
relationship between all the domains of dyspnea and RMSSD (-0.45 < r <-0.48; 
p<0.05) (2). However, the other study (low methodological quality) was unable to 
demonstrate any significant correlation between dyspnea and LF/HFnu ratio 
(p>0.05) (26). Based on the quality and level of evidence of the studies, the evidence 
supporting the influence of pulmonary function, arterial blood gas and dyspnea 
on autonomic function in subjects with COPD is inconsistent.  
Physical activity, physical fitness and body composition
Five studies of low (26) and high (1, 2, 8, 45)  methodological quality reported the 
relationship between autonomic function and physical activity, physical fitness 
and exercise capacity level in subjects with COPD. Camillo et al (2008) (1) concluded 
that total daily energy expenditure, daily energy expenditure in activities 
requiring >3 metabolic equivalents, number of steps per day and time spent daily 
in activities demanding >3 metabolic equivalents significantly affected the SDNN 
index (0.36 < r < 0.60; p < 0.05). The energy expenditure also correlated with SDNN 
index (r = 0.60; p = 0.003) and the LF/HF ratio (r = 0.36; p<0.05). Furthermore, they 
found also significant correlations between RRi and time spent walking (r = 0.46) 
and standing (r = 0.41), and between SDNN index and total score of activities of 
daily living (r = -0.44). 
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van Gestel et al (8) reported that there was a significant correlation between mean 
NN intervals and 6- min walk distance (r= 0.43) and physical activity levels (r=0.42). 
However, no correlation was reported between mean NN intervals and peak 
oxygen uptake and maximal workload (p>0.05). Similarly, the time spent walking 
per day was significantly correlated with heart rate variability (r=0.47; p < 0.05) (2). 
In another study, loss of activities of daily living was significantly correlated with 
LF/HFnu ratio (r=-0.41; p=0.003), in addition to a weak relationship that was 
reported between the functional status and LF/HFnu analysis over 24 h (r = 0.29) 
and in the daytime (r = 0.29) (45). Conversely,  a study of low methodological quality 
reported that there was no significant relationship between exercise capacity and 
LF/HFnu ratio in patients with COPD (26). 
 The influence of muscle force and muscle strength on the autonomic function in 
COPD was reported in 3 studies with high methodological quality (1, 2, 36). SDNN 
significantly correlated with biceps brachii (r=0.61) (2) and triceps brachii (r=0.56) 
muscle force (2), and the quadriceps and triceps muscle force also correlated with 
SDNN and LF/HF (0.37 > r < 0.44, p <0.05) in another study (1). Furthermore, inspiratory 
muscle weakness was also significantly associated with ΔIE (r = 0.60) (36).  
 Only one study reported on the relationship between body composition and 
autonomic function (1). The results revealed that there was a significant 
relationship between body mass index and SDNN (r=0.44) and RRi (r = 0.37) and 
also between fat-free mass and SDNN (r = 0.49) and LF/HF (r = 0.40). However, no 
significant correlation was reported between heart rate variability and total fat 
mass (p > 0.05). Based on the quality and level of evidence of the studies, there is 
strong evidence to support the influence of physical activity level and muscle 
function (force and strength) on autonomic function in subjects with COPD, but 
only a limited evidence to support the influence of body composition. 
Socio-demographic variables
Four studies of high methodological quality reported on the relationship between 
QOL and autonomic function (1, 2, 5, 44). The results showed inconsistent findings. 
Significant relationships were reported between QOL and RMSSD (r = 0.34, P= 
0.012) (5), SDNN (r=5.4, P =0.02), RRi (r=-0.38, P <0.05) and HF (r = 0.35, P = 0.01) (5), 
and LF/HF ratio (r= -0.40, P <0.05) (5). However, in 2 studies, there were no significant 
correlations (p>0.05) between QOL and several heart rate variability parameters (1, 
2). In a similar trend, the relationship between age and autonomic function in 
subjects with COPD was reported in 3 studies with high methodological quality 
(32, 41, 45). In one of the studies, the results indicated that there was a significant 
correlation between age and LF/HF ratio (r=-317; p=0.044) (41), whereas the other 2 
studies reported that age was not significantly associated with LF/HFnu values 
(p>0.05)(32) and autonomic function (p>0.05) (45). 
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The influence of cigarette smoking on autonomic function in COPD patients was 
investigated in 3 studies with low (27) and high (1) (45), methodological quality. 
Despite this, no correlation was found between smoking and RMSSD (1), baroreceptor 
sensitivity  (27), skin sympathetic response (45) and RRi (45). Also, one study of high 
methodological quality reported on the influence of anxiety on autonomic function 
revealed that anxious subjects with COPD had impaired SDNN and HF values 
compared to non-anxious subjects (p<0.05) (6). Based on the quality and level of 
evidence of the studies, the evidence supporting the influence of QOL and age on 
autonomic function is inconsistent. Furthermore, there is a strong evidence to 
support that smoking does not influence autonomic function, and limited evidence 
to support the influence of anxiety on autonomic function in subjects with COPD.
Time of day (circadian rhythm)
Four studies with low (26) and high (4, 41, 46) methodological quality  reported on 
the influence of circadian rhythm on autonomic function in subjects with COPD. 
The results from Bedard et al (41) showed that patients with COPD  have a reduced 
LF/HF ratios (median and interquartile range) compared with healthy controls 
during daytime (2.6 [1.5–3.8] vs. 3.5 [2.9–5.6]), nighttime (1.8 [1.1–4.3] vs. 4.2 [2.7–6.9]) 
as well as during the entire 24-hour (1.9 [1.5–3.4] vs. 3.9 [3.2–5.6]) recordings (p< 
0.005). In another study, SDNN (p= 0.021) and SDANN (P = 0.02) values measured at 
night time were significantly higher compared with daytime values in subjects 
with COPD (46). Similarly, time-dependent fluctuations in HRV parameters were 
reported among patients with COPD, which were significantly reduced during 
morning periods compared to night periods (p<0.001) (4). Antonelli Incalzi et al 
(26) also reported that patients with COPD showed fluctuations in VLF during 24-h 
and daytime periods, and also lower LFnu, higher HFnu and lower LF/HFnu during 
the daytime period compared to night time (all,  P<0.05). Based on the quality and 
level of evidence of the studies, there is strong evidence to support that circadian 
rhythm influences the autonomic function in subjects with COPD. 
Discussion
The objective of this systematic review was to determine the level of evidence for 
the autonomic function and its influencing factors in subjects with COPD. This 
was the first attempt to provide concise information and a systematic review 
evidence on autonomic function in subjects with COPD. Our review included 33 
studies comprising about 1, 000 subjects with COPD. Additionally, the results of 
this review provided a more global representation of the several parameters that 
make up autonomic function in these studies.
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The results of this review showed that the heart rate variability time-domain 
parameters were significantly lowered among patients with COPD in most of the 
studies. In general, it would appear that this reduction in heart rate variability 
timing may be an indication of a problem with time-series of normal RRi in 
subjects with COPD. This may also imply that these subjects have a lower autonomic 
activity level when compared with healthy controls. Consequently, the time 
domain could readily serve as a yardstick for ascertaining autonomic function. 
Moreover, time-domain indices of heart rate variability have been reported to be of 
independent prognostic significance (47).
 On the other hand, frequency-domain heart rate variability parameters 
revealed a more conflicting outcome. The results ranged from lower to comparable 
and even higher values for LF, HF, LFnu, HFnu, LF/HF and TP variables in subjects 
with COPD compared with healthy controls. Consequently, evidence supporting 
impaired frequency domain parameters could not be ascertained. The results 
obtained with the frequency-domain parameters tend to suggest, for these 
variations and inconsistencies, that they are random and may not provide the best 
measure for stratification. However, there appears to be a preponderance of lower 
LF presentations in subjects with COPD. This may be an indication of sympathetic 
tone dominance, as earlier reported in chronic diseases that are closely linked 
with cardiovascular death (48, 49). Therefore, in view of our results, time domain 
analyses may provide a better interpretation and prognostic value compared to 
frequency domain for patients with COPD. Moreover, Lanza et al (50) demonstrated 
that there is a strong association between low time-domain heart rate variability 
and mortality. They further stated that little data are available regarding the 
prognostic value of frequency-domain heart rate variability analysis.
 In this review, we also found strong evidence in support of baroreceptor 
sensitivity depression in subjects with COPD. The baroreflex mechanism plays a 
key role in cardiovascular function, especially in the short-term regulation of 
blood pressure during normal and pathological conditions (51, 52).  The possible 
contributors to the depression in for baroreceptor sensitivity include intra-thoracic 
pressure changes, hypoxia and oxidative stress (5). Moreover, these are regular 
features of COPD. Therefore, it is not surprising that for baroreceptor sensitivity 
was impaired even in subjects with mild COPD (10, 19, 27). Our review has shown 
that even during the early stages of COPD, baroreceptor sensitivity is impaired. 
Hence, it can be utilized as a reliable marker by clinicians who are presented with 
patients with COPD for a more comprehensive intervention. 
 The results from 3 studies showed that muscle sympathetic nerve activity was 
considerably higher (reflection of increased sympathetic excitation) in subjects 
with COPD compared with their healthy counterparts (31-33). Furthermore, like 
baroreceptor sensitivity, muscle sympathetic nerve activity is significantly 
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associated with some features of COPD such as decreased oxygen concentration, 
impairment in BRS (through the inhibitory afferent systems), high oxidative stress 
and systemic inflammation (5, 53-55). Moreover, our review also found elevated 
muscle sympathetic nerve activity in normoxic subjects and subjects with mild 
COPD (5). 
 Generally, this review has shown that heart rate variability was impaired 
mainly in the time-domain parameters in subjects with COPD. Similarly, the same 
outcome was found for baroreceptor sensitivity and muscle sympathetic nerve 
activity, thereby enhancing the inference that can be drawn from our results. Our 
review also found that fewer studies have reported variables (baroreceptor 
sensitivity and muscle sympathetic nerve activity) other than the heart rate 
variability (see Figure 2). Moreover, only one study reported on the sympathetic 
skin response parameter (17). However, it is very likely that sympathetic skin 
response is impaired in patients with COPD, despite the limited evidence. Unlike 
heart rate variability, baroreceptor sensitivity and muscle sympathetic nerve 
activity, sympathetic skin response assesses the sudomotor function of 
unmyelinated sympathetic fibers through electromyography. It is non-invasive, 
requires less equipment, and can be easily be performed (less expertise) (56, 57), 
and it may provide an alternative to assess autonomic function (sympathetic).  This 
review has shown that a strong level evidence in support of autonomic function 
impairment in patients with COPD. Subsequent research can focus on providing 
evidence for intervention modes for enhancing autonomic function in these 
population.  
 This review also focused on the influencing factors of autonomic function in 
subjects with COPD. For these, we categorized the influencing factors from the 
studies into 5 groups: disease severity features, pulmonary function and respiratory 
parameters, physical activity and body composition, socio-demographic variables 
and circadian rhythm. This categorization made analyzing the evidence easier. 
The results suggests that the physical activity level (energy expenditure, duration 
of activities of daily living , duration of walking/day, and number of steps taken/
day) is the major factor that may be useful in enhancing autonomic function 
(heart rate variability). Additionally, this may be a useful intervention strategy due 
to the high level of deconditioning that is a common feature in these patients. 
Moreover, physical activity is known to modulate the autonomic nervous system 
(10, 58). A similar level of evidence was also reported in support of the positive 
association of muscle function and autonomic function. However, further studies 
are needed to help to determine the optimal mode for incorporating these 
parameters as key components of COPD rehabilitation. 
 The results from the studies in our review showed strong evidence that 
cigarette smoking does not influence autonomic function in subjects with COPD. 
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This finding is at variance with earlier reports that have linked smoking with 
reductions in the baseline levels of vagal-cardiac nerve activity through its effect 
on the arterial baroreceptor-cardiac reflex response and increasing sympathetic 
activity through arterial pressure reductions (59).  Moreover, smoking is one of the 
major causes of COPD, and most patients with COPD are required to stop smoking. 
The evidence for other socio-demographic circumstances was mostly conflicting, 
limited or non-existence. For example, inconsistent evidence was reported for age 
and QOL. No explicit reason could be deduced except for the normal physiological 
aging process because subjects with COPD are generally older (60-62). Our review 
did not find any study that reported on the influence factors such as sleep quality, 
fatigue, depression and sex. Hence, further studies are needed to explore the 
potential links between these variables and autonomic function in subjects with 
COPD. 
 In most of the studies, the use of medication that can influence the autonomic 
function in patients with COPD such as systemic sympathomimetic drugs, calcium 
channel blockers, beta (β) blockers, other cardiac medications, caffeine/tea, 
smoking and alcohol, were suspended before and/or during autonomic function 
assessment. However, in some studies the patients were not stopped from using 
their regular medications such as anticholinergic, β2-agonists, corticosteroids, 
aminophylline and bronchodilators (4, 11, 27, 32, 36, 38, 40). Still, in other studies, 
medication use was completely withdrawn for a period of between 6-24 h before 
autonomic function assessment (17, 29, 34, 39). Nevertheless, these variations in 
medication use are not likely going to affect our result since none of the studies 
included medications that could have had any significant effect on the autonomic 
nervous system. We also noticed also noticed differences in the heart rate 
variability assessment across the studies. The differences were mostly in terms of 
number of RRi points utilized in the heart rate variability analysis. In some studies, 
a detailed description of the setting was given, while in others, this was not the 
case. On a general note, however, the analyses were reliable to draw conclusions 
for both time- and frequency domain heart rate variability analysis because all of 
the procedures were standardized and reproducible. For baroreceptor sensitivity 
assessment, a more uniform procedure was also observed across the studies. Elec-
trocardiogram monitoring was done in a rested and recumbent position, systolic 
blood pressure was continuously measured using cuff technique, and the limb 
lead with the greatest R waves was used for assessment (10, 11, 27). The muscle 
sympathetic nerve activity assessment also utilized the same modalities and 
protocol (31-33). 
 The results of our review had some demographic variations. Slightly more 
than half of the participants (except for 3 studies that did not provide information 
on the sex (10, 28, 30)) were males (524 of 100). Moreover, COPD is traditionally 
115
AUTONOMIC FUNCTION AND ITS INFLUENCING FACTORS IN SUBJECTS WITH COPD: A SYSTEMATIC REVIEW
3
known to be higher in males compared to females (63). Also, few studies subjects 
who were not clinically stable and/or free from comorbidities that may have had 
an effect on the autonomic function. Moreover, the subjects also presented with 
diverse COPD disease stages in the studies. However, the checklist that was used to 
grade the study quality took these points into consideration. Additionally, the 
majority of the studies included mainly patients with moderate COPD; only a few 
included subjects with mild (10, 19, 27), severe (1, 2, 28, 40, 46) and a mixed stage 
(5, 13, 17, 29, 37) COPD. Consequently, our results could be a global reflection of the 
general autonomic function trend in subjects with COPD. 
 The major limitation of this review is the general lack of blinding across the 
studies, perhaps due to the technical and cumbersome nature of assessing 
autonomic function in a laboratory setting. However, we use a standardized 
methodological quality rating approach (>60% for high quality), which showed 
that most of the studies had high scores, thus providing a firm base for our results. 
In addition, a few of the studies had low sample sizes. Also, the quality assessment 
criteria used in arriving at the results in this review did not take the sample size 
of the studies into account. However, the results of the heart rate variability 
parameters are likely to be reliable because of the large number of studies (some 
with large sample sizes) that were reviewed. For muscle sympathetic nerve activity 
and baroreceptor sensitivity, the sample sizes were relatively smaller. However, 
this this would not likely change the results due to the feasibility of recording a 
larger sample because the study procedures are not only technical, but also 
invasive, as in the case of muscle sympathetic nerve activity. 
 The findings of this systematic review are important to clinicians and other 
health-care providers given the high evidence backing our conclusion and the 
more concise information we presented. Moreover, this review has highlighted 
specific and important physiological markers that should be taken into 
consideration for prognostication, stratification and management of patients with 
COPD. Additionally, our review can serve as a basis for future studies and reviews 
that will provide information on the effect of various intervention modes on 
autonomic function in these patients. 
Conclusion
There is a strong level evidence supports the impairment of autonomic function 
parameters in subjects with COPD. A similar evidence level also suggests that 
physical activity level, muscle function and circadian rhythm significantly 
influence autonomic function and may play a role in autonomic function 




[1] Camillo CA, Pitta F, Possani HV, Barbosa MV, Marques DS, Cavalheri V, et al. Heart rate variability and 
disease characteristics in patients with COPD. Lung. 2008;186(6):393-401.
[2] Camillo CA, Laburu Vde M, Goncalves NS, Cavalheri V, Tomasi FP, Hernandes NA, et al. Improvement 
of heart rate variability after exercise training and its predictors in COPD. Respir Med. 2011;105(7):1054-62.
[3] Carvalho TD, Pastre CM, de Godoy MF, Fereira C, Pitta FO, de Abreu LC, et al. Fractal correlation 
property of heart rate variability in chronic obstructive pulmonary disease. Int J Chron Obstruct 
Pulmon Dis. 2011;6:23-8.
[4] Lewis MJ, Annandale J, Lewis KE. Influence of long-term oxygen therapy on heart rate and QT 
time-series in hypoxic patients with chronic obstructive pulmonary disease. Clin Physiol and Funct 
Imaging. 2009;29(6):431-9.
[5] van Gestel AJR, Kohler M, Steier J, Teschler S, Russi EW, Teschler H. Cardiac autonomic dysfunction 
and health-related quality of life in patients with chronic obstructive pulmonary disease. Respirology. 
2011;16(6):939-46.
[6] Suh S, Ellis RJ, Sollers JJ, Thayer JF, Yang HC, Emery CF. The effect of anxiety on heart rate variability, 
depression, and sleep in Chronic Obstructive Pulmonary Disease. J Psychosomatic Res. 2013;74(5):407-13.
[7] Ricci-Vitor AL, Bonfim R, Fosco LC, Bertolini GN, Ramos EM, Ramos D, et al. Influence of the resistance 
training on heart rate variability, functional capacity and muscle strength in the chronic obstructive 
pulmonary disease. Eur J Phys Rehabil Med. 2013;49(6):793-801.
[8] van Gestel AJR, Kohler M, Steier J, Teschler S, Russi EW, Teschler H. The Effects of Controlled Breathing 
during Pulmonary Rehabilitation in Patients with COPD. Respiration. 2012;83(2):115-24.
[9] Borghi-Silva A, Mendes RG, Trimer R, Oliveira CR, Fregonezi GA, Resqueti VR, et al. Potential effect of 
6 vs 12-weeks of physical training on cardiac autonomic function and exercise capacity in chronic 
obstructive pulmonary disease. Eur J Phys Rehabil Med. 2014.
[10] Costes F, Roche F, Pichot V, Vergnon JM, Garet M, Barthelemy J-C. Influence of exercise training on 
cardiac baroreflex sensitivity in patients with COPD. Eur Respir J. 2004;23(3):396-401.
[11] Bartels MN, Gates GJ, Downey JA, Armstrong HF, De Meersman RE. Baroreceptor sensitivity after Valsalva 
maneuver in women with chronic obstructive pulmonary disease. Clin Auton Res. 2012;22(4):185-9.
[12] Meeus M, Goubert D, De Backer F, Struyf F, Hermans L, Coppieters I, et al. Heart rate variability in 
patients with fibromyalgia and patients with chronic fatigue syndrome: A systematic review. Sem in 
Arthr and Rheum. 2013;43(2):279-87.
[13] Dias de Carvalho T, Marcelo Pastre C, Claudino Rossi R, de Abreu LC, Valenti VE, Marques Vanderlei 
LC. Geometric index of heart rate variability in chronic obstructive pulmonary disease. Revista 
Portuguesa de Pneumologia (English Edition). 2011;17(6):260-5.
[14] Pagani M, Montano N, Porta A, Malliani A, Abboud FM, Birkett C, et al. Relationship between spectral 
components of cardiovascular variabilities and direct measures of muscle sympathetic nerve activity 
in humans. Circulation. 1997;95(6):1441-8.
[15] Shahani BT, Halperin JJ, Boulu P, Cohen J. Sympathetic skin response--a method of assessing 
unmyelinated axon dysfunction in peripheral neuropathies. J Neurol Neurosurg Psy. 1984;47(5):536-42.
[16] Robinson TG, Dawson SL, Eames PJ, Panerai RB, Potter JF. Cardiac baroreceptor sensitivity predicts 
long-term outcome after acute ischemic stroke. Stroke. 2003;34(3):705-12.
[17] Bir LS, Ozkurt S, Daloglu G, Kurt T. Impaired sympathetic skin response in chronic obstructive 
pulmonary disease. Tohoku J Exp Med. 2005;207(4):243-8.
[18] van Gestel AJR, Steier J. Autonomic dysfunction in patients with chronic obstructive pulmonary 
disease (COPD). J Thoracic Dis. 2010;2(4):215-22.
[19] Haider T, Casucci G, Linser T, Faulhaber M, Gatterer H, Ott G, et al. Interval hypoxic training improves 
autonomic cardiovascular and respiratory control in patients with mild chronic obstructive 
pulmonary disease. J Hypertens. 2009;27(8):1648-54.
[20] Marquis K, Maltais F, Lacasse Y, Licourciere Y, Fortin C, Poirier P. Effects of aerobic exercise training 
and irbesartan on blood pressure and heart rate variability in patients with chronic obstructive 
pulmonary disease. Can Respir J. 2008;15(7):355-60.
117
AUTONOMIC FUNCTION AND ITS INFLUENCING FACTORS IN SUBJECTS WITH COPD: A SYSTEMATIC REVIEW
3
[21] Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. The PRISMA statement 
for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: 
explanation and elaboration. PLoS Med. 2009;6(7):e1000100.
[22] Vandenplas G, De Bacquer D, Calders P, Fiers T, Kaufman J-M, Ouwens DM, et al. Endogenous oestradiol 
and cardiovascular disease in healthy men: a systematic review and meta-analysis of prospective 
studies. Heart. 2012;98(20):1478-82.
[23] Molenaers G, Calders P, Vanderstraeten G, Himpens E, Van den Broeck P, Christine. The Evidence-base 
for Conceptual Approaches and Additional Therapies Targeting Lower Limb Function in Children 
with Cerebral Palsy: A Systematic Review Using the International Classification of Functioning, 
Disability and Health as a Framework. J Rehab Med. 2012;44(5):396-405.
[24] Himpens E, Van den Broeck C, Oostra A, Calders P, Vanhaesebrouck P. Prevalence, type, distribution, 
and severity of cerebral palsy in relation to gestational age: a meta-analytic review. Developmental 
Med & Child Neurol. 2008;50(5):334-40.
[25] Bakker EW, Verhagen AP, van Trijffel E, Lucas C, Koes BW. Spinal mechanical load as a risk factor for 
low back pain: a systematic review of prospective cohort studies. Spine. 2009;34(8):E281-E93.
[26] Antonelli Incalzi R, Corsonello A, Trojano L, Pedone C, Acanfora D, Spada A, et al. Heart rate variability 
and drawing impairment in hypoxemic COPD. Brain and Cognition. 2009;70(1):163-70.
[27] Bernardi L, Casucci G, Haider T, Brandstatter E, Pocecco E, Ehrenbourg I, et al. Autonomic and cerebro-
vascular abnormalities in mild COPD are worsened by chronic smoking. Eur Respir J. 2008;32(6):1458-65.
[28] Chang E-T, Silberstein D, Rambod M, Porszasz J, Casaburi R. Heart rate variability during constant 
work rate exercise at and above the critical power in patients with severe chronic obstructive 
pulmonary disease. Tzu Chi Med J. 2011;23(2):42-5.
[29] Ramos E, Vanderlei L, Ramos D, Teixeira L, Pitta F, Veloso M. Influence of pursed-lip breathing on heart 
rate variability and cardiorespiratory parameters in subjects with chronic obstructive pulmonary 
disease (COPD). Brazilian J Phys Ther. 2009;13:288-93.
[30] Yazici M, Uzun Kra, Ulgen M, Teke T, Maden E, Kayrak M, et al. The acute effect of bi-level positive 
airway pressure on heart rate variability in chronic obstructive pulmonary disease patients with 
hypercapnic respiratory failure. Anadolu kardiyoloji dergisi. 2008;8(6):426-30.
[31] Raupach T, Bahr F, Herrmann P, Luethje L, Heusser K, Hasenfuss G, et al. Slow breathing reduces sym-
pathoexcitation in COPD. Eur Respir J. 2008;32(2):387-92.
[32] Fatouleh R, Macefield VG. Respiratory modulation of muscle sympathetic nerve activity is not increased 
in essential hypertension or chronic obstructive pulmonary disease. J Physiol. 2011;589(Pt 20):4997-5006.
[33] Raupach T, Bahr F, Herrmann P, Luthje L, Hasenfuss G, Andreas S. Inspiratory resistive loading does 
not increase sympathetic tone in COPD. Respir Med. 2010;104(1):107-13.
[34] Chen WL, Chen GY, Kuo CD. Hypoxemia and autonomic nervous dysfunction in patients with chronic 
obstructive pulmonary disease. Respir Med. 2006;100(9):1547-53.
[35] Gunduz H, Talay F, Arinc H, Ozyildirim S, Akdemir R, Yolcu M, et al. Heart rate variability and heart 
rate turbulence in patients with chronic obstructive pulmonary disease. Cardiol J. 2009;16(6):553-9.
[36] Reis MS, Arena R, Deus AP, Simoes RP, Catai AM, Borghi-Silva A. Deep breathing heart rate variability 
is associated with respiratory muscle weakness in patients with chronic obstructive pulmonary 
disease. Clinics (Sao Paulo). 2010;65(4):369-75.
[37] Chhabra SK, De S. Cardiovascular autonomic neuropathy in chronic obstructive pulmonary disease. 
Respir Med. 2005;99(1):126-33.
[38] Reis MS, Deus AP, Simoes RP, Aniceto IA, Catai AM, Borghi-Silva A. Autonomic control of heart rate in 
patients with chronic cardiorespiratory disease and in healthy participants at rest and during a 
respiratory sinus arrhythmia maneuver. Rev Bras Fisioter. 2010;14(2):106-13.
[39] Borghi-Silva A, Reis MS, Mendes RG, Pantoni CBF, Simões RP, Martins LEB, et al. Noninvasive 
ventilation acutely modifies heart rate variability in chronic obstructive pulmonary disease patients. 
Respir Med. 2008;102(8):1117-23.
[40] Zamarrón C, Lado MJ, Teijeiro T, Morete E, Vila XA, Lamas PF. Heart rate variability in patients with 




[41] Bédard M-E, Marquis K, Poirier P, Provencher S. Reduced Heart Rate Variability in Patients with 
Chronic Obstructive Pulmonary Disease Independent of Anticholinergic or β-agonist Medications. 
COPD. 2010;7(6):391-7.
[42] Aggarwa l S, Meena A, Kaur N, Bachhal R, Sidhu RS. Atonomic nervous system changes in chronic 
obstructive pulmonary disease (Copd) patients. J Clin and Diagnostic Res. 2011;5(8):1533-6.
[43] Rossi RC, Vanderlei FM, Bernardo AF, Souza NM, Goncalves AC, Ramos EM, et al. Effect of pursed-lip 
breathing in patients with COPD: Linear and nonlinear analysis of cardiac autonomic modulation. 
COPD. 2014;11(1):39-45.
[44] Zupanic E, Zivanovic I, Kalisnik JM, Avbelj V, Lainscak M. The Effect of 4-week Rehabilitation on Heart 
Rate Variability and QTc Interval in Patients with Chronic Obstructive Pulmonary Disease. COPD. 
2014;11(6):659-69.
[45] Tug T, Terzi SM, Yoldas TK. Relationship between the frequency of autonomic dysfunction and the 
severity of chronic obstructive pulmonary disease. Acta Neurol Scand. 2005;112(3):183-8.
[46] Sin DD, Wong E, Mayers I, Lien DC, Feeny D, Cheung H, et al. Effects of nocturnal noninvasive mechanical 
ventilation on heart rate variability of patients with advanced COPD. Chest. 2007;131(1):156-63.
[47] Zuanetti G, Neilson JM, Latini R, Santoro E, Maggioni AP, Ewing DJ. Prognostic significance of heart rate 
variability in post–myocardial infarction patients in the fibrinolytic era. Circulation. 1996;94(3):432-6.
[48] Pal G, Pal C, Adithan P, Ananthanarayanan P, Pal N, Nanda T, et al. Sympathovagal Imbalance 
Contributes to Prehypertension Status and Cardiovascular Risks Attributed by Insulin Resistance, 
Inflammation, Dyslipidemia and Oxidative Stress in First Degree Relatives of Type 2 Diabetics. PLoS 
ONE. 2013;8(11):e78072.
[49] Huikuri H, Huikuri T, Mäkikallio KEJ, Airaksinen R, Mitrani A, Castellanos R, et al. Measurement of 
heart rate variability: a clinical tool or a research toy? J Am Col of Cardiol. 1999;34(7):1878-83.
[50] Lanza GA, Guido V, Galeazzi MM, Mustilli M, Natali R, Ierardi C, et al. Prognostic role of heart rate 
variability in patients with a recent acute myocardial infarction. Am J Cardiol. 1998;82(11):1323-8.
[51] Tank J, Diedrich A, Szczech E, Luft F, Jordan J. Baroreflex regulation of heart rate and sympathetic 
vasomotor tone in women and men. Hypertension. 2005;45(6):1159-64.
[52] Gmitrov J. Static Magnetic Field Effect on Cardiovascular Regulation: A Review. British J Med and 
Medical Res. 2014;4(8):1612.
[53] Bernardi L, Porta C, Spicuzza L, Bellwon J, Spadacini G, Frey A, et al. Slow breathing increases arterial 
baroreflex sensitivity in patients with chronic heart failure. Circulation. 2002;105(2):143-5.
[54] Gerritsen J, Dekker JM, TenVoorde BJ, Kostense PJ, Heine RJ, Bouter LM, et al. Impaired autonomic 
function is associated with increased mortality, especially in subjects with diabetes, hypertension, or 
a history of cardiovascular disease: the Hoorn Study. Diabetes Care. 2001;24(10):1793-8.
[55] Charkoudian N, Charkoudian J, Rabbitts. Sympathetic Neural Mechanisms in Human Cardiovascular 
Health and Disease. Mayo Clinic Proceedings. 2009;84(9):822-30.
[56] Vetrugno RM, Liguori RM, Cortelli PM, Montagna PM. Sympathetic skin response. Clin Autonom Res. 
2003;13(4):256-70.
[57] Gutrecht JA. Sympathetic Skin Response. Journal of Clinical Neurophysiology. 1994;11(5).
[58] Nagai N, Nagai T, Moritani. Effect of physical activity on autonomic nervous system function in lean 
and obese children. Int J of Obesity. 2003;28(1):27-33.
[59] Niedermaier ON, Smith ML, Beightol LA, Zukowska Grojec Z, Goldstein DS, Eckberg DL. Influence of 
cigarette smoking on human autonomic function. Circulation. 1993;88(2):562-71.
[60] O’Brien IA, O’Hare P, Corrall RJ. Heart rate variability in healthy subjects: effect of age and the 
derivation of normal ranges for tests of autonomic function. British heart journal. 1986;55(4):348-54.
[61] Liao D, Liao R, Barnes L, Chambless R, Simpson P, Sorlie G, et al. Age, race, and sex differences in 
autonomic cardiac function measured by spectral analysis of heart rate variability—The ARIC study. 
Am J Cardiol. 1995;76(12):906-12.
[62] van Durme YM, Verhamme KM, Stijnen T, van Rooij FJ, Van Pottelberge GR, Hofman A, et al. 
Prevalence, incidence, and lifetime risk for the development of COPD in the elderly: the Rotterdam 
study. Chest. 2009;135(2):368-77.
[63] Mannino DM, Buist AS. Global burden of COPD: risk factors, prevalence, and future trends. The 
Lancet.370(9589):765-73.
119
AUTONOMIC FUNCTION AND ITS INFLUENCING FACTORS IN SUBJECTS WITH COPD: A SYSTEMATIC REVIEW
3






chronic obstructive pulmonary disease

Chapter 4
Autonomic symptoms in 
patients with moderate and severe 
chronic obstructive pulmonary disease
Jibril Mohammed,1,2 Eric Derom,3 Inge De Wandele,4 Lies Rombaut,4  
and Patrick Calders1
1 Department of Rehabilitation Sciences Physiotherapy, Ghent University, Ghent, Belgium
2 Department of Physiotherapy, Bayero University Kano, Kano State, Nigeria
3 Department of Internal Medicine, Ghent University- Ghent University Hospital, Ghent, Belgium
4 Center for Medical Genetics, Ghent University- Ghent University Hospital, Ghent, Belgium
2017 (Article in Press) 
Impact Factor= 0.62




Objectives: A synoptic description of the autonomic symptoms profile (ASP) of 
patients with COPD is not available. Therefore, we aimed to provide an overview of 
autonomic symptoms and its associates in COPD. 
Methods: We evaluated 89 subjects with COPD (65±7.3 years; 66 males; GOLD II-IV) 
with an equal number of age and sex matched control subjects by means of the 
composite autonomic symptom score (COMPASS-31) questionnaire, which assesses 
autonomic symptoms across six domains (orthostatic intolerance, vasomotor, secreto - 
motor, gastrointestinal, urinary and pupillomotor). Lung function, medication use, 
and health status variables (quality of life: physical/mental component summary 
[PCS/MCS], fatigue, anxiety, depression & dyspnea levels) were also assessed. 
Results: Compared to controls, all subjects with COPD reported significantly 
higher orthostatic intolerance, secretomotor and total autonomic symptom scores 
(p<.05). Additionally, subjects with moderate COPD also reported significantly 
higher scores for vasomotor, gastrointestinal, urinary and pupillomotor symptoms 
compared to controls (p<.05). Nevertheless, these symptoms were comparable 
between the moderate and severe COPD sub-groups (p>.05). The COPD subjects had 
poorer health status compared to controls as exhibited by significantly higher 
scores for depression, anxiety, fatigue and dyspnea, and lower scores for PCS and 
MCS (p<.05). These health status variables were mildly associated with autonomic 
symptoms (0.214≤ r ≥0.421; p<.05), but not with demographic and lung function 
(p>.05). The MCS was the only significant predictor of total autonomic symptoms 
score in COPD (p=0.001; beta=-0.430). 
Conclusion: Autonomic symptoms are present in all domains of the COMPASS-31 
in COPD, irrespective of disease severity and demographic variables. Autonomic 
symptoms in COPD were mainly influenced by poor mental health.
Keywords: Autonomic nervous system, chronic obstructive, pulmonary disease, symptoms, 
health status
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Introduction
Cardiovascular and autonomic nervous system (ANS) abnormalities have been 
reported in patients with COPD (1-3). Previous studies that have focused on the 
ANS abnormalities in COPD have highlighted profound impairments of autonomic 
function indices. Some of these indices include heart rate variability (3, 4), heart 
rate recovery following exercise testing (5), baroreceptor reflex sensitivity (4, 6), 
sympathetic skin response (4, 7) and muscle sympathetic nerve activity (4, 8).The 
results from these studies also indicated that these impairments, mostly in the 
form of increased sympathetic tone/activity, are important factors contributing to 
the morbidity and mortality rates in patients with COPD.  
 The ANS is an important system in the assessment and treatment of a number 
of pathophysiological conditions involving the cardiovascular system (9), and for 
identifying problems in the cardiac autonomic control (10). Assessing autonomic 
symptoms is a simple and easy means of assessing signs of ANS dysfunction (11). 
Since autonomic symptoms occur in events of sympathovagal imbalance or 
hormonal disturbances (12), it is utilized as a valuable means of clinical evaluation. 
The autonomic symptoms can be categorized into more pure physical symptoms 
and into more mixed psychosomatic symptoms. A few examples of autonomic 
symptoms that are indicative of ANS abnormalities include deficiency in sweating, 
tear formation and salivation, orthostatic intolerance, poor pupil reflex, gastro-
intestinal complaints, poor sexual and bladder function, and cardiac rhythm 
disturbances (13). 
 The prevalence of autonomic symptoms has been reported in several chronic 
diseases (13-16). Autonomic symptom severity is also associated with frequently 
occurring COPD comorbidities like depression, anxiety, dyspnea, cognitive 
dysfunction, psychiatric complications and sleep disturbances (17-20). However, a 
comprehensive and synoptic evaluation of autonomic symptoms is not available 
for patients with COPD. The information in the literature regarding autonomic 
symptoms for  patients with COPD are sparse and often limited to specific 
symptoms such as problems with gastro-intestinal (21, 22) orthostatic (22, 23), 
visual(23) and urinary(22, 23) functioning. A comprehensive assessment of 
autonomic symptoms in a large COPD cohort is necessary to provide relevant and 
easy means of understanding the extent of ANS affectation from the symptomatic 
point of view among patients with COPD. 
Therefore, the main objective of the present study is to examine the autonomic 
symptoms profile in COPD based on disease severity (GOLD classification) in 
comparison to age-matched controls. A secondary objective of this study is to 






Eighty-nine subjects with COPD (predicted FEV1 <70%; GOLD II-IV) who attended 
the Department of Respiratory Medicine of Ghent University Hospital between 
April, 2015 and December, 2016 participated in this study. A list of potential 
participants who fulfilled the following criteria was retrieved from the hospital 
database; (i) have a stable condition (no recent exacerbation or hospitalization 
within the last 3 months), (ii) have no chronic co-morbidities such as chronic heart 
diseases, hormonal dysfunction that can significantly impair the ANS like hyper- 
or hypothyroidism and/or mental disorders, and (iii) hove no history of any recent 
major surgical operation. The eligible subjects were thereafter contacted to 
participate in the study either during scheduled hospital visitations or by post. 
 A healthy control group consisting mainly of persons without a diagnosis of 
COPD, or who have no known systemic medical condition that can significantly 
impair the ANS such as chronic heart diseases, congenital disorders and hormonal 
dysfunction, were also recruited. The control group participants were matched by 
age and sex (ratio 1:1). The age matching was done using a three age-bracket 
classification method (50-60 years; 61-70 years; and above 70 years). The control 
group participants were contacted via personal contacts, social media and/or by 
post.
 All participants had to understand and speak the Dutch language. A study 
information form and a consent form was also made available to the participants 
along with the study instruments. The study was reviewed and approved by the 




Characteristics of the participants such as age, sex, civil state, educational 
attainment, occupational status, smoking history, alcohol use, weight and height 
were collected using a general questionnaire. 
Autonomic symptom profile 
Autonomic symptoms were assessed using the composite autonomic symptoms 
score (COMPAS-31). The COMPASS-31 is the shortest and the most recent 
questionnaire for assessing autonomic symptoms profile (ASP). The psychometric 
properties of the questionnaire have been previously established (16, 24). 
The COMPASS delineates the severity, distribution and frequency of autonomic 
symptoms, and it also evaluates the autonomous capacity across six domains; 
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pupillomotor function. An electronic version of the COMPASS-31 (in Dutch) is 
available via https://goo.gl/forms/0MUSGANc1J8lFVtH2. In the end, each domain 
has an assigned weight factor that is based on a predetermined formula. Upon 
analyses, a possible minimal score of 0 (best) to 100 (worst), indicating more 
autonomic symptoms, was reached for each participant. 
Pulmonary function
The pulmonary function tests of patients with COPD were collected from the 
hospital records of the participating COPD patients. These parameters included 
forced expiratory volume in first second (FEV1), forced vital capacity (FVC), peak 
expiratory flow (PEF) and the Tiffeneau index (FEV1/FVC). The parameters were 
utilized in grading the disease severity in COPD.  Mild (FEV1/FVC < 70% but FEV1 
≥ 80% predicted), moderate (30% ≤ FEV1 < 80% predicted) and severe (FEV1<30% 
predicted) GOLD stages served as the means for classifying the disease severity in 
subjects with COPD in this study (25). 
Health status 
Four different instruments, also validated in Dutch language, were used to 
ascertain the general health status of the patients with COPD. These instruments 
Figure 1   Flowchart of the recruitment process of study participants.
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were the hospital anxiety and depression scale (HADS), checklist individual 
strength (CIS), the medical research council dyspnea scale and the short form 
36 (SF-36). The score from each instrument was converted to percentage scores 
for the purpose of analyses (0-100). 
- HADS: The HADS is an instrument consisting of 14 items, which comprises 
depression and anxiety sub-scales (7 items each). The HADS is a widely used 
instrument with good psychometric properties(26). Each question item is scored 
using a scale of 0–3 to achieve a minimum score of 0 and a maximum score of 
21 points for the sub-scales (anxiety & depression). Higher scores are interpreted 
as indicating more depressive or anxiety symptoms.
- CIS: The CIS scale is an instrument used to measure the subjective fatigue and 
behavior related to fatigue of an individual over the last two-week period. 
The questionnaire comprises 20 questions on a 7-point likert scale (27). On the 
CIS, a higher score indicates worsened symptoms or more feelings of fatigue.
- MRC dyspnea scale: The medical research council (MRC) dyspnea scale has been 
proven to be useful in assessing disability in COPD (28). This is a 5-item scale that 
is used for measuring perceived respiratory distress. The question items were 
graded from “1 - 5”. Higher scores here indicated worsened perceived level of 
respiratory distress.
- SF-36: The SF-36 questionnaire assesses quality of life of the individuals. 
The questionnaire comprises 36 questions structured across eight different 
domains. The domains are reported in two components, physical and mental 
components summaries. The physical component summary (PCS) comprises 
four domains namely, general health, physical functioning, limitation due to 
physical health and body pain, whereas the mental component summary (MCS) 
comprises the domains of vitality (energy/fatigue), emotional wellbeing, 
limitation due to emotional health and social functioning domains (29). 
The questionnaire is reported in a scale of 0 to 100. Lower the scores in either 
the PCS or MCS indicates lower quality of life.
Medication use 
The participants were asked about their medication use. Information regarding 
brand or generic name, dosage and intake frequency of medication were collected 
using a tabular form. Grouping of medications was subsequently carried out based 
on the pharmaceutical compendium. 
Statistics
 Statistical analysis was performed using Social Packages Social Sciences version_22 
(SPSS Inc., Chicago, IL, USA). Normality of the data was evaluated using Shapiro-Wilk 
test and also by manual inspection of histograms and QQ plots.. Demographic and 
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other clinical characteristics were summarized using descriptive statistics. 
Differences in the study variables between moderate and severe COPD and the 
control group participants were compared using Chi square test for categorical 
variables, and independent samples t-test  for normally distributed continuous 
variables. On the other hand, Mann-Whitney U and/or Kruskal-Wallis H non- 
parametric tests were performed to analyze differences in variables that were not 
normally distributed. Spearman rho correlation coefficient was utilized to assess 
correlations between variables. A multiple stepwise regression analyses was 
performed to identify predictors of autonomic symptoms from the study variables. 
Significance was set at P<0,05.
Results
General characteristics
Table 1 summarizes the general characteristics of the participants. Overall, the 
patients with COPD were similar to the control participants with respect to weight, 
BMI and civil state (p> 0.05). Subjects with COPD presented with significantly 
higher prevalent rates of comorbidities/risk factors such as diabetes mellitus and 
gastrointestinal complaints, arthritis and headaches compared to the control 
group participants. Hypercholesterolemia was more prevalent among the control 
group participants (21 vs 12%). The healthy control group participants had a 
significantly higher educational attainment qualification, and a significant 
proportion of them were employed fulltime.
Autonomic symptoms profile scores
The participants in our study reported autonomic symptoms across all the domains 
assessed. Significant differences were seen across the autonomic symptoms 
domain scores for subjects with COPD (moderate and severe) as well as the control 
group participants (p<0.05). Specifically, orthostatic intolerance domain symptoms 
score was significantly higher for the moderate (7.0±9.44) and severe COPD 
(7.3±11.42) subjects compared to controls (2.3±6.38). Similarly, the secretomotor 
domain symptoms score was significantly higher for moderate (4.6±3.37) and 
severe COPD (4.2±3.17) compared to that of the control subjects (1.5±2.01). The 
results further showed that only subjects in the moderate severity COPD subgroup 
reported significantly higher vasomotor (0.5 vs 0.18), gastrointestinal (4.65 vs 2.92) 
, urinary (1.28 vs 0.8) and pupillomotor (1.46 vs 1.09) domain symptoms score 
compared to the control group(p<0.05). The results for the total autonomic 
symptoms score also indicated that both moderate (19.5±13.66) and severe 
(17.7±15.58) COPD subjects reported significantly higher scores compared to the 
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Height (cm) 168.7±7.75 172.8±9.37 0.002 a
Weight (kg) 75.1±17.84 76.9±12.99 0.457 a
BMI (kg/m2) 26.4±6.02 25.7±3.39 0.321 a
Educational attainment 
Elementary school










































High blood pressure 
Diabetes mellitus 
High cholesterol














FEV1 (% FEV1 predicted)
FVC (% FVC predicted)
Tiffeneau index 









Notes: Data are expressed as mean ± standard deviation for continuous variables and as absolute 
frequency and percentages for categorical variables. 
Key: cm, centimeter; kg, kilogram, m, meters; n, number; FEV1, forced expiratory volume in first second; 
FVC, forced vital capacity; PEF, peak expiratory flow rate; %, percent; BMI, body mass index, GI, gastro-
intestinal. Tiffeneau index=  FEV1/FVC.
*Significance level for comparison between COPD and control groups. 
a   Students t-test for independent samples: comparison of continuous variables between COPD and control. 
b   Chi square test: comparison of categorical variables between COPD and control group participants.
133
AUTONOMIC SYMPTOMS IN PATIENTS WITH MODERATE AND SEVERE COPD
4
subjects in the control group (8.7±9.91) as illustrated in figure 2. Additionally, no 
significant differences were found in the autonomic symptoms domain scores 
between the moderate and severe COPD group (p> 0.05). 
Health status of patients with COPD
As illustrated in Figure 3, subjects with COPD reported significantly lower quality 
of life scores based on the PCS and MCS outcomes compared to the control group 
(p<0.05). Higher values in the rates of fatigue, anxiety, depression and dyspnea 
were recorded in COPD compared to the control group(p<0.05). No differences 
were found in the values of these variables between the moderate and severe COPD 
subgroups (p>0.05), except for the dyspnea scores, which  was significant higher 
among the severe COPD subgroup(p<0.05). 
Figure 2   Line graph showing the distribution of autonomic symptoms  
(domain scores and total ASP score).
Notes: *= Significant difference between both COPD stages and the control group (Kruskal-Wallis); 
# = significant difference between moderate COPD and control group (Mann-Whitney U); p, significant at 
0.05 alpha probability level.
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Correlation between autonomic symptoms and health status   
The correlation matrix (Table 2) generated from the results of the Spearman rho 
correlation coefficient analyses showed that the demographic (age, height & 
weight) and lung functions variables did not significantly correlate with autonomic 
symptom scores (p> 0.05). Only the parameters the comprising the health status 
(anxiety, depression, fatigue, and the physical & mental health) scores indicated a 
mild to moderate correlation with autonomic symptoms scores (p< 0.05).  
Multiple regression analyses
The multiple regression (stepwise) analyses revealed that only the MCS (mental 
health) score was a significant covariate (predictor) of total autonomic symptoms 
score in patients with COPD (p =0.000; beta = -.430;  adjusted R2 = .175). Here, for every 
unit increase in the MCS score, the total autonomic symptoms burden is reduced 
by 0.4 unit (Figure 4). All other variables entered into the stepwise regression 
model did not show any potential significant influence (p>0.05).   
Figure 3   Health status of the participants using various parameters.
Notes: PCS, physical component summary; MCS, mental component summary; CIS, checklist individual 
strength, MRC, medical research council dyspnea scale; *= significant differences between COPD and 
control group (Kruskal-Wallis H  test); # = significant differences between COPD stages (Mann-Whitney 
U);  p, significant at 0.05 alpha probability level.
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Medication use
The majority of patients with COPD (94.3%) and a significant proportion of the 
control subjects (24.6%) reported using various medications. Table 3 shows the 
breakdown of the medication use. Subjects with COPD reported a significantly higher 
use of pulmonary, cardiovascular, gastro intestinal, analgesic/anti-inflammatory, 
neuropsychiatric, antibiotic, diabetic mellitus, antidepressants and lipid lowering 
medications compared to the control groups subjects (p<0.05). Within the COPD 
group, those with sever COPD reported  significantly higher intake of inhaled 
 corticosteroids and significantly less intake of cardiovascular diabetic, gastro 
intestinal  medications(p<0.05).  None of the control group subjects reported using 
any pulmonary medications.
Table 2   Correlation matrix of the autonomic symptoms and other variables  




















Anxiety 0.253 0.406 0.214 0.361
Depression 0.223 0.347 0.231 0.334
Fatigue 0.313 0.304 0.279 0.379
PCS - 0.244 - 0.265 - 0.292 - 0.351
MCS - 0.298 - 0.228 - 0.332 - 0.307 - 0.421
Notes: Only significance correlation (r) values levels are shown in the matrix (p< .05). PCS, physical 
component score on SF-36; MCS, mental component score on SF-36; BMI, body mass index; FEV1, forced 




This study aimed to examine the profile of autonomic symptoms among patients 
with COPD. Our results indicated that autonomic symptoms were significantly higher 
in subjects with COPD compared to the control group participants. In general, 
autonomic symptoms were more prevalent in the orthostatic intolerance and 
secretomotor function domains in subjects with COPD. Additionally, higher symptoms 
were also recorded for autonomic symptoms relating to the gastrointestinal and 
vasomotor domains in the moderate COPD subgroup in comparison with control. 
Subjects with COPD also reported higher levels of anxiety, depression, fatigue 
symptoms as well as the lower quality of life (physical and mental component 
summary) scores compared to the control group, indicating poorer health status. 
Despite matching the participants by age and gender to eliminate potential 
baseline differences, slight demographic differences were still observed (Table 1). 
 A major finding of our study that is was the high rate of orthostatic intolerance 
and secretomotor symptoms reported in subjects with COPD. This finding is 
supported by an earlier report, which describes both orthostatic intolerance and 
Figure 4   Regression (correlation) coefficient between the MCS and the total 
autonomic symptoms scores.
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secretomotor disorders as the best predictors of autonomic failure in both healthy 
and diseased populations (11). This finding is clinically important for a few reasons; 
orthostatic intolerance is linked to sudden tachycardia and cerebral vasoconstriction 
(30) and orthostatic intolerance symptoms is a major clinical test that is capable of 
ascertaining symptoms of cerebral hypo-perfusion (following an upright position) 
that is secondary to inadequate hemodynamic regulation by the ANS  (13, 31, 32). 
It is not surprising that subjects with COPD in our study reported high rates of 
orthostatic symptoms. Orthostatic intolerance can appear in many forms such as 
fatigue, diminished concentration, a feeling of absence, brain fog, chest pain, 
shortness of breath, palpitations, coat-hanger headache, and vision disturbances 
(31). Moreover, COPD patients who have shortness of breath due to reduced 
ventilatory capacity, hypercapnia and/or lowered oxygen saturation have been 
reported to be at more risks of orthostatic symptoms compared to those without 
these symptoms (33). 
 Our results also showed a significant presence of a possible secretomotor 
disorder in COPD. The COMPASS-31 questionnaire used in this study assessed 
secretomotor domain function using questions centered around tear formation, 
salivary gland secretion and sweating. In general, secretomotor disorders also 
include conditions that are characteristic of thermoregulatory dysfunction that 
include heat intolerance, impaired body sweating and dryness of the eyes and 
mouth (13, 34). Problems with the secretomotor function are important to patients 
because of its correlation with quality of life and perceived mental health status 
(35). By the way, the COPD subjects in this study did not only report a significantly 
higher secretomotor symptoms compared to controls, but these symptoms were 
also associated with the levels of anxiety, depression, fatigue and mental health, 
suggesting a negative influence of health status on the ANS. The presence of 
secretomotor symptoms in COPD may explain the results of poor performance in 
sympathetic skin response, a measure of sudomotor function (36) and acetylcholine 
sweat test (7, 37) among patients with COPD in earlier reports. However, further 
studies are needed to prove this.  
 Only the moderate COPD group in our study reported higher rates of 
vasomotor, gastrointestinal urinary and pupillomotor symptoms compared to the 
control group participants. Although rather unexpected, nevertheless, we can 
attribute this present finding to the relatively low number of participants that 
make up the severe COPD sub-group. It is likely that a future similar survey with 
larger sample sizes of severe COPD cohort will report similar findings. For the 
gastro intestinal symptoms reported, there is also a possibility that the high rate 
of gastrointestinal medications use might have influenced these results. Moreover, 
both COPD groups reported a significantly higher use of gastrointestinal medication. 
The link between autonomic symptoms and the presence of ANS (in both para-
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Table 3  Profile of the medication use reported by the study participants.










Reported medication use 22(24.6%)  63(95.4%) 21 (91.3%)
Analgesic/anti-
inflammatory drugs 
(paracetamol, NSAIDs & 
opiates)
0(0%) 8(12.1%) 1(4.3%) 0.003*
0.353
Antibiotics 0(0%) 12(18.2%) 7(30.4%) 0.001*
0.269
Anticoagulants 6(6.7%) 34(51.5%) 5(21.7%) 0.001*
0.003#








(ACE inhibitors, beta 
blockers, calcium channel 
blockers, diuretics & anti-
arrhythmic)
















laxatives & proton pump 
inhibitors)





15(16.9%) 25(37.9%) 4(17.4%) 0.008*
0.051
Other Medications
 (calcium supplements, 
vitamins, hormone 
therapy, cancer [prostate] 
therapy & uric acid)
3(3.4%) 21(33.8%) 9(39.1%) 0.001*
0.526
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sympathetic and sympathetic branches)) disorders may have been recently 
explained (22). Here, the having parasympathetic nervous system disorder was 
reported to be linked with the prevalence of secretomotor, bladder and gastroin-
testinal symptoms. On the other hand, sympathetic involvement was identified as 
a major variable for reported orthostatic symptoms, impaired sweating and 
vasomotor dysfunction. To further elaborate on this result, our next study will be 
to investigate the correlations between autonomic symptoms and objective 
autonomic function tests such as autonomic reactivity tests in COPD. 
 Another interesting finding from this study was that the components that 
make up the health status (anxiety, depression, fatigue, physical & mental health) 
of subjects with COPD significantly correlated with autonomic symptoms. It is 
equally surprising that demographic variables and lung functions did not correlate 
with autonomic symptoms in COPD.  It can only mean that these findings 
represents the importance of patient subjective outcomes (38). Moreover, previous 
studies have linked subjective symptoms with several patient important health 
outcomes with clinical implication (17-20). For example, the COPD patients in this 
study also exhibited high rate of depression as earlier observed other similar 
studies (39). 
Table 3  Continued.













0(0%) 63(95.5%) 21(91.3%) 0.001*
0.943
Mucolytic(s) and nasal 
decongestants 
0(0%) 19(28.8%) 8(34.8%) 0.001*
0.296
LABA+LAMA+ICS, ICS 0(0%) 12(18.2%) 9(39.1%) 0.001*
0.016#
Notes: P, significant at 0.05 alpha probability level, *= significant difference between both COPD and 
control groups derived from Kruskal-Wallis H test, # = significant difference between only the 
moderate and severe COPD groups based on Mann-Whitney U test. n= number, %=percentages and 
frequency of drugs comparison is based upon groups (moderate & severe COPD) and for those who 
reported medication use, GOLD= global initiative for obstructive lung disease, SSRI= selective 
serotonin reuptake inhibitor, NSAIDS= non-steroidal anti-inflammatory drugs, ACE= angiotensin 
converting enzyme. SABA= Short acting beta agonists, LABA= long acting beta agonists, SAMA = short 




A significant medication use was recorded in our study. It is also very plausible that 
the reported medication use had influence on the autonomic symptoms reported 
in the results of this study. Even though no statistical analyses were carried out to 
reveal if any relationship exist between medication use and autonomic symptoms 
in this study, the presence of significant variation in the pattern and profile of 
medication use between COPD and control group subjects (Table 3), is suggestive 
of a potential medication influence on the autonomic symptoms. A recent review 
attributed significant increases in the sympathetic nervous activity and heart 
rate activity, as well as poor heart rate variability in COPD patients to the use of 
 sympathomimetic drugs (40). Although there are differences in the reported 
medication use (especially vasoactive drugs) between the moderate and severe 
COPD and also between COPD and controls, we cannot explain at present whether 
this had any effect on the autonomic symptoms profile (Figure 2). Moreover, a few 
studies have even suggested the COPD medication does not significantly contribute 
to the impairments in autonomic function (7, 36, 40).   
 Our results must be viewed within the limitations of the study. Using a 
self-report method for symptom and health status questioning may not provide a 
real prevalence of symptoms since symptoms that are not intensely present or 
frequently experienced by the patient may not have been reported. However, we 
are convinced that this method accurately identifies patient important health 
outcomes, hence, a significant treatment goal. Another limitation of this study is 
the cross-sectional design. Follow-up studies may be warranted in order to 
accurately evaluate the course of autonomic symptom in these patients. 
 The present study also recorded a few areas of strengths. Firstly, this is the 
first study to focus on autonomic symptoms in COPD, and to assess the impact of 
those symptoms by evaluating the relationship with measures of quality of life 
and mood. Secondly, our study also recorded a response rate of about 59.7% of the 
population that was contacted for the survey. Therefore, the findings from 
specifically, our study sample adequately represents the autonomic profile of 
patients with moderate and severe COPD. Lastly, our results only presented a 
profile of autonomic symptoms in COPD. More studies are still needed in order to 
provide better clinical awareness and proper identification of the underlying 
mechanisms of the autonomic symptoms, and its evolution in COPD. 
Conclusion
This study demonstrates that patients with moderate and severe COPD have 
autonomic symptoms in the orthostatic, secretomotor, vasomotor, gastrointesti-
nal urinary and pupillomotor systems that is independent of COPD severity. The 
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presence of these symptoms was somewhat associated with high levels of 
depression, anxiety, fatigue and poor quality of life in COPD. Our study also 
revealed that only mental health status considerably influences the total autonomic 
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Patients with chronic obstructive pulmonary disease (COPD) show impairments in 
the autonomic nervous systems (ANS) function, which is responsible for cardiac 
autonomic regulation. This study assessed the autonomic function and cardio-vagal 
reactivity in conveniently sampled subjects with COPD participating in a pulmonary 
rehabilitation (PR) program.  26 subjects with COPD and 22 age and gender matched 
control subjects were evaluated. R-R intervals were collected at rest in supine 
position. Thereafter, resting autonomic function parameters comprising linear and 
nonlinear analyses of heart rate variability (HRV) and baroreceptor sensitivity (BRS) 
were calculated. Autonomic reactivity tests comprising deep breathing (DB), 
Valsalva maneuver (VM) and head up tilt (HUT) were also performed. The results of 
this study indicated that resting autonomic function variables were generally 
reduced in COPD compared to controls. However, this difference was only statistically 
significant for a few HRV parameters: mean RR intervals, low frequency (LF), 
standard deviation of dispersion of points perpendicular to the line-of-identity 
(SD1) and approximate entropy (ApEn) (p<0.05). The results also indicated that all 
cardio-vagal indices following the autonomic reactivity tests were comparable 
between COPD and controls (p>0.05). It was concluded that subtle autonomic 
impairments exist in physically active COPD patients, and these autonomic 
function deficits were mainly recognized by resting HRV indices and not autonomic 
reactivity tests.    
Keywords: autonomic reactivity, chronic obstructive, pulmonary disease, autonomic function, 
physically active, COPD.
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Introduction
Chronic obstructive pulmonary disease (COPD) is a pulmonary disease mainly 
characterized by airflow limitation in the lungs and also multi-systemic 
manifestations on a number of extra-pulmonary systems especially the cardio- 
vascular and autonomic nervous systems (ANS) (1-3). These manifestations are 
associated with COPD comorbidities, most of which contribute to poor 
prognosis, risks of arrhythmias, and COPD related mortality rates (1, 4). Specifically, 
patients with COPD present with functional alterations and dysfunction of the 
cardiac autonomic modulation, which is primarily reflected in the form of an 
elevation in the resting heart rate and/or reduction in heart rate variability (HRV) 
indices (2, 3, 5).
 Therefore, the assessment of various ANS parameters have been the focal point 
in understanding the autonomic function, and its clinical implications in COPD (3). 
Current reports have also shown that ANS parameters (physiological biomarkers) 
such as heart rate variability (HRV) (1, 6, 7), heart rate response (HRR) to exercise (1), 
muscle sympathetic nerve activity (MSNA) and baroreceptor sensitivity (BRS) (8) are 
significantly impaired in patients with COPD. The HRV in particular is an autonomic 
function parameter that represents a powerful research tool for quantifying the 
state of the ANS, with reliable clinical applications (9). Moreover, autonomic 
function parameters are utilized for calculating the sympathetic tone, vagal 
modulation of the sinus node and the sympatho-vagal balance with a view to 
optimizing treatment (10). A number of limitations have been observed in the 
existing studies over the years. For example, in our recent systematic review, we 
found that most of the available studies often do not take into account variables 
such as  differences in disease stage (global obstructive lung disease [GOLD] criteria) 
or presence of variable COPD comorbidities and no evidence exist for a number of 
autonomic function variables (11). Additionally, autonomic function has been 
found to be influenced by several factors such as circadian rhythm (12), clinical and 
even demographic variables and physical activity status (11). 
 Furthermore, several important autonomic function parameters like the 
nonlinear HRV analyses (including entropy changes), which has recently become 
more useful in assessing the ANS function remain under-reported in patients with 
COPD (2, 13-15). Specifically, the nonlinear HRV values have the capacity to reflect 
important nonlinear heart dynamics or patterns in the ECG data. Moreover, no 
systematic evidence is presently available to support a severely impaired nonlinear 
HRV indices in COPD (11). Additionally, conflicting results have been reported 
among different subgroups of COPD. Cardiac autonomic control is a complex 
mechanism that require careful interpretation and application in clinical settings 
(4). Nevertheless, since autonomic function is widely reported in COPD, it is largely 
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assumed to be impaired in these patients. We hypothesize that there will be a 
diminished or impaired ANS function (e.g. lower LF or impaired baroreflex 
activation) among a subgroup of individuals with COPD who are physically active 
and fairly homogenous. Furthermore, the use of the widely used autonomic 
reactivity tests (comprising validated test battery for assessing autonomic failure) of 
cardio-vagal autonomic function indices has been inadequately reported for 
patients with COPD (16).
 To address these gaps, this study was conducted to evaluate both parameters of 
resting autonomic function and cardio-vagal responses to validated autonomic 
reactivity tests among non-sedentary individuals with COPD.
Methods
Subjects
The population of this study comprised twenty-six patients with severe COPD (23 
males & 3 females; %predictedFEV1 of 39.5%) aged between 50 and 80 years. 
All COPD subjects were non-sedentary, and this was defined as participating in a 
pulmonary rehabilitation (PR) program continuously for at least two months. COPD 
subjects fulfilling the following inclusion criteria were eligible for participation in 
the study: (i) a stable condition (no acute exacerbation or change in therapeutic 
treatment plan in the past three months), (ii) no severe co-morbidity such as chronic 
heart diseases, uncontrolled diabetes mellitus, neurological problems, cancer, 
mental disorder and complex cardiac arrhythmias, and (iii) no recent surgery 
(<6 months). 
 A control group comprising 22 age and sex- matched healthy individuals (19 
males and 3 females) without COPD or any other chronic disease was recruited 
from the general population. The participants in the control group were screen 
using the Baecke physical activity questionnaire (17), and only those with a 
moderate or high physical activity level participated in the study.    
 All participants signed an informed consent form prior to commencement of 
study measurements. The research protocol was approved by the ethical committee 
of Ghent University Hospital. 
Procedure
The measurements were conducted in a room with constant temperature between 
21-23° Celsius. All measurements were carried out in the morning hours between 8 
and 11 am to avoid the influence of circadian rhythm. The participants were also 
instructed to refrain from coffee and nicotine use prior to the test moment on the 
scheduled day. Prior to the measurements, the participants were questioned 
149
AUTONOMIC FUNCTION AND REACTIVITY TESTS IN COPD
5
regrading age, gender, smoking status, alcohol use was measured, and their body 
mass index (BMI) was also calculated. Information regarding medical history, and 
medication use of subjects with COPD was retrieved from their hospital based 
medical records. The ECG and beat-to-beat blood pressure recordings were 
conducted via 3-lead electrodes (placed on the chest) and bicep/finger (plethysmog-
raphy) cuffs attached to  a Finometer PRO® ECG machine (Finapres Medical Systems, 
The Netherlands). The finger volume pulse waveform measured by Finometer device 
has been recently confirmed to be a reliable source for analysis of HRV (18).
Autonomic function tests  
Data acquisition and analysis
The data files were retrieved from the Finometer PRO machine. The files were then 
transformed into a readable (Excel) format in order to extract stable signals 
corresponding to the middle 5 minutes of resting autonomic function recordings. 
The pulse interval (RRi) in TXT format was then imported into Kubios (software 
package version 2.2, University of Eastern Finland, Kuopio) (19) for further analyses. 
Artefact correction was set at ‘very strong’ in all cases. 
Resting heart rate variability analysis
The resting HRV was assessed by linear as well as by nonlinear analyses. For linear 
HRV analyses, this was done for both time and frequency domain parameters. The 
time domain HRV analyses included;  mean of RR (mean RR) intervals, the standard 
deviation of the mean of all RR intervals (SDRR or SDNN), the square root of the 
mean squared differences of successive RR intervals (RMSSD), mean heart rate (HR), 
number of pairs of adjacent NN intervals differing by more than 50ms in the entire 
recording (NN50),  NN50 count divided by the total number of all NN intervals 
(pNN50),  the triangular index (RRi tri) and triangular interpolation of NN interval 
histogram (TINN). In general, higher values in the time domain HRV analyses 
reflects vagal influence over the heart control. 
 The frequency domain HRV analyses, which were based on the Fast Fourier 
Transformation (Welsh periodogram estimates) included the very low frequency 
(VLF), low frequency (LF) and high frequency (HF), were expressed in milliseconds 
squared (ms2). Higher values of the HF index represent parasympathetic activity, 
while the LF characterizes both sympathetic and parasympathetic outflows. The 
normalized units (nu) of the LF and HF, as well as the LF/HF ratio, which represents 
the sympathovagal balance were also calculated. 
 The indices of the nonlinear HRV analysis, which provide a more robust 
information relating to the behavior of the cardiac control were also retrieved. 
These included the standard deviation measuring the dispersion of points in the 
plot perpendicular to the line of identity (SD1) and the standard deviation measuring 
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the dispersion of points along the line of identity (SD2). The SD1 measures short 
term HRV in ms, while the SD2 represents both the short and long term HRV in 
milliseconds (ms). Other nonlinear parameters included the (i) approximate 
entropy (ApEn), which measures the complexity or irregularity or randomness 
within the HRV data (series). Small ApEn values is indicative of a regular and 
predictable signal (20) (ii) Shannon entropy (ShannEn), is also a measure of short 
term HRV that reflects the degree of complexity of the signal similar to ApEn, and 
(iii) mean line length (Lmean) and max line length (Lmax) of the data series. 
Furthermore, we also reported on the sample entropy (SampEn), which is a measure 
of signal regularity and complexity, and small values also represent regular signals. 
The detrended fluctuation analysis (DFA) measures the rate of fluctuation in the 
data series, and it is described in terms of both brief (‐1) and long term (‐2) 
fluctuations that represents baroreceptor reflex and regulatory mechanisms that 
limit fluctuation of the beat cycle was also assessed (20, 21). DFA is decreased in 
cardiovascular disorders such as myocardial infarction . And lastly, we calculated 
the correlation dimension (D2) which estimates the minimum number of variables 
required to construct a model of system dynamics. Here, higher values indicate 
greater complexity (20). 
Resting baroreceptor ref lex sensitivity
The resting BRS reported in this study was the time domain cross-correlation BRS 
(xBRS), which was computed according to the method of Westerhof (22). Other xBRS 
parameters such as interval (in milliseconds), delay time (in seconds) and the 
regression coefficient of determination (R2) were also extracted.
Autonomic reactivity tests
The autonomic reactivity tests of cardio-vagal indices were conducted by means of 
continuous ECG and cardiovascular monitoring during three test moments based 
on a validated and standardized protocol (23). They include heart rate response to 
deep breathing (HRDB), Valsalva maneuver (VM) and head up tilt (HUT). 
heart rate response to deep breathing 
For the HRDB, the participants were asked to perform 8 cycles of deep inspirations 
(via the nose) and expirations (via the mouth) at a breathing rate corresponding to 
6 breaths/minute. They were provided with a visual biofeedback on a computer 
screen. The maneuver was repeated twice with a resting time interval of five 
minutes. The best trial comprising at least 5 cycles good of breaths was retrieved. 
The average of the range of maximum HR achieved during inspiration and the 
minimum HR during expiration for each cycle of breath was calculated. This 
parameter assesses the vagal control of the heart, a measure of parasympathetic 
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reactivity (normal: >15 beat/minute, borderline: 11-14 beats/minute, and abnormal: 
<11 beats/minute) (24).  
Valsalva maneuver 
The VM was evoked by asking the subjects to continuously blow for 15 seconds, 
through a mouthpiece attached onto a sphygmomanometer at pressure between 40 
and 50 mmHg. A visual feedback was provided on a computer screen to aid the 
maneuver. This maneuver was repeated three times with a resting interval time of 
3 minutes between the maneuvers. For each subject, only the best of the 3 trials 
showing adequate pressure, duration and normal mean arterial pressure response 
that reflects the 4 phases of VM(23, 25) was selected for analyses. This decision was 
taken after a careful inspection of the maneuver (excel graph plot) was made. 
 Several parameters were calculated from the data of subjects who completed at 
least one adequate VM trial. They include: Valsalva ratio (VR), which represents 
vagal activity, was calculated as the ratio of the maximum HR (HRmax) during 
Valsalva maneuver and the maximum HR within 30 seconds from the HRmax. The 
Valsalva index (VI), which is also an indirect measure of the ANS integrity, was 
calculated as the ratio between the longest RRi during VM recovery (phase 4) and 
the shortest RRi during the peak of VM. A VI of less than 1.4 is considered abnormal. 
Three BRS parameters comprising adrenergic baroreceptor sensitivity (BRS_a), 
vagal baroreceptor sensitivity (BRS_v) and global baroreceptor sensitivity (BRS_g) 
indices were also calculated using an existing protocol (26). 
Head up tilt  
After a 5-minute period of continuous recording in a supine position, the table was 
slowly tilted up to 60° angle and maintained for 10 minutes. The participants were 
asked to report any symptoms of light headedness, feelings of dizziness, discomfort 
or pain throughout the duration of the tilt. The HUT test was terminated only if 
severe orthostatic intolerance complaints or signs of vasovagal syncope were 
suspected (27). 
Statistical analysis
Statistical analysis were performed using the Statistical Package for the Social 
Sciences vaersion_22 (SPSS Inc. Chicago IL, USA). Demographic and other clinical 
characteristics were mainly summarized using descriptive statistics. All the 
variables were subjected to the Shapiro-Wilk’s test and manual inspection of both 
QQ plots and histograms to ascertain whether or not they were normality 
distributed. To evaluate the significance of differences of variables between COPD 
and controls, we used independent samples t-test or Mann-Whitney U-test, where 
appropriate. For non-parametric variable comparison, we used Chi square test. 
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Lastly, to assess the cardiovascular responses during the HUT, two-way repeated 
measure ANOVA was utilized. Alpha probability value was considered significant at 
< 0.05 level in all cases.
Results
Demographic characteristics
The demographic and baseline clinical characteristics are presented in Table 1. 
These results show that the majority of the study variables such as age, body weight, 
BMI, systolic and diastolic blood pressures as well as mean arterial pressure (MAP) 
variables were all comparable between patients with COPD and healthy control 
subjects (p>0.05). However, the control subjects were significantly taller (p=0.008). 
The Table further shows that subjects with COPD had a significantly higher resting 
HR, and they reported significantly higher use of two vasoactive medications (beta 
blockers and ACE inhibitors) compared to controls (p<0.05).
Resting autonomic function
Table 2 shows the results for resting autonomic function indices between subjects 
with COPD and the healthy controls. Subjects with COPD were found to consequently 
have lower values for almost all the time domain HRV analyses compared to 
controls. However, only the differences for mean RR was statistically significant 
(p=0.011). This is suggestive of a decreased vagal activity of subjects with COPD 
compared to controls. Similarly, frequency domain indices with the exception of 
HF (nu) were decreased in COPD compared to controls, however, only the LF(ms2) 
power was of significance (p=0.035). 
 For the nonlinear HRV analyses, all reported variables were comparable between 
subjects with COPD and control subjects except for SD1, which was significantly 
decreased in COPD (p=0.041). The ApEn was also found to be significantly increased 
in COPD compared to the controls (p=0.02), suggesting a higher complexity and 
lower signal predictability.  Lastly, the results of this study revealed that subjects 
with COPD had lower resting BRS parameters compared to the control group (5.5 vs 
8.0, ms.mmHg). However, these differences did not reach statistical significance 
(p>0.05).
Cardio vagal autonomic reactivity
The results from the autonomic reactivity tests are presented in Table 3. The HRDB 
were comparable between subjects with COPD and controls (p=0.869). All parameters 
derived from the VM including the VR, VI, BRS_a, BRS_v, BRS_g, PRT and PP drop 
were comparable between subjects with COPD and controls (p>0.05). For HUT, even 
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Age (years) 65.8±8.99 64.2±8.5 .538t 
Sex, male(%) 23 (88.5%) 19 (86.4%) .582X
Height (m) 1.70±0.06 1.76±0.08 .008*t
Weight (kg) 75.3±10.22 76.0±10.57 .807t 
BMI (Kg/m2) 26.2±3.47 24.6±2.82 .102t 
HR (bpm) 72.9±11.48 61.3±7.82 .001*t
Systolic BP 139.7±23.48 136.8±17.67 .642t 
Diastolic BP 75.5±11.7 71.7±7.50 .191t 
MAP 99.1±15.69 95.2±9.64 .313t 
Lung function 
        FEV1 (% FEV1 predicted)
        FVC (% FVC predicted)
       Tiffeneau index 










       Meters




       Opiates
       Antidepressants (tricyclic)
       Diuretics
       Beta-blockers
       Calcium channel blockers
       ACE inhibitors
       Sedatives

























Notes: bpm, beats per minute; m, meters; kg, kilogram; ms, milliseconds; %, percentage; mmHg, millimeter of 
mercury; MAP, mean arterial pressure; BP, blood pressure; FEV1, forced expiratory volume in first second; 
FVC, forced vital capacity; PEF, peak expiratory flowrate; ACE, angiotensin converting enzyme; HR, heart 
rate; BMI, body mass index; MAP, mean arterial pressure. ~ not available in published version.
*, significant difference at p<0.05 alpha probability level; t , results based upon independent samples 
T-test statistics; X, results based on Chi2 tests.
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Time domain HRV analyses
       SDNN (ms)
       RMSSD(ms)
       NN50(count)
       pNN50(%)
       RR tri
       TINN






















Frequency domain HRV analyses
       LF (ms2)
       HF (ms2)      
       LF (n.u.)
       HF (n.u.)

















       SD1(ms)
       SD2(ms)
           Lmean (beats)
   Lmax (beats)
   Detrended fluctuations (DFA): α1
   Detrended fluctuations (DFA): α2
   Shannon entropy (ShannEn)
   Approximate entropy (ApEn)
   Sample entropy (SampEn)
































       xBRS (ms.mmHg)
       Mean tau (s)
       R2













Notes: SDNN, standard deviation of all normal R-R intervals; RMSSD, the root mean square of differences 
of successive RR intervals;  NN50, number of consecutive RR intervals that differ more than 50 ms; 
pNN50, the percentage of NN50, SD1, the standard deviation of the Poincaré plot perpendicular to the 
line-of-identity ; SD2, the standard deviation of the Poincaré plot along the line-of-identity; RR tri, the 
integral of the RR interval histogram divided by the maximum of the histogram; LF, low frequency; HF, 
high frequency;  LF/HF, ratio of LF and HF frequency band powers; ms= milliseconds, nu= normalized 
units; xBRS, cross-correlational baroreceptor sensitivity;  %, percentage; 
*, significant difference at p<0.05 alpha probability level; t , results based upon independent samples 
T-test; m, results based on Mann-Whitney U-Test.
155
AUTONOMIC FUNCTION AND REACTIVITY TESTS IN COPD
5
though subjects with COPD reported more orthostatic symptoms compared with 
controls, these were not statistically significant (p>0.05). Further analyses of the 
HUT results revealed that the subjects with COPD also recorded a slightly higher 
drop in both systolic and diastolic blood pressures, as well as a slightly increased 
heart rate during the HUT. The results from the 2 way repeated measures ANOVA 
analyses indicated that these variations were no statistically significant interaction 
(between subject’s effects) in the systolic blood pressure (F, 2.302; p=137), diastolic 
blood pressure (F, 0.034; p=0.855), and heart rate (F, 0.975; p=0.330) of both COPD 
and control groups. These results are illustrated in a graphical manner in Figure 1. 
Table 3   Results of cardio-vagal reactivity indices for COPD and control subjects.
COPD Healthy controls p-value
Deep breathing
      HRDB (bpm) 12.1±6.87 12.3±7.09 .869m 
Valsalva maneuver
     VR
     VI
     BRS_a  (mmHg/sec)
     BRS_v (sec/mmHg)
     BRS_g 
     PRT (sec)
     PP drop


























     Initial OH
     OH
     Delayed OH
     POTS
















Notes: data expressed as mean ± standard deviation for continuous variables and as absolute frequency 
and percentages for categorical variables. Bpm, beats per minute; mmHg, millimeter of mercury; OH, 
orthostatic intolerance; POTS, postural orthostatic tachycardia syndrome; HRDB, heart rate response to 
deep breathing; BRS_a, adrenergic baroreceptor sensitivity; BRS_v, vagal baroreceptor sensitivity; BRS_g, 
global baroreceptor sensitivity; PP drop, pulse pressure drops; PRT, Pressure recovery time; VI, valsalva 
index, VR, valsalva ratio; VM, Valsalva maneuver.   




Figure 1   Cardiovascular responses to head up tilt (HUT).
Graphs are plotted as a function the relevant time (categorical) intervals of HUT parameter. The standard 
deviation (SD) of each time point is represented by the error bars.
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Discussion 
This study was aimed at providing additional extensive assessment of the ANS or 
autonomic function in COPD.  We limited our study population to a specific cohort 
of COPD-patients that were non-sedentary or were ‘physically active’ due to the 
heterogeneous and complex nature of COPD, and also because of the feasibility of 
testing in this specific population. Consequently, it is important that our results 
should be understood in this context. We also included a control group so that our 
results can be viewed in perspective of the prevailing autonomic function health 
status of their counterparts in the general population. More importantly, our study 
reported several autonomic function parameters some of which are not frequently 
reported in COPD in existing studies. Also, including autonomic reactivity tests 
represents a first attempt in the area of autonomic function research in COPD. 
 The major results of our study are as follows: (i) subjects with COPD have a 
significantly lowered RR intervals compared to controls, (ii) most HRV and BRS 
indices were lower in subjects with COPD compared to the control group, however 
only a few of these indices were of statistical significance, (iii) the autonomic 
responses to the three autonomic reactivity tests of (deep breathing, valsalva 
maneuver and tilting) were largely normal and similar between COPD and controls, 
and (iv) further analyses of tilting revealed that subjects with COPD have a slightly 
poorer cardiovascular response to tilting in comparison to controls. The significant 
decrease in LF among the COPD and marginal reduced the baroreflex control 
(measured by resting BRS) in COPD are important results that is in line with past 
trend. There is evidence –at least in cardiovascular diseases – that the baroreflex 
control and LF power in HRV are associated (28). Additionally, we found that the 
ApEn, which is a measure of signal regularity and complexity was significantly 
increased in COPD. The ApEn has been reported to be a very useful tool for predicting 
individual risk of cardiovascular disease (29). All of these results put together are 
suggestive of residual autonomic function deficits in COPD, thereby lending 
credence to earlier reports that have stated that ANS is impaired in COPD (3, 30). 
Nevertheless, our results for resting HRV parameters including mean RR, SDNN, 
RMSSD, LF(ms2) LF(n.u.), HF(ms2) HF (n.u) and LF/HF ratio, were largely comparable 
with the normative value reported among heathy adults during short term HRV 
measurements in a systematic review by Nunan et al (31). 
 We understand that several factors may have influenced the results of our 
study. The use of COPD subjects participating in a rehabilitation program may have 
explained the similarity in the results in most of the autonomic function variables 
that were assessed, and also the non-statistical difference for the cardio-vagal 
indices following the autonomic reactivity tests. A number of studies including our 
recent systematic review has demonstrated that participating in an aerobic exercise 
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training program, which forms the core of pulmonary rehabilitation or a maintenance 
program affects the autonomic function in COPD (2, 7, 32-34). For example, a 4-week 
rehabilitation have been shown to significant increase HRV indices, which were 
also associated with health related quality of life in COPD (35). Furthermore, 
pulmonary rehabilitation programs may comprise interventions that have been proven 
to influence the autonomic function in COPD such as controlled breathing techniques 
and noninvasive mechanical ventilation (36). The LF/HF ratio, which is an index of 
sympathovagal balance was found to be higher among the controls, albeit not 
statistically significant. Nevertheless, this results is indicative of a generally higher 
sympathetic functioning among the controls over the COPD group (37). In addition, 
the results could mean that autonomic function, represented by both sympathetic 
and parasympathetic branches in COPD is deficient. Comparing the results in this 
study with existing studies demonstrate that the subjects in our study had a higher 
average resting HRV (2, 38-40) and BRS (41) parameters. However, the resting BRS 
was found to be similar to the values reported in COPD patients who were much 
younger (51 years) (42). Again, the use of beta blockers and ACE inhibitors by subjects 
with COPD may have also contributed to the largely comparable results, since these 
medications are known to affect HRV in the direction of normalization. 
 Even though the cardio-vagal response indices (HRDB, BRS_a, BRS_v, BRS_g, VI 
and VR) and the HUT parameters were comparable between COPD and controls, 
further analyses may provide extra information.  For example, both groups had a 
HRDB value that has been is classified to be a borderline parasympathetic response 
(24), suggesting a possible influence of ageing. We  also discovered that the average 
VI and VR in COPD recorded in our study was just  above the normal reference 
cut-offs reported for healthy adults  (4, 24, 26), which may indicate that both groups 
have normal parasympathetic responses. Moreover, the HRV during deep breathing 
in the context of autonomic function testing has been successfully used for 
detecting parasympathetic disorders or rates of parasympathetic activity (43). 
Nevertheless, more studies are needed for other COPD populations. 
 We used a number of VM parameters to describe the autonomic reaction to the 
maneuver all of which showed a normal trend, and even higher values for COPD. 
The higher VR results of subjects with COPD in our study can be explained by a 
more rapid HR increase during second phase of VM, which is as a result of vagal 
activity withdrawal over the sinus node that is only reactivated after the Valsalva 
strain is removed (44). The average value of the adrenergic, vagal and global BRS 
indices and even the VR of the participants (COPD and control) of this study  were 
comparable to the values obtained for subjects with orthostatic hypotension, but 
lower than those of the healthy controls in the study of Schrezenmaier et al (26). 
However, the participants of our study were much older compared to those in the 
latter study (65 vs 51 years).     
159
AUTONOMIC FUNCTION AND REACTIVITY TESTS IN COPD
5
After further analyzing the cardiovascular responses to tilting (Figure 1), a few 
differences were observed. Even though these differences were not statistically 
significant, they still represent signs of residual autonomic function impairments 
in subjects with COPD. During HUT, the ensuing orthostatic change triggers an 
increased sympathetic nervous system outflow (45), which produces a shift in 
spectral power from HF bands to LF bands (or increased LF/HF ratio). This is reflected 
in the cardiovascular system in the form of peripheral vasoconstriction in order to 
maintain hemodynamic functioning. The marginal lowering of the systolic and 
diastolic blood pressures as well as the increased baseline HR we found in our 
results could be suggestive of a diminishing sympathovagal response to orthostatic 
stimuli, as is already known (6, 8, 46). 
 As mentioned earlier, the non-sedentary nature of the subjects with COPD in 
this study may be an important factor that influenced the non-significant differences 
between COPD patients and healthy controls in the majority of the autonomic 
function indices. We also must take into account that the COPD patients used more 
vasoactive medications (beta agonists and ACE inhibitors) that are known to 
influence autonomic test results (47, 48). which are to allow us assess the subjects 
autonomic function in their current (day-to-day) conditions, and for ethical 
concerns that might be related to withdrawal of prescribed medications. Therefore, 
the extent by which any of these factors in addition to certain lifestyle circumstances 
may have affected the results is presently not clear. This study has highlighted the 
need for more focus on reporting tests of physiological biomarkers in various COPD 
phenotypes in. Our study has provided new and noteworthy results that could form 
the basis for further autonomic function analyses in COPD. Notably, our study has 
shown that the cardiovascular response to tilting offers a more discriminatory 
ability of autonomic reactivity tests in COPD even when other cardio-vagal variables 
appear to be within normal range. All these findings can assist clinicians in defining 
the presence of autonomic failure and even their response to treatment (49).
 The results of this study must be viewed within the limitations of the study. 
A significant proportion of the participants were males and we did not carry out any 
gender based analyses. However, this was taken into account by the gender/age 
matching (maximum 5-year interval) that was used during subject recruitment. 
Cardio-vagal index represents only 2 of 3 aspects of the composite autonomic scoring 
scale (CASS) (50), which is a validated test protocol for assessing autonomic failure. 
Future studies assessing these tests in addition to sudomotor function which can be 
evaluated with the quantitative sudomotor axon reflex test and the thermoregulatory 
sweat test, also impaired in COPD(51, 52),  may be necessary. Lastly, the study utilized 
a cross-sectional case-control design. We recommend study designs with either larger 
number of participants and /or follow-up analyses in order to accurately evaluate the 




To summarize, our results in this study suggest that autonomic impairment exists 
in COPD. However, COPD patients who are non-sedentary or physically active may 
show several comparable autonomic function indices with their healthy counter- 
parts. Autonomic reactivity tests are not of any discriminatory value over resting 
autonomic function indices in the COPD cohort in this study. 
161
AUTONOMIC FUNCTION AND REACTIVITY TESTS IN COPD
5
References
[1] Andreas S, Anker SD, Scanlon PD, Somers VK. Neurohumoral activation as a link to systemic 
manifestations of chronic lung disease. Chest. 2005;128(5):3618-24.
[2] Borghi-Silva A, Mendes RG, Trimer R, Oliveira CR, Fregonezi GA, Resqueti VR, et al. Potential effect of 6 
versus 12-weeks of physical training on cardiac autonomic function and exercise capacity in chronic 
obstructive pulmonary disease. Eur J Phys Rehabil Med. 2015;51(2):211-21.
[3] van Gestel AJK, M.( Clarenbach, C. F. Sympathetic overactivity and cardiovascular disease in patients 
with chronic obstructive pulmonary disease (COPD). Discov Med. 2012;14(79):359-68.
[4] da Luz Goulart C, Cabiddu R, de Borba Schneiders P, San Martin EA, Trimer R, Borghi-Silva A, et al. Is cardiac 
autonomic modulation during upper limb isometric contraction and Valsalva maneuver impaired in COPD 
patients? International Journal of Chronic Obstructive Pulmonary Disease. 2017;12:849.
[5] Jensen MT, Marott JL, Lange P, Vestbo J, Schnohr P, Nielsen OW, et al. Resting heart rate is a predictor of 
mortality in COPD. European Respiratory Journal. 2013;42(2):341-9.
[6] Volterrani M, Scalvini S, Mazzuero G, Lanfranchi P, Colombo R, Clark AL, et al. Decreased heart rate 
variability in patients with chronic obstructive pulmonary disease. Chest. 1994;106(5):1432-7.
[7] Camillo CA, Laburu Vde M, Goncalves NS, Cavalheri V, Tomasi FP, Hernandes NA, et al. Improvement of 
heart rate variability after exercise training and its predictors in COPD. Respir Med. 2011;105(7):1054-62.
[8] Costes F, Roche F, Pichot V, Vergnon JM, Garet M, Barthelemy JC. Influence of exercise training on cardiac 
baroreflex sensitivity in patients with COPD. Eur Respir J. 2004;23(3):396-401.
[9] Stein PK, Nelson P, Rottman JN, Howard D, Ward SM, Kleiger RE, et al. Heart rate variability reflects 
severity of COPD in PiZ α 1-antitrypsin deficiency. Chest. 1998;113(2):327-33.
[10] Lombardi F. Clinical implications of present physiological understanding of HRV components. Cardiac 
Electrophysiol Rev. 2002;6(3):245-9.
[11] Mohammed J, Meeus M, Derom E, Da Silva H, Calders P. Evidence for autonomic function and its 
influencing factors in subjects with COPD: a systematic review. Respiratory Care. 2015;60(12):1841-51.
[12] Massin MM, Maeyns K, Withofs N, Ravet F, Gérard P. Circadian rhythm of heart rate and heart rate 
variability. Archives of Disease in Childhood. 2000;83(2):179-82.
[13] Zivanovic I, Zupanic E, Lainscak M, Avbelj V, Kalisnik JM. Nonlinear dynamics of heart rate variability in 
patients with chronic obstructive pulmonary disease and changes after 4-week rehabilitation. European 
Respiratory Journal. 2014; 44(suppl. 58) P3541.
[14] Goulart Cda L, Simon JC, Schneiders Pde B, San Martin EA, Cabiddu R, Borghi-Silva A, et al. Respiratory 
muscle strength effect on linear and nonlinear heart rate variability parameters in COPD patients. Int J 
Chron Obstruct Pulmon Dis. 2016;11(6):1671-7.
[15] Mazzuco A, Medeiros WM, Sperling MP, de Souza AS, Alencar MC, Arbex FF, et al. Relationship between 
linear and nonlinear dynamics of heart rate and impairment of lung function in COPD patients. Int J 
Chron Obstruct Pulmon Dis. 2015;10:1651-61.
[16] Volterrani M, Scalvini S, Mazzuero G, Lanfranchi P, Colombo R, Clark AL, et al. Decreased heart rate 
variability in patients with chronic obstructive pulmonary disease. Chest. 1994;106(5):1432-7.
[17] Baecke JA, Burema J, Frijters J. A short questionnaire for the measurement of habitual physical activity 
in epidemiological studies. The American journal of clinical nutrition. 1982;36(5):936-42.
[18] Linder JR, Stauss HM, Gindes H, Pierce GL, Von Bergen NH, Haynes WG, et al. Finger volume pulse 
waveforms facilitate reliable assessment of heart rate variability, but not blood pressure variability or 
baroreflex function. BMC cardiovascular disorders. 2014;14(1):180-7.
[19] Langewouters G, Settels J, Roelandt R, Wesseling K. Why use Finapres or Portapres rather than 
intraarterial or intermittent non-invasive techniques of blood pressure measurement? Journal of 
medical engineering & technology. 1998;22(1):37-43.
[20] Shaffer F, Ginsberg J. An Overview of Heart Rate Variability Metrics and Norms. Frontiers in Public 
Health. 2017;5:258 (1-17).
[21] Francesco B, Maria Grazia B, Emanuele G, Valentina F, Sara C, Chiara F, et al. Linear and nonlinear heart 




[22] Westerhof BE, Gisolf J, Stok WJ, Wesseling KH, Karemaker JM. Time-domain cross-correlation baroreflex 
sensitivity: performance on the EUROBAVAR data set. Journal of Hypertension. 2004;22(7):1371-80.
[23] Novak P. Quantitative autonomic testing. Journal of visualized experiments: JoVE. 2011(53).
[24] O’Brien I, O’Hare P, Corrall R. Heart rate variability in healthy subjects: effect of age and the derivation 
of normal ranges for tests of autonomic function. Heart. 1986;55(4):348-54.
[25] Vogel ER, Sandroni P, Low PA. Blood pressure recovery from Valsalva maneuver in patients with 
autonomic failure. Neurology. 2005;65(10):1533-7.
[26] Schrezenmaier C, Singer W, Swift NM, Sletten D, Tanabe J, Low PA. Adrenergic and vagal baroreflex 
sensitivity in autonomic failure. Archives of Neurology. 2007;64(3):381-6.
[27] De Wandele I, Rombaut L, Leybaert L, Van de Borne P, De Backer T, Malfait F, et al., editors. Dysautonomia 
and its underlying mechanisms in the hypermobility type of Ehlers–Danlos syndrome. Seminars in 
Arthritis and Rheumatism; 2014; 44(1):93-100.
[28] Goldstein DS, Bentho O, Park MY, Sharabi Y. Low‐frequency power of heart rate variability is not a 
measure of cardiac sympathetic tone but may be a measure of modulation of cardiac autonomic 
outflows by baroreflexes. Experimental Physiology. 2011;96(12):1255-61.
[29] Wessel N, Schumann A, Schirdewan A, Voss A, Kurths J. Entropy measures in heart rate variability data. 
Lecture Notes in Computer Science. 2000:78-87.
[30] van Gestel AJ, Steier J. Autonomic dysfunction in patients with chronic obstructive pulmonary disease 
(COPD). J Thorac Dis. 2010;2(4):215-22.
[31] Nunan D, Sandercock GR, Brodie DA. A quantitative systematic review of normal values for short‐term 
heart rate variability in healthy adults. Pacing and Clinical Electrophysiology. 2010;33(11):1407-17.
[32] Mohammed J, Derom E, Van Oosterwijck J, Da Silva H, Calders P. Evidence for aerobic exercise training 
on the autonomic function in patients with chronic obstructive pulmonary disease (COPD): a systematic 
review. Physiotherapy 2017; doi: 10.1016/j.physio.2017.07.004.
[33] Borghi-Silva A, Arena R, Castello V, Simoes RP, Martins LEB, Catai AM, et al. Aerobic exercise training 
improves autonomic nervous control in patients with COPD. Respiratory Medicine. 2009;103(10):1503-10.
[34] Cheng STW, Y. K.( Yang, M. C.( Huang, C. Y.( Huang, H. C.( Chu, W. H.( Lan, C. C. Pulmonary rehabilitation 
improves heart rate variability at peak exercise, exercise capacity and health-related quality of life in 
chronic obstructive pulmonary disease. Heart Lung. 2014;43(3):249-55.
[35] Zupanic E, Zivanovic I, Kalisnik JM, Avbelj V, Lainscak M. The effect of 4-week rehabilitation on heart rate 
variability and QTc interval in patients with chronic obstructive pulmonary disease. COPD: Journal of 
Chronic Obstructive Pulmonary Disease. 2014;11(6):659-69.
[36] Mohammed J, Da Silva H, Van Oosterwijck J, Calders P. Effect of respiratory rehabilitation techniques on 
the autonomic function in patients with chronic obstructive pulmonary disease: A systematic review. 
Chronic Respiratory Disease. 2016;14(3):217-30.
[37] Heart rate variability. Standards of measurement, physiological interpretation, and clinical use. Task 
Force of the European Society of Cardiology and the North American Society of Pacing and Electrophys-
iology. Eur Heart J. 1996;17(3):354-81.
[38] Carvalho TD, Pastre CM, de Godoy MF, Fereira C, Pitta FO, de Abreu LC, et al. Fractal correlation property 
of heart rate variability in chronic obstructive pulmonary disease. International Journal of Chronic 
Obstructive Pulmonary Disease. 2011;6:23-8.
[39] Borghi-Silva A, Reis MS, Mendes RG, Pantoni CBF, Simoes RP, Martins LEB, et al. Noninvasive ventilation 
acutely modifies heart rate variability in chronic obstructive pulmonary disease patients. Respiratory 
Medicine. 2008;102(8):1117-23.
[40] Borghi-Silva A, Arena R, Castello V, Simoes RP, Martins LEB, Cataii AM, et al. Aerobic exercise training 
improves autonomic nervous control in patients with COPD. Respiratory Medicine. 2009;103(10):1503-10.
[41] Bartels MN, Gates GJ, Downey JA, Armstrong HF, De Meersman RE. Baroreceptor sensitivity after Valsalva 
maneuver in women with chronic obstructive pulmonary disease. Clin Auton Res. 2012;22(4):185-9.
[42] Haider T, Casucci G, Linser T, Faulhaber M, Gatterer H, Ott G, et al. Interval hypoxic training improves 
autonomic cardiovascular and respiratory control in patients with mild chronic obstructive pulmonary 
disease. Journal of Hypertension. 2009;27(8):1648-54.
163
AUTONOMIC FUNCTION AND REACTIVITY TESTS IN COPD
5
[43] Ewing DJ, Clarke BF. Diagnosis and management of diabetic autonomic neuropathy. Br Med J (Clin Res 
Ed). 1982;285(6346):916-8.
[44] Minatel V, Karsten M, Neves LM, Beltrame T, Borghi-Silva A, Catai AM. Heart rate assessment during 
maximal static expiratory pressure and Valsalva maneuver in healthy young men. Rev Bras Fisioter. 
2012;16(5):406-13.
[45] Burke D, Sundlof G, Wallin G. Postural effects on muscle nerve sympathetic activity in man. J Physiol. 
1977;272(2):399-414.
[46] Pagani ML, D.( Pizzinelli, P.( Sergi, M.( Bosisio, E.( Mela, G. S.( Malliani, A. Effects of aging and of chronic 
obstructive pulmonary disease on RR interval variability. Journal of the Autonomic Nervous System. 
1996;59(3):125-32.
[47] bv E-WN. COPD - samenvatting. 2015.
[48] Sharif R, Cuevas CR, Wang Y, Arora M, Sharma G. Guideline adherence in management of stable chronic 
obstructive pulmonary disease. Respir Med. 2013;107(7):1046-52.
[49] Low PA, Tomalia VA, Park K-J. Autonomic function tests: some clinical applications. Journal of Clinical 
Neurology. 2013;9(1):1-8.
[50] Suarez GA, Opfer-Gehrking T, Offord K, Atkinson E, O’brien P, Low PA. The autonomic symptom profile a 
new instrument to assess autonomic symptoms. Neurology. 1999;52(3):523-.
[51] Bir LS, Özkurt S, Daloglu G, Kurt T. Impaired sympathetic skin response in chronic obstructive 
pulmonary disease. The Tohoku Journal of Experimental Medicine. 2005;207(4):243-8.
[52] Stewart A, Marsh F, Waterhouse J, Howard P. Autonomic nerve dysfunction in COPD as assessed by the 
acetylcholine sweat-spot test. European Respiratory Journal. 1994;7(6):1090-5.

“The good physician treats the disease. The great physician treats 




Non-pharmacological aspects to 
autonomic function modulation in COPD

Chapter 6
Effects of respiratory 
rehabilitation techniques on the 
autonomic function in patients with 
chronic obstructive pulmonary disease: 
a systematic review
Jibril Mohammed,1,2 Hellen Da Silva,1 Jessica Van Oosterwijck,1,3  
and Patrick Calders1
1 Department of Rehabilitation Sciences Physiotherapy, Ghent University, Ghent, Belgium
2 Department of Physiotherapy, Bayero University Kano, Kano State, Nigeria
3 Research Foundation – Flanders (FWO), Brussels, Belgium
2017; 14(3):217-230
Impact Factor (2016) = 1.82




Patients with chronic obstructive pulmonary disease (COPD) show several extra- 
pulmonary abnormalities such as impairment in the autonomic function. Similarly, 
the use of respiratory training techniques such as controlled breathing techniques, 
non-invasive mechanical ventilation (NIMV) and oxygen supplementation for 
autonomic function modulation in patients with COPD is popular in existing 
literature. However, the evidence supporting their use is non-existent. A systematic 
search of studies reporting on the effect of controlled breathing techniques, 
NIMV, and/or oxygen supplementation techniques on autonomic function outcome 
parameters was conducted in three databases: PubMed, Embase and Web of Science. 
Following the Preferred Reporting Items for Systematic reviews and Meta-Analyses 
statement, relevant studies were retained for evidence synthesis. The methodological 
quality in these studies was evaluated using the evidence based guideline 
development (EBRO) check-lists per designs provided by the Dutch Cochrane 
Centre. Eighteen studies met the inclusion criteria of the review and were included 
and discussed. The evidence synthesis revealed that a strong and moderate level 
evidence supported the significant effect of oxygen supplementation and slow 
breathing techniques, respectively in significantly enhancing the baroreceptor 
sensitivity (BRS) values in patients with COPD. The effect of the examined 
techniques on heart rate variability (HRV) and muscle sympathetic nerve activity 
(MSNA) was of a limited or inconsistent evidence. The findings from this review 
suggest that oxygen supplementation and controlled breathing techniques have 
profound positive influence on the BRS in patients with COPD. However, it is not 
fully known if the effects of these influence translate to any therapeutic benefit on 
the general autonomic function of patients with COPD in the long term.
Keywords: COPD, sympathetic, parasympathetic, review, autonomic nervous system, respiratory 
training techniques.
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Introduction
Chronic obstructive pulmonary disease (COPD) is a complex, heterogeneous, and 
highly prevalent clinical syndrome, which is associated with high morbidity and 
mortality (1-3). The scourge of COPD, which is mainly as a result of ageing and 
tobacco use, is on the increase and it is presently projected to be among the top 
three leading causes of mortality by the year 2020 (4). COPD is mainly characterized 
by a progressive and nonreversible airflow obstruction, and patients with the 
disease present with other numerous extra-pulmonary abnormalities (5, 6). For 
example, conditions like chronic fatigue syndrome, arrhythmias, reduced exercise 
capacity and impaired autonomic functions have been repeatedly reported in 
patients with COPD (7, 8). 
 The autonomic function in patients with COPD has been widely reported in 
literature due to its prognostic value in determining the cardiovascular health 
status of these patients. Unfortunately, the trends reflected in the results in most 
of these studies have shown that autonomic function parameters like  heart rate 
variability (HRV) (1, 6), baroreceptor sensitivity (BRS) (9, 10), heart rate recovery 
(HRR) (11), chemoreflex sensitivity (12), skin sympathetic responses (SSR) (13), and 
the muscle sympathetic nerve activity (MSNA) (10, 14, 15) are significantly 
impaired. Similarly, There is also an increasing report on the use of non-pharma-
cological approaches for the management of patients with COPD  These approaches 
range from smoking cessation programs to, nutritional intervention, psychosocial 
support and in some cases surgical interventions (16). A group of respiratory 
rehabilitation techniques such as hypoxic training/oxygen supplementation 
(17-20), non-invasive mechanical ventilation (NIMV) (5, 21-23), aerobic exercises 
(24, 25), and controlled breathing techniques (8, 26-28) are also employed for a 
variety of important outcomes for patients with COPD. While the effect of 
these respiratory rehabilitation techniques on most COPD symptoms is clear, 
the evidence to support their effects on the autonomic function outcomes is 
non-existent. Therefore, a clear overview of the existing evidence regarding the 
effects of these techniques on autonomic function is warranted. Also, it is necessary 
to make a distinction between various autonomic function parameters with a 
view to highlighting possible clinical implications.
 The aim of this systematic review is to provide a grade 2 evidence to support 
the effects of three distinct respiratory rehabilitation techniques; namely, 
controlled breathing, NIMV application and oxygen supplementation on the 
autonomic function parameters in patients with COPD. Conclusions regarding the 
evidence generated from the existing can shape the direction of future studies, 
and also aid clinicians in making an informed choice regarding the use of 




This systematic review is reported in accordance with the Preferred Reporting 
Items for Systematic reviews and Meta-Analyses (PRISMA) (29).
Information sources and search strategy 
To identify relevant articles, the online databases of PubMed (1966 to August 23, 
2015), Embase (1966 to August 23, 2015) and Web of Science (1955 to August 23, 
2015) were searched for published articles. For PubMed, the search strategy was 
conducted using a combination of Medical Subject Headings (MeSH) terms in the 
following order: “(pulmonary disease, chronic obstructive [MeSH Terms]) AND 
autonomic function OR heart rate variability OR baroreceptor sensitivity OR muscle 
sympathetic nerve activity AND breathing exercises OR rehabilitation”. For the 
Embase and Web of Science databases, two free-text keywords (“COPD AND autonomic 
function”) were utilized for the search strategy. Search filters were applied to 
restrict search outputs in all three databases for article type (clinical trials), species 
(humans) and language (English). In addition, the reference list of the potentially 
relevant studies were screened to make the review as complete as possible.
Eligibility criteria
To be included in this systematic review, studies had to report on the effect of 
controlled breathing, NIMV and/or oxygen supplementation (I) on autonomic 
function outcomes (O) in patients with COPD (P).
Study selection 
After de-duplication, the search results (articles) were screened based on title and 
abstract (for fulfillment of the review eligibility criteria). Thereafter, the full-text 
reports of articles that were considered potentially eligible and relevant were 
retrieved for further evaluation. The second round of evaluation of the studies was 
based upon six clearly stated predetermined inclusion criteria before any study 
was included in the review:
i. Study participants were clinically diagnosed with COPD using standardized 
measures (%FEV1 predicted, global initiative for obstructive lung disease 
(GOLD), American Thoracic Society);
ii. Study design ranging from randomized controlled trials (RCTs), case-control, 
cohort, crossover, and cross-sectional studies, expert opinions, reviews, and 
letters were excluded;
iii. A respiratory rehabilitation technique was used for intervention, and this was 
delimited to controlled breathing techniques, NIMV application and oxygen 
supplementation;
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iv. Reported any autonomic function outcome measures, 
v. article was published in English language; and 
vi. Full-text original research report, short communications such as congress 
proceedings and abstracts were excluded.
Qualification of searchers
Literature search and screening were conducted by two authors; JM (Master of 
Science in Physiotherapy) and PC (who has obtained the degree of PhD). Both authors 
have experience with publishing systematic reviews (30-34). 
Data items and collection 
Data regarding author information and year of publication, sample size and char-
acteristics of participants, inclusion and exclusion criteria, respiratory training 
intervention, reported autonomic function outcomes, main results and conclusions 
were extracted from the included studies (Table 1).
Assessment of methodological quality
The Checklists of the EBRO platform (an evidence-based guideline development in 
the Netherlands) present on the website of the Dutch Cochrane Centre [http://dcc.
cochrane.org/]) were used to assess methodological quality of the included studies. 
The appropriate checklist related to each study design was applied accordingly. 
All question items criteria used for the methodological quality evaluation are 
presented in Table 2. 
 The methodological quality was evaluated by two assessors (authors; JM and 
HDS) who were initially blinded from each other’s evaluation. Author HDS is 
(Master of Science in Rehabilitation Sciences and Physiotherapy) a PhD candidate 
working on the “autonomic function in patients with heart failure”.  
 The assessors rated each question item with either a positive (+) or a negative 
(-) score. A positive score was obtained for each question item when questions items 
if adequate information when provided  regarding: (i) the definition of the study 
population (both patients or control) reported in terms of place and time of 
recruitment, mean age and sample size, (ii) selection bias sufficiently excluded 
stated in terms of  the study population concerned or when a random sample of 
the source population with a participation rate at baseline of at least 70% was 
adopted, (iii) clearly defined exposure and assessment fulfilled if  appropriately 
described in terms of duration, dosage and frequency, (iv)clearly defined outcomes 
that are reproducible in terms of internationally accepted values, (v) outcome- 
assessment method clearly defined and adequate if they were presented in terms 
standardized autonomic function outcome measures , (vi)  blinding, if this was 
implemented during outcome assessment, (vii) follow-up period, if reported and 
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Table 1   
Reference Sample Inclusion criteria Intervention Outcome Results Conclusion
Bartels  
et al.(35)
51 COPD  
*Gender distribution  
not reported  
63.18±7.92 years 
COPD: Medically diagnosed (severe), no any other active 
respiratory disease, maintain their normal daily routine  
and medications. 
All patients refrained from short-acting bronchodilators 
during assessment.
Oxygen supplementation:
Acute administration of 31% SuppO2 and CA; 
both treatments were randomized (double 








SuppO2 in COPD patients 
significantly and favor-




 70 COPD  
(35♂, 35♀)
62.8±8.5 years  
COPD: %FEV1: 30.4, %FVC:  <70% (of predicted.  
All patients were medically diagnosed as moderate-severe,  
and they maintained daily routine and medications.
Oxygen supplementation:
Acute administration of 31% SuppO2 and CA. 
The intervention was delivered in a counter 
balanced randomized double-blind cross over 
design.
BRS BRS↑ Oxygen supplementation 




15 COPD (10♂, 5♀)
 52.2±2.6 years  
 
28 CON (13♂,15♀)  
47.2±1.7 years  
 
COPD: Mild (GOLD: I-II), smoking status (mixed),
on medication such as B-agonists, anticholinergic,  
cortisone and theophylline.
Controlled breathing and oxygen 
supplementation:
Acute administration of a 2-minute 
controlled breathing at 15 breaths/minute 
(spontaneous breathing, and 2 minutes of 
controlled breathing at 6 breaths/minute 
(slow breathing. The treatments were 
randomly done by turns. 
Intervention also included progressive 
hypercapnic hyperoxia, isocapnic hypoxia 
and oxygen administration were also done.
BRS BRS↑ Slow breathing and oxygen 
administration improved BRS 
in patients with COPD. 
Borghi-Silva 
et al. (37)
19 COPD (19♂)   
69±8 years       
8 CON (8♂) 68±5 years  
COPD: FEV1 <50%, FVC<70% of predicted, (moderate-severe), 
clinically stable, ex-smokers, sedentary, no other  
chronic diseases, B2-agonists, xanthene derivatives 
and steroid treatments were suspended for 24 hours to 
measurement time.
NIMV
 Acute administration of BIPAP (1 minute) 
comprising of; IPAP, which was initially set 
at 6 cmH2O (increased gradually at 2 cmH2O  
per minute to a maximum of 14 cmH2O), 
and EPAP, which was set  at 3 cmH2O (and 
increased gradually at 1 cmH2O per minute 







 HF(nu) ↓ 
LF/HF 
ratio↑ 
Ventilation improved but 
autonomic function  
decreased as HF was 
significantly reduced while 
LF was significantly increased 
during BIPAP  in patients  
with COPD. 
Haidar 
et al.(20)  
18 COPD (10♂,8♀)   
51.7±2.4 years
14 CON (5♂, 9♀)  
47.7±2.8 years  
COPD: Mild (GOLD: I-II), normoxic, those on COPD were 
allowed to continue with their medications. Smokers and  
 ex-smokers were allowed to participate.
Oxygen supplementation: 
3 weeks (15 sessions) of passive interval 
hypoxic training for the TG for 3-5 times at 
15% down to 12% of oxygen was administered 
progressively, meanwhile the placebo group 






Patients with mild COPD 
with signs of cardiovascular 
autonomic abnormalities at 
baseline normalized (similar 
to healthy individuals) to 
following 3 weeks of hypoxic 
training.
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*Gender distribution  
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COPD: Medically diagnosed (severe), no any other active 
respiratory disease, maintain their normal daily routine  
and medications. 
All patients refrained from short-acting bronchodilators 
during assessment.
Oxygen supplementation:
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SuppO2 in COPD patients 
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Oxygen supplementation:
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design.
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Controlled breathing and oxygen 
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Acute administration of a 2-minute 
controlled breathing at 15 breaths/minute 
(spontaneous breathing, and 2 minutes of 
controlled breathing at 6 breaths/minute 
(slow breathing. The treatments were 
randomly done by turns. 
Intervention also included progressive 
hypercapnic hyperoxia, isocapnic hypoxia 
and oxygen administration were also done.
BRS BRS↑ Slow breathing and oxygen 
administration improved BRS 
in patients with COPD. 
Borghi-Silva 
et al. (37)
19 COPD (19♂)   
69±8 years       
8 CON (8♂) 68±5 years  
COPD: FEV1 <50%, FVC<70% of predicted, (moderate-severe), 
clinically stable, ex-smokers, sedentary, no other  
chronic diseases, B2-agonists, xanthene derivatives 
and steroid treatments were suspended for 24 hours to 
measurement time.
NIMV
 Acute administration of BIPAP (1 minute) 
comprising of; IPAP, which was initially set 
at 6 cmH2O (increased gradually at 2 cmH2O  
per minute to a maximum of 14 cmH2O), 
and EPAP, which was set  at 3 cmH2O (and 
increased gradually at 1 cmH2O per minute 







 HF(nu) ↓ 
LF/HF 
ratio↑ 
Ventilation improved but 
autonomic function  
decreased as HF was 
significantly reduced while 
LF was significantly increased 
during BIPAP  in patients  
with COPD. 
Haidar 
et al.(20)  
18 COPD (10♂,8♀)   
51.7±2.4 years
14 CON (5♂, 9♀)  
47.7±2.8 years  
COPD: Mild (GOLD: I-II), normoxic, those on COPD were 
allowed to continue with their medications. Smokers and  
 ex-smokers were allowed to participate.
Oxygen supplementation: 
3 weeks (15 sessions) of passive interval 
hypoxic training for the TG for 3-5 times at 
15% down to 12% of oxygen was administered 
progressively, meanwhile the placebo group 






Patients with mild COPD 
with signs of cardiovascular 
autonomic abnormalities at 
baseline normalized (similar 
to healthy individuals) to 




Table 1   Continued.
Reference Sample Inclusion criteria Intervention Outcome Results Conclusion
Jaju  
et al.(6)
11 COPD (7♂,4♀) 
43.9±20.6 years
 
6 CON (4♂, 2♀)  
43.5±14.6 years  
COPD: FEV1 <60% predicted, No diabetes, CCF or hypertension. 
The patients were allowed to continue medications. Patients 
had normal BMI (21.9±5.52kg/km2).
Controlled breathing
3 months of PBE was administered once, 
which comprise the closing of one nostril 
with the thumb, and inhale slowly over (6 
seconds), afterwards, both nostrils are close 
for another count of 6 seconds. The second 
nostril was then open for slow exhalation 
over 6 seconds. Thereafter, inhalation with 
the same nostril slowly over 6 seconds is 
done. This constituted a single sequence, 
which was repeated for a duration of 30/min/







shifted towards  
the sympathetic in both  
patients with COPD,  
but it was not significant.
Lewis 
et al. (19)
10 COPD (7♂, 3♀)
73.9±7.2 years
COPD:  Severe (GOLD III- IV). All patients were hypoxic but 
stable. Patients on drugs affecting ANS were excluded and 
they had other comorbidities like hypertension (pulmonary) 
and ischemic heart disease. Patients had normal BMI 
(24.8±4.2kg/km2). 
Oxygen supplementation:
3 sessions of LTOT was prescribed to be taken 
for 16 hours per 24-hour period at home. The 




An increase in HRV  multi-fractal 
properties following LTOT were 
observed. However, the beneficial 
effects was mainly expressed 
during the morning hours. 
Ramos 
et al(27)
16 COPD (12♂,4♀) 
64±11 years
COPD: COPD (GOLD 1-3), mean FEV1 was 60±25% of predicted. 
The mean weight was 66±14kg and BMI 24±4kg/m2. No 
medication was taken 12 hours prior to trials, non ANS 
associated diseases or comorbidities. They were asked to 
abstain from stimulating substances such as coffee, and 
alcohol.
Controlled breathing
Initial spontaneous breathing for ten 
minutes (Rest), then PLB for 8 continuous 
minutes and rest for another ten minutes 





Analysis of only the 
RMSSD index showed that 




15 COPD (11♂, 4♀)
60.9±1.4 years 
15 CON (11♂, 4♀) 
60.7±1.4 years
COPD: FEV1 ≤60% predicted (GOLD), and the mean BMI 
was 27±1.1kg/m2. All were between 30-80 years No diuretic 
medication was taken. The patients were also normoxic, 
had stable sinus rhythm and nonsmoking. All those with 
comorbidities and those on sympathomimetic drugs were 
excluded.
Controlled breathing
15 breaths/min-1 for 4 min, followed by 
another 4 min respiration at 6 breaths/
minute (3 seconds inspiration, 7 s expiration. 
Breathing at a rate of 6 breaths/minute was 
done using visual feedback.
MSNA/BRS BRS↑
MSNA↓   
Slow breathing
significantly enhanced
BRS and MSNA in patients  
with COPD.
Raupach 
et al. (15)  
15 COPD (11♂, 4♀)
60.9±1.4 years 
15 CON (11♂, 4♀) 
60.7±1.4 years  
COPD: FEV1 ≤60% predicted (GOLD), and the mean BMI 
was 27±1.1kg/m2. All were between 30-80 years No diuretic 
medication was taken. The patients were also normoxic, 
had stable sinus rhythm and nonsmoking. All those with 
comorbidities and those on sympathomimetic drugs were 
excluded.
Controlled breathing
IRL was performed while patients were 
breathing through a spirometer. Work of 
breathing was increased (tension-time index) 
by roughly 110% (from 0 to 10 hPa/l/s).  
MSNA MSNA= Short term doubling the  
work of breathing does not 
affect sympathetic activation 
in COPD patients. 
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Reference Sample Inclusion criteria Intervention Outcome Results Conclusion
Jaju  
et al.(6)
11 COPD (7♂,4♀) 
43.9±20.6 years
 
6 CON (4♂, 2♀)  
43.5±14.6 years  
COPD: FEV1 <60% predicted, No diabetes, CCF or hypertension. 
The patients were allowed to continue medications. Patients 
had normal BMI (21.9±5.52kg/km2).
Controlled breathing
3 months of PBE was administered once, 
which comprise the closing of one nostril 
with the thumb, and inhale slowly over (6 
seconds), afterwards, both nostrils are close 
for another count of 6 seconds. The second 
nostril was then open for slow exhalation 
over 6 seconds. Thereafter, inhalation with 
the same nostril slowly over 6 seconds is 
done. This constituted a single sequence, 
which was repeated for a duration of 30/min/







shifted towards  
the sympathetic in both  
patients with COPD,  
but it was not significant.
Lewis 
et al. (19)
10 COPD (7♂, 3♀)
73.9±7.2 years
COPD:  Severe (GOLD III- IV). All patients were hypoxic but 
stable. Patients on drugs affecting ANS were excluded and 
they had other comorbidities like hypertension (pulmonary) 
and ischemic heart disease. Patients had normal BMI 
(24.8±4.2kg/km2). 
Oxygen supplementation:
3 sessions of LTOT was prescribed to be taken 
for 16 hours per 24-hour period at home. The 




An increase in HRV  multi-fractal 
properties following LTOT were 
observed. However, the beneficial 
effects was mainly expressed 
during the morning hours. 
Ramos 
et al(27)
16 COPD (12♂,4♀) 
64±11 years
COPD: COPD (GOLD 1-3), mean FEV1 was 60±25% of predicted. 
The mean weight was 66±14kg and BMI 24±4kg/m2. No 
medication was taken 12 hours prior to trials, non ANS 
associated diseases or comorbidities. They were asked to 
abstain from stimulating substances such as coffee, and 
alcohol.
Controlled breathing
Initial spontaneous breathing for ten 
minutes (Rest), then PLB for 8 continuous 
minutes and rest for another ten minutes 





Analysis of only the 
RMSSD index showed that 




15 COPD (11♂, 4♀)
60.9±1.4 years 
15 CON (11♂, 4♀) 
60.7±1.4 years
COPD: FEV1 ≤60% predicted (GOLD), and the mean BMI 
was 27±1.1kg/m2. All were between 30-80 years No diuretic 
medication was taken. The patients were also normoxic, 
had stable sinus rhythm and nonsmoking. All those with 
comorbidities and those on sympathomimetic drugs were 
excluded.
Controlled breathing
15 breaths/min-1 for 4 min, followed by 
another 4 min respiration at 6 breaths/
minute (3 seconds inspiration, 7 s expiration. 
Breathing at a rate of 6 breaths/minute was 
done using visual feedback.
MSNA/BRS BRS↑
MSNA↓   
Slow breathing
significantly enhanced
BRS and MSNA in patients  
with COPD.
Raupach 
et al. (15)  
15 COPD (11♂, 4♀)
60.9±1.4 years 
15 CON (11♂, 4♀) 
60.7±1.4 years  
COPD: FEV1 ≤60% predicted (GOLD), and the mean BMI 
was 27±1.1kg/m2. All were between 30-80 years No diuretic 
medication was taken. The patients were also normoxic, 
had stable sinus rhythm and nonsmoking. All those with 
comorbidities and those on sympathomimetic drugs were 
excluded.
Controlled breathing
IRL was performed while patients were 
breathing through a spirometer. Work of 
breathing was increased (tension-time index) 
by roughly 110% (from 0 to 10 hPa/l/s).  
MSNA MSNA= Short term doubling the  
work of breathing does not 
affect sympathetic activation 
in COPD patients. 
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COPD:  FEV1 ≤60% predicted (GOLD: II), FEV/FVC: <0.7 
and the mean BMI was 23±3.3kg/m2. The patients were 
stable clinically and were taking their normal medication 
(nonsmokers).
CON: Healthy and none of them had cardiac or metabolic 
diseases.
COPD and CON matched by several parameters.
Controlled breathing
Patients underwent 2 minutes of 
spontaneous breathing at rest, then  
4 minutes of R-SAM, which is a series of 
deep/slow inspirations and expirations to 
provide a pulmonary volume that varied 
from the TLC to RV. Each respiratory cycle 
was performed for 10 second (5 each for 
inspiration and expiration) corresponding  










COPD patients demonstrated 
impaired cardiac autonomic, 
which remained unchanged 
both at rest and during RSA-M 
when compared with healthy 










COPD: FEV1 <60% (GOLD: II), FVC<0.7 predicted and the mean 
BMI was 23±3.3kg/m2. Patients were clinically stable, non-
alcoholics, sedentary and they took their normal medication 
(bronchodilators). They were also nonsmokers, free from 
cardiac and metabolic diseases, patients avoided B2-agonists, 
xanthene derivatives and steroids for 24 hours before the 
experimental test.
NIMV
I.  Spontaneous breathing
II: Randomly treated with three different 
levels of CPAP on the same day: sham 
ventilation, 5 cmH2O (CPAP5) and 10 cmH2O 
(CPAP10) for 10 minutes.











that acute treatment NIMV led 
to altered   HRV parameters, 
also significant negative effects 
occurred during CPAP10 







COPD: GOLD II-IV and their mean BMI was 25.54±4.44kg/
m2. All smokers, alcoholics and those with <2 months 
exacerbation, metabolic/cardiac disease, cannot perform 
procedure were excluded. Those with other chronic 
comorbidities and those on ANS influencing medications 
were also excluded. 
Controlled breathing
Comprised of three 20-minute phases –  
The first (rest) and third being spontaneous 
breathing while the second phased is PLB. 
Protocol between 8 am and 12 pm in a room 
with temperature between 21 and 23°C and 









PLB led to improvements in 
booth linear and non-linear 
HRV parameters as well as  








COPD: ATS criteria with chronic hypercapnia, FEV1: 28±9%,  
FVC: 42±13 % predicted, excluded patients with other co 
morbidities such as cancer and those who cannot perform 
the procedure. 
Oxygen supplementation:
Two groups of patients had an alternate 
application of both; (a) control breathing 
while breathing room air in a tilted position 
and (b) control breathing with oxygen 
supplementation in a tilted position.





(therapy) only partially 
reversed ANS derangements  
in hypoxemic patients  
with COPD.
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COPD:  FEV1 ≤60% predicted (GOLD: II), FEV/FVC: <0.7 
and the mean BMI was 23±3.3kg/m2. The patients were 
stable clinically and were taking their normal medication 
(nonsmokers).
CON: Healthy and none of them had cardiac or metabolic 
diseases.
COPD and CON matched by several parameters.
Controlled breathing
Patients underwent 2 minutes of 
spontaneous breathing at rest, then  
4 minutes of R-SAM, which is a series of 
deep/slow inspirations and expirations to 
provide a pulmonary volume that varied 
from the TLC to RV. Each respiratory cycle 
was performed for 10 second (5 each for 
inspiration and expiration) corresponding  










COPD patients demonstrated 
impaired cardiac autonomic, 
which remained unchanged 
both at rest and during RSA-M 
when compared with healthy 










COPD: FEV1 <60% (GOLD: II), FVC<0.7 predicted and the mean 
BMI was 23±3.3kg/m2. Patients were clinically stable, non-
alcoholics, sedentary and they took their normal medication 
(bronchodilators). They were also nonsmokers, free from 
cardiac and metabolic diseases, patients avoided B2-agonists, 
xanthene derivatives and steroids for 24 hours before the 
experimental test.
NIMV
I.  Spontaneous breathing
II: Randomly treated with three different 
levels of CPAP on the same day: sham 
ventilation, 5 cmH2O (CPAP5) and 10 cmH2O 
(CPAP10) for 10 minutes.











that acute treatment NIMV led 
to altered   HRV parameters, 
also significant negative effects 
occurred during CPAP10 







COPD: GOLD II-IV and their mean BMI was 25.54±4.44kg/
m2. All smokers, alcoholics and those with <2 months 
exacerbation, metabolic/cardiac disease, cannot perform 
procedure were excluded. Those with other chronic 
comorbidities and those on ANS influencing medications 
were also excluded. 
Controlled breathing
Comprised of three 20-minute phases –  
The first (rest) and third being spontaneous 
breathing while the second phased is PLB. 
Protocol between 8 am and 12 pm in a room 
with temperature between 21 and 23°C and 









PLB led to improvements in 
booth linear and non-linear 
HRV parameters as well as  








COPD: ATS criteria with chronic hypercapnia, FEV1: 28±9%,  
FVC: 42±13 % predicted, excluded patients with other co 
morbidities such as cancer and those who cannot perform 
the procedure. 
Oxygen supplementation:
Two groups of patients had an alternate 
application of both; (a) control breathing 
while breathing room air in a tilted position 
and (b) control breathing with oxygen 
supplementation in a tilted position.





(therapy) only partially 
reversed ANS derangements  




Table 1   Continued.
Reference Sample Inclusion criteria Intervention Outcome Results Conclusion
Sin  
et al. (23)
21 COPD (10♂,11♀): 
64.1±9.7 years      
COPD: All patients had clinical diagnosis of COPD, and a ≥10 
pack/year smoking history. The FEV1 was <70% predicted. 
Patients were excluded if they had cardiac disease (coexisting), 
cognitive impairment or a poor prognosis.
NIMV
I: Training group (TG): 3 months of standard 
medical therapy plus nocturnal NIMV  
(4 cm H2O of EPAP and 8 cm H2O of IPAP).
II: Control group (CG): 3 months of standard 













NIMV applied nocturnally over 
3 months may improve  HRV 
parameters in patients with 
COPD.
Skyba 
et al.  (40)
23 COPD (18♂,5♀) 
68.2±1.7 years    
COPD: FEV1: 45.5±3.9% predicted; FVC: 66.1±3.8 % predicted 
(ATS/ERS), with acute exacerbation on beta agonist and 
anticholinergics.
Exclusion criteria were respiratory arrest, decreased level 
of consciousness, severe exacerbation of COPD requiring 
intubation.
NIMV
Acute NIMV using BIPAP technique for  
60 minutes at a level of 4 cmH2O of EPAP and  




BIPAP may potentially cause 
sustained improvements in the 
autonomic control of heart 
rate. The LF also significantly 
increased only during post 
BIPAP phase.
Van Gestel 
et al.(28)  
40 COPD (23♂, 37♀) 
66.1 ± 6.4 years
COPD: all patients were clinically diagnosed (GOLD), FEV1: 
45.9 + 17.4% predicted. Patients had no clinical signs or 
symptoms of acute exacerbations, hospital
admissions preceding 6 weeks. And, they all had normal BMI.
20 patients randomly assigned to TG and CG.
Controlled breathing
I: TG; 4-week conventional PR + RFT, 30-min/
sessions of controlled breathing using
techniques of biofeedback with rapid shallow 
breathing, breath-to-breath irregularity
in rate and depth and predominant thoracic
breathing.







Adding RFT to conventional  
PR intervention did not have
additional effect on cardiac 




28 COPD 64 ±
10 years
COPD: the patients were clinically diagnosed using the ATS/
ERS criteria. All patients had HRF. However, those
with cardiovascular diseases, diabetes, hemodynamic 
instability, systemic disorders that can affect ANS were
excluded.
The HRF was defined by arterial blood gas criteria (partial 
pressure of CO2: PaCO2 >45 mmHg (6kPa), and pH< 7.35).
NIMV
BIPAP was administered at a level of 5 
cmH2O of EPAP and 15 cmH2O of IPAP in 












The NIMV may improve HRV 
indices of parasympathetic
modulation of heart rate in 
COPD cases with HRF and 
decrease arrhythmic
potential.
Notes: CON: control; #: significantly lower; “: significantly higher; (¼): no significant difference; _: male; \: female; 
vs: versus; GOLD: global initiative for obstructive lung disease; LF: lung function; %FEV1: percent forced expiratory 
volume in 1 s; FVC: forced vital capacity; BIPAP: bi-level positive airway pressure; BRS: baroreceptor sensitivity; 
CPAP; continuous positive air way pressure; HRV: heart rate variability; IPAP: inspiratory positive airway pressure; 
MSNA: muscle sympathetic nerve activity; EPAP: inspiratory positive airway pressure; TLC: total lung capacity; RV: 
residual volume; SuppO2: supplemental oxygen; CA: compressed air; PBE: pranayama breathing exercise; HRF: 
hypercapnic respiratory failure; BMI: body mass index; RFT: respiratory feedback training; ATS: American 
Thoracic Society; ERS: European Respiratory Society; ANS: autonomic nervous system; R-SAM: respiratory 
sinusoidal arrhythmia maneuver; IRL: inspiratory resistive loading; PLB: pursed lip breathing; cmH2O: centimeter 
of water (pressure); RRi: R-R waves interval; RMSSD: square root of the mean of the sum of the squares of differences 
between adjacent normal RRi within a given time minus one; pNN50: percentage of RRi that differs each other 
more than 50 ms; SDNN: standard deviations of all NN intervals; SDANN: standard deviation of the averages of NN 
intervals in all 5-min segments of the entire recording; TINN: triangular interpolation of RRi; NIMV: noninvasive 
mechanical ventilation; NNmean: average RRi; RMSSDNN: RMSSD between adjacent RRi; SDSD: standard 
deviations between adjacent NN intervals; SDRR: standard deviation of RRi for time domain analyses. For 
frequency domain analyses, these included TP (total power), HF (high-frequency power), VLF (very low-frequency 
power), LF (low-frequency power), and LF/HF (low frequency/high frequency ratio).
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Reference Sample Inclusion criteria Intervention Outcome Results Conclusion
Sin  
et al. (23)
21 COPD (10♂,11♀): 
64.1±9.7 years      
COPD: All patients had clinical diagnosis of COPD, and a ≥10 
pack/year smoking history. The FEV1 was <70% predicted. 
Patients were excluded if they had cardiac disease (coexisting), 
cognitive impairment or a poor prognosis.
NIMV
I: Training group (TG): 3 months of standard 
medical therapy plus nocturnal NIMV  
(4 cm H2O of EPAP and 8 cm H2O of IPAP).
II: Control group (CG): 3 months of standard 













NIMV applied nocturnally over 
3 months may improve  HRV 
parameters in patients with 
COPD.
Skyba 
et al.  (40)
23 COPD (18♂,5♀) 
68.2±1.7 years    
COPD: FEV1: 45.5±3.9% predicted; FVC: 66.1±3.8 % predicted 
(ATS/ERS), with acute exacerbation on beta agonist and 
anticholinergics.
Exclusion criteria were respiratory arrest, decreased level 
of consciousness, severe exacerbation of COPD requiring 
intubation.
NIMV
Acute NIMV using BIPAP technique for  
60 minutes at a level of 4 cmH2O of EPAP and  




BIPAP may potentially cause 
sustained improvements in the 
autonomic control of heart 
rate. The LF also significantly 
increased only during post 
BIPAP phase.
Van Gestel 
et al.(28)  
40 COPD (23♂, 37♀) 
66.1 ± 6.4 years
COPD: all patients were clinically diagnosed (GOLD), FEV1: 
45.9 + 17.4% predicted. Patients had no clinical signs or 
symptoms of acute exacerbations, hospital
admissions preceding 6 weeks. And, they all had normal BMI.
20 patients randomly assigned to TG and CG.
Controlled breathing
I: TG; 4-week conventional PR + RFT, 30-min/
sessions of controlled breathing using
techniques of biofeedback with rapid shallow 
breathing, breath-to-breath irregularity
in rate and depth and predominant thoracic
breathing.







Adding RFT to conventional  
PR intervention did not have
additional effect on cardiac 




28 COPD 64 ±
10 years
COPD: the patients were clinically diagnosed using the ATS/
ERS criteria. All patients had HRF. However, those
with cardiovascular diseases, diabetes, hemodynamic 
instability, systemic disorders that can affect ANS were
excluded.
The HRF was defined by arterial blood gas criteria (partial 
pressure of CO2: PaCO2 >45 mmHg (6kPa), and pH< 7.35).
NIMV
BIPAP was administered at a level of 5 
cmH2O of EPAP and 15 cmH2O of IPAP in 












The NIMV may improve HRV 
indices of parasympathetic
modulation of heart rate in 
COPD cases with HRF and 
decrease arrhythmic
potential.
Notes: CON: control; #: significantly lower; “: significantly higher; (¼): no significant difference; _: male; \: female; 
vs: versus; GOLD: global initiative for obstructive lung disease; LF: lung function; %FEV1: percent forced expiratory 
volume in 1 s; FVC: forced vital capacity; BIPAP: bi-level positive airway pressure; BRS: baroreceptor sensitivity; 
CPAP; continuous positive air way pressure; HRV: heart rate variability; IPAP: inspiratory positive airway pressure; 
MSNA: muscle sympathetic nerve activity; EPAP: inspiratory positive airway pressure; TLC: total lung capacity; RV: 
residual volume; SuppO2: supplemental oxygen; CA: compressed air; PBE: pranayama breathing exercise; HRF: 
hypercapnic respiratory failure; BMI: body mass index; RFT: respiratory feedback training; ATS: American 
Thoracic Society; ERS: European Respiratory Society; ANS: autonomic nervous system; R-SAM: respiratory 
sinusoidal arrhythmia maneuver; IRL: inspiratory resistive loading; PLB: pursed lip breathing; cmH2O: centimeter 
of water (pressure); RRi: R-R waves interval; RMSSD: square root of the mean of the sum of the squares of differences 
between adjacent normal RRi within a given time minus one; pNN50: percentage of RRi that differs each other 
more than 50 ms; SDNN: standard deviations of all NN intervals; SDANN: standard deviation of the averages of NN 
intervals in all 5-min segments of the entire recording; TINN: triangular interpolation of RRi; NIMV: noninvasive 
mechanical ventilation; NNmean: average RRi; RMSSDNN: RMSSD between adjacent RRi; SDSD: standard 
deviations between adjacent NN intervals; SDRR: standard deviation of RRi for time domain analyses. For 
frequency domain analyses, these included TP (total power), HF (high-frequency power), VLF (very low-frequency 
power), LF (low-frequency power), and LF/HF (low frequency/high frequency ratio).
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was sufficiently long, (viii) selective loss-to-follow-up was excluded at analysis also 
represented as the total number of drop-outs or loss to follow-up >20%, and (ix) 
identification and consideration of confounders if and differences in medication 
use and patients characteristics were reported and accounted for. 
 A negative score (-) was allotted when noninformative description was provided 
to answer any of the question item or when the provided information was 
insufficient. After evaluating the included studies individually, the assessors met to 
compare their evaluation and to discuss areas of differences to obtain a consensus. 
Each study received a total methodological quality score by collating the number 
of positive item scores (+) over the number of question items. The scores were then 
converted into percentages (100%) in order to facilitate comparability across 
different study designs (Table 2). Only studies with high methodological quality 
(≥60%) were included for evidence synthesis.
Assessment of evidence synthesis 
For each respiratory training technique, the evidence synthesis was based on specific 
autonomic function outcome. In total, five possible evidence levels; strong, moderate, 
limited, inconsistent and no evidence could be reached. A strong evidence signifies 
consistent findings reported in at least three studies. Moderate evidence connotes 
consistent findings reported in two studies. A limited evidence was when results 
were found in only one study. Inconsistent evidence indicates conflicting findings in 
the available studies, while no evidence is when no study was available.  Findings in 
two or more studies were considered to be consistent only when similar results 
formed at least 75% of the results in the studies evaluated.
Results
Study selection
As shown in Figure 1, a total of 724 hits were identified from the database search. 
After de-duplication, 633 articles remained. Of these, 613 articles were excluded 
for not fulfilling the eligibility criteria (during title and abstract screening). 
Six potential articles were also added following a search of the reference lists of 
the articles that fulfilled the eligibility criteria. Altogether, the full-text reports of 
26 articles were retrieved and evaluated based on the inclusion and exclusion 
criteria. Eight articles were further excluded for failure to meet all the inclusion 
criteria. In the end, 18 studies comprising eleven case-controlled (6, 8, 10, 15, 35-39, 41) 



































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Study characteristics and outcome measures 
A total of 322 (197 males) patients with COPD participated across the studies. 
However, two studies did not provide information on gender distribution (5, 35). 
The FEV1 among the participants was generally <70% of predicted value (indicating 
a sign of obstructive lung disease). The  participants across the reviewed studies 
varied from mild COPD (GOLD I-II) (8, 20, 22, 41), to moderate-severe COPD (GOLD 
II-III) (27, 36, 37) to severe COPD (GOLD III-IV) (19, 35), and a mixture of all stages 
(GOLD II-IV) in one study (38). Generally, most study participants were clinically 
stable since, those with chronic comorbidities and/or other active respiratory 
diseases were largely excluded. 
 The respiratory rehabilitation techniques reported on in the studies included 
are oxygen supplementation (six studies) (8, 19, 20, 35, 36, 39), NIMV (five studies) 
(5, 22, 23, 37, 40) and controlled breathing techniques (eight studies) in form of; 
slow breathing (8, 10), purse lip breathing (27, 38), resistive loading (15) and 
breathing maneuvers (6, 28, 41). Only three autonomic function outcomes were 
reported in the included studies. Majority of the studies (14 of 18) reported on the 
HRV indices (5, 6, 19, 20, 22, 23, 27, 28, 35, 37-41) followed by the BRS (8, 20, 35, 36) 
Figure 1   A flowchart of literature search used in the review.
Number of articles from different
databases PubMed = 451, Web of
Science = 107, Embase = 166




26 full texts screened
8 excluded:




reference lists = 6
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in four studies and then the MSNA in two studies (10, 15). Furthermore, the HRV 
parameters were represented in terms of time and frequency domain analyses. 
The time analyses of HRV reported in the included studies are; R-R waves interval 
(RRi), square root of the mean of the sum of the squares of differences between 
adjacent normal RRi within a given time minus one (RMSSD), the percentage of 
RRi that differ each other more than 50 ms (pNN50), standard deviations of all NN 
intervals (SDNN), standard deviation of the averages of NN intervals in all 5-min 
segments of the entire recording (SDANN),  triangular interpolation of RRi (TINN) 
average RRi (NNmean), RMSSD between adjacent RRi (RMSSDNN), standard deviation 
1 (SD1), standard deviation 2 (SD2) from the Poincare plots, standard deviations 
between adjacent NN intervals (SDSD) and standard deviation of RRi for time domain 
analyses (SDRR). For frequency domain analyses, these included; total power (TP), 
high frequency power (HF), very low frequency power (VLF), low frequency power 
(LF), and low-high frequency ratio (LF/HF). The frequency parameters were also 
expressed either in terms of absolute or normalized units (nu). 
Methodological Quality Assessment 
Initially, the assessors were in agreement regarding the evaluation of 116 out of 
125 question items. A consensus was only reached for the remaining nine question 
items after both assessors met to discuss initial points of disagreement. Table 2 
shows the results of the methodological assessment. Generally, none of the studies 
fulfilled the criteria for blinding. However, the other question items (criteria) were 
mostly fulfilled. The overall methodological quality score in terms of percentages 
ranged from 63 to 83% across all the reviewed studies.
Synthesis of Results 
Controlled breathing techniques
Eight studies (6, 8, 10, 15, 27, 28, 38, 41) reported on the effect of different controlled 
breathing techniques on three autonomic function outcome parameters in the 
reviewed studies. The results from two of these studies that investigated the effect 
of pursed lip breathing (PLB)  indicated that significant increases  were recorded 
for some HRV indices including RMSSD (27, 38), SDNN (38), SD1 (38), SD2 (38) , LF (38) 
and HF (38). Simultaneously, no significant changes were reported for other HRV 
indices such as SD1/SD2 ratio (38), LFnu (27), HFnu (27) and LF/HF ratio (27, 38). 
 The results from the studies that utilized other fairly known controlled 
breathing maneuvers (pranayama breathing exercise, respiratory sinus arrhythmia 
maneuver and resistance breathing) all reported that there were  no significant 
changes for the HRV indices such as NNmean (28), SDNN (28, 41), RMSSD (28, 41), LF 
(6, 28, 41), HF (6, 28, 41), LFnu (6, 41), HFnu (6, 41) and LF/HF (6, 28, 41). Similarly, 
inspiratory resistive loading did not have any significant effect on the MSNA of 
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patients with COPD (15). On the other hand, however, slow breathing techniques 
(6 breaths/minute) was reported to positively influence both MSNA (10) and BRS 
(8, 10)  in patients with COPD in two studies. 
 Based on the results of these studies, the evidence to support the effects of 
controlled breathing techniques on the HRV and MSNA parameters of autonomic 
function is inconsistent. A moderate level evidence seems to support the effect of 
slow breathing on the BRS.
Noninvasive mechanical ventilation
Five studies (5, 22, 23, 37, 40) reported on the effect of NIMV application on the 
HRV indices in both time and frequency domain analyses in patients with COPD. 
Both significant and non-significant changes were reported in the results of the 
reviewed studies. Specifically, the results across the studies showed that just as no 
significant changes occurred for RMSSD(5, 23, 37), SDNN(5, 22, 23, 37), SDNN index 
(5, 23), SDSD (23), LF (5, 22), HF(22, 37), LFnu (22), HFnu (22), TP (22), LF/HF (5, 22) and 
VLF (40), significant increases were seen for pNN50(5) SDNN(23), TINN(23), SDANN(23), 
HRVi(5, 23), RMSSD(22), LF(22, 37, 40), HF(5, 40) LFnu(22, 37) and LF/HF(37) indices. 
Furthermore, a significant decrease was also reported for HFnu (22, 37). 
 Based on the reviewed studies, the evidence to support the effect of NIMV 
application on the HRV indices is inconsistent. 
Oxygen supplementation
Five studies (19, 20, 35, 36, 39) examined the effects of oxygen supplementation on 
the HRV and BRS parameters in patients with COPD. Of these, the results from four 
studies that reported on the effect of oxygen supplementation led to significant 
increase in the value of HRV indices like RRi(20), RMSSDNN(19), SDNN(19) and HF. (35) 
A significant decrease was also seen in for LF/HF in one study (35). However, another 
results across three studies reported that HRV indices like SDRR (39), HF (39), 
TP (19) and LF (35)  were not  significantly influenced by oxygen supplementation. 
 Four studies assessing the effect of oxygen supplementation on the BRS of 
patients with COPD reported significant increases in the results of all four studies 
(p<0.05) (8, 20, 35, 36). 
 Based on the results of the reviewed studies, the evidence to support the effect 
of oxygen supplementation on HRV indices in patients with COPD is inconsistent. 
Second, a strong evidence was found to support the effect of oxygen supplementation 
on the BRS in these patients.
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Discussion
This systematic review evaluated the existing evidence to support the effect of 
three respiratory rehabilitation techniques (controlled breathing, NIMV and 
oxygen supplementation) on the autonomic function indices in patients with 
COPD. The inclusion of different study designs provided an opportunity to include 
as much studies as possible with a view to answering our review objectives. 
Additionally, all the included studies had high methodological quality, despite the 
lack of blinding and follow-up in most of the studies. 
 The results of this review indicated that most of the evidence profile for the 
effect of respiratory rehabilitation techniques on the autonomic function in 
patients with COPD was inconsistent, except for the evidence found to support the 
effect of controlled breathing and oxygen supplementation on the BRS values. This 
widespread inconsistency in the evidence validates the importance of our review. 
Hence, careful interpretation of autonomic function parameters is warranted. 
Presently, it is known that lower values for BRS and time domain analyses of the 
HRV such as RMSSD, SDNN and RRi is a sign of poor autonomic functioning. On 
the other hand, a high value for the MSNA variables signifies sympathetic activation, 
which is causes an imbalance in the autonomic function. Furthermore, the values 
for frequency domain parameters such as the LF HF and LF/HF ratio have variable 
interpretations, and they present robust information that can be utilized for 
monitoring patient’s prognosis. In a few occasions, however, differences may arise 
as a result of different laboratory assessment protocols or human error. However, 
the general output is reliable and indicative of the patients’ autonomic status. 
 The positive effects of controlled breathing on the BRS has a potential for 
future application in clinical settings in addition to its current application for risk 
stratification. Moreover, the BRS  is known for its protective role in regulating the 
blood pressure changes through its impact on the heart rate in individuals, as well 
as its role in monitoring the prognosis of patients with chronic diseases (42).  With 
these results, the mechanism by which BRS in particular responded to controlled 
breathing can be further brought to spotlight with a view to increasing it use for 
different purposes. Currently, it is known that this significant and consistent 
findings for the BRS values may have been as a result of increased oxygenation of 
the blood in the tissues independent of changing minute ventilation (43). This 
implies that control breathing techniques may be of significant benefit for patients 
with COPD. Besides, reduced peripheral chemoreflex has been demonstrated in 
normal individuals who are instructed to slow down their ventilatory patterns (44). 
 The HRV indices were mostly reported in the studies included in this review. 
However, the inconsistent evidence that were recorded for the HRV indices in 
both time and frequency domain analyses following respiratory rehabilitation 
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techniques poses a challenge in postulating the actual effects of these techniques 
on the HRV, as well as their potential use for HRV modulation. Unfortunately, HRV 
indices provides a better and more robust information of the cardiovascular 
health, and it also acts as a powerful independent prognostic factor for risks 
stratification (45). Nonetheless, there is need for more studies focusing on separate 
control breathing techniques so as to re-enforce our findings. For instance, PLB 
showed a slight beneficial effect on a few important HRV indices (27, 38). However, 
the presence of other controlled breathing maneuvers like pranayama, respiratory 
sinus arrhythmia maneuver, respiratory feedback training and inspiratory 
resistance exercises(6, 15, 28, 41), all of which had no significant effect on the HRV 
in patients with COPD contributed to the inconsistent evidence. 
 Another result of this review revealed that an inconsistent evidence also 
supported the effect of NIMV application on the HRV (5, 22, 37, 40). This results is 
also corroborated by  the findings of an earlier study that reported that NIMV has 
opposing influence on the HRV (46). Three studies also reported significant 
increases in the values of LF HRV indices (22, 37, 40). This is an indication of 
sympathetic activation, which is undesirable for patients with COPD. Second, a 
significant decrease in the HF indices, which is reflective of parasympathetic 
deactivation was also recorded in two studies following NIMV application (22, 37). 
From this finding, it can be inferred that NIMV as a technique may have no 
potentially beneficial therapeutic effect on the autonomic function of patients 
with COPD.  However, this does not underestimate the role of NIMV in enhancing 
other clinical variables such as oxygen perfusion and breathing pattern that have 
been widely established for patients with COPD (22, 23, 37).
 One of the most important findings of our review was the strong evidence in 
support of oxygen supplementation on the BRS in patients with COPD. Oxygen 
supplementation showed a more potent and consistent effect on the BRS compared 
to other outcomes. This evidence clearly shows that oxygen supplementation has 
an unambiguous influence on the cardiovascular health of patients with in COPD 
as represented by the BRS indices (8, 9, 20, 47).  It is also known that oxygen 
 supplementation could have enhanced the BRS through its action in reducing 
the levels of the pulmonary arterial tension and vasoconstriction, reduced right 
ventricular wall stress and also in improving the central venous oxygen saturation 
levels, all of which in turn causes a reduction in sympathetic tone (35). Moreover, 
oxygen supplementation leads to an increase of the resting oxygen saturation and 
ventilation/perfusion (PO2), which in turn causes a reduction in the sensation of 
dyspnea thereby activating the chemoreflex sensitivity (42). 
 This review had a few limitations. First, the autonomic function outcome 
parameters were mostly reported for the HRV indices. Fewer studies reported for 
BRS and MSNA, and there were no studies were available for parameters like the 
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heart rate recovery, chemoreflex sensitivity and sympathetic skin responses, 
all of which are known to be significant markers of autonomic function. Second, 
we observed the heterogeneity in some of the clinical characteristics of the study 
participants: stage of COPD disease, BMI, degree of %FEV1 predicted values, age and 
medication use across the included studies. Nevertheless, our findings remain 
relevant due to the multiplicity of studies and the need to shape the focus of future 
research in the topic area.  
 This review has showed that a variety of respiratory rehabilitation techniques 
may have a beneficial influence that can be clinically applied for the management 
of impairments of the sympathetic and parasympathetic systems, hence, making 
important modifications in the cardiovascular health possible among patients 
with COPD. Finally, the findings from our systematic review will  help draw the 
attention of researchers in the field of rehabilitation of chronic respiratory disease 
to the impact of conservative treatment approaches on the extra-pulmonary system. 
Conclusion
It was concluded that oxygen supplementation and controlled breathing techniques 
had profound influence on the autonomic function of patients with COPD, albeit 
mainly on the BRS indices. However, it is not yet clear whether this influence is of 
any therapeutic value in the long term. Hence, future studies may focus on specific 
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Objective: To assess evidence for the effectiveness of exercise training on autonomic 
function outcomes in patients with chronic obstructive pulmonary disease (COPD). 
Data sources: Online databases of PubMed, CINAHL and Web of Science were 
systematically searched for all years till 26th of January, 2017 using a combination 
of predefined keywords; COPD/exercise/autonomic function outcomes. Study 
selection: Research studies assessing any measure of autonomic function following 
exercise training in patients with COPD were included. Data extraction and 
synthesis: Data were extracted from studies with high methodological quality  for 
evidence synthesis. The review was reported in accordance with the PRISMA 
statement, while rating of evidence quality was determined GRADE guidelines. 
Results: Majority of the included studies utilized continuous exercise training 
mode with a vigorous level of intensity. Each exercise training session lasted 
between 30-40 minutes, and the frequency of intervention was ≥3 times/week. 
Evidence synthesis of the studies with high methodological quality per outcome 
revealed that a high quality evidence supported significant increases in time- 
domain heart rate variability (HRV) analyses and the heart rate recovery (HRR). 
However, the frequency domain HRV analyses were not significantly enhanced 
following exercise training. The evidence to support the effect of exercise training 
on baroreceptor sensitivity (BRS) in patients with COPD is very low. Conclusion: 
Exercise training demonstrated beneficial but limited effects on the autonomic 
function in COPD.  Presently, it is not clear whether these effects are sustained in 
the long term. Only a limited number of RCTs were available indicating a 
significant gap in the literature.   
Keywords: Pulmonary disease; chronic obstructive; autonomic function; exercise training; 
systematic review.
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Introduction
Chronic obstructive pulmonary disease (COPD) is a highly prevalent systemic 
disease that is caused by both environmental determinants and genetic risk 
factors (1). Although COPD is primarily associated with airflow obstruction that is 
not fully reversible, it is also known to negatively affect other systems such as cardio- 
vascular, muscular and autonomic functions (2, 3). Moreover, impairments in 
autonomic function has been reported in patients with COPD. In a recent systematic 
review of our group (Mohammed et al. [2015])(4), a strong level of evidence was 
reported supporting impairments as altered heart rate variability (HRV), baro- 
receptor sensitivity (BRS) and muscle sympathetic nerve activity (MSNA), all reflecting 
a potential dominance of the sympathetic activity in COPD (2, 5). 
 The HRV is a sensitive, noninvasive measurement tool that is utilized for assessing 
the autonomic input to the heart. It reflects the beat-to-beat changes of the heart 
known as R-R intervals, which relates to the interplay between the sympathetic 
and parasympathetic nervous systems (6). The HRV is widely recognized as a 
parameter for the estimation of cardiac autonomic modulations (of sinus node). 
Owing to a continuous improvements in its standards of measurements, physiological 
interpretation and clinical applications (7), the indices of the HRV are able reflect 
cardiac mortality related arrhythmia, identify early stages of disorders like of 
myocardial infarction, heart failure (ejection fraction) and the overall integrity of 
the ANS (8, 9). Other autonomic function parameters that have shown clinical 
applicability are the BRS and the MSNA, both of which are significant correlates of 
the HRV indices (10). Additionally, the heart rate recovery (HRR), a vagal mediated 
recovery of the heart to pre-exercise levels has been equally used as an outcome for 
assessing the effect of exercise intervention on the autonomic control in both 
healthy and diseased populations.
 An effective COPD management plan includes four components: (i) disease 
assessment and monitoring; (ii) risk factors reduction; (iii) achieving a stable 
condition; and (iv) treatment of exacerbations. Pulmonary rehabilitation (PR) and 
physiotherapy is a cornerstone in this management plan (3, 11, 12). In this review, 
we focused on the effect of exercise training in patients with COPD, which is a 
major part of PR and physiotherapy, on autonomic function indices. Exercise 
training has been shown to significantly improve exercise capacity, dyspnea, 
medical consumption, self-confidence and quality of life (2, 13-16). 
 Effects of exercise training on autonomic function have been reported and 
discussed in other chronic disease such as chronic heart failure (17), spinal cord 
injury (18), chronic kidney disease (19), all of them reporting an amelioration of 
the autonomic dysfunction. In COPD, several studies have investigated the effect of 
exercise training on sympatho-vagal balance. However, their conclusions seems to 
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not be concordant (3, 5, 20-24). Consequently, this systematic review has the aim to 
provide  summative and more reliable information on the role and effects of 
exercise training on autonomic function modulation in patients with COPD.
Methods
This systematic review was reported in accordance with the preferred reporting 
items for systematic reviews and meta-analyses (PRISMA) (25) statement.
Eligibility criteria
To be included in this systematic review, (RCTs and non RCTs) articles had to report the 
effect of exercise training on autonomic function parameters in patients with COPD. 
Information sources and search strategy 
To identify relevant articles, the online databases of PubMed (from inception to 
26th January , 2017), Web of Science (1955 – 26th January, 2017) and CINAHL (1983 
– 26th January, 2017) were searched. The search was conducted using a combination 
of free text words and subject headings as search terms (Table 1). Furthermore, 
search filters were applied to restrict search outputs for the type of article (clinical 
trial), species (humans) and language (English).
Study selection 
The studies included in the review fulfilled the following inclusion criteria:
i. study participants were clinically diagnosed with COPD (GOLD criteria/FEV1); 
ii. RCTs or non-RCTs;  
iii. exercise training parameters was clearly described (with parameters);
iv.  autonomic function parameters such as (i) HRV, interpreted as the variability 
of time between successive R waves of the heart beats in time and/or frequency 
domains outcomes, (ii) BRS, expressed in millisecond per millimeter of 
mercury, and (iii) heart rate recovery (HRR) expressed in beats per minutes 
were the main outcomes; 
v. article was published in English; and 
vi. full-text original research report. 
Initially, the titles and abstracts of all search results were screened for fulfillment 
of the inclusion criteria. The reference lists of articles that were included from the 
title and abstract screening was manually searched to identify potentially relevant 
articles. Thereafter, articles which did not fulfill all of the criteria were excluded 
from the review (Figure 1). 
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Data items and collection
Relevant information such as name of author(s) and year of publication, sample 
size and clinical characteristics of the participants, inclusion and exclusion 
criteria, intervention, outcomes, main results and conclusion were retrieved from 
the included studies (Table 2).
Table 1   Search strategy utilized in the database search.
S/no Database Search builder Hits
1 PubMed ((“Pulmonary Disease, Chronic Obstructive”[Mesh] OR 
COPD) AND (“Heart Rate”[Mesh] OR autonomic function OR 
baroreflex OR HRV) AND (“Exercise”[Mesh] OR exercise OR 
physical training))
75
2 CINAHL (((MH “Heart Rate Variability”) OR “heart rate variability” 
OR “baroreflex” OR “heart rate recovery” OR “autonomic 
function”) AND ((MH “Exercise”) OR “exercise”) AND ((MH 
“Pulmonary Disease, Chronic Obstructive”) OR “COPD”)))
43
3 Web of Science TS=(COPD AND exercise* AND (HRV OR autonomic*)) 9
Figure 1   Flowchart of the methodology used in the review.
Total hits from database(s) search  
127 
1 article added from manual 
search of references 
After screening (titles and  abstract)= 111 
16 duplicates removed 
18 full-texts screened 
6 excluded based on inclusion criteria  
12 articles included in the review 
92 articles excluded:  
       Reasons:  
(i) population, 15  
(ii) intervention, 23  
(iii) outcomes, 25  
(iv) both intervention and outcomes, 25  
(v) others (design & non English language), 4  
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Table 2   Table of evidence synthesis and study characteristics.
Reference Sample  Inclusion criteria/
characteristics






The COPD patients had  %FEV1 predicted of 40%, had 
normal BMI values and were sedentary individuals.  Those 
with orthopedic conditions and other comorbidities were 
excluded. In addition, all patients were allowed to continue 
their regular medications. 
RCT The TG underwent a 6-week of 30 minutes treadmill 
training (ambulation) 3 times/week + stretching exercises 
for upper and lower limbs.
The training intensity was set at 70% of the maximal speed 
achieved during the symptom-limited exercise test. 








altered the neural 
control of heart rate in 







COPD: Moderate to severe (GOLD II-IV) with a %FEV1 
predicted of 32±11% and 35±12% for TG and CG, 
respectively.
All patients were sedentary and had no other chronic 
diseases.
RCT The TG received 6 and 12  weeks of 30 minutes treadmill 
training at 70% the maximal speed (achieved during the 
symptom-limited exercise test). All stable and optimized 
medication was also continued. 




Improvement in cardiac 
autonomic modulation 








COPD: The %FEV1 predicted for the TG and CG were 
40±13% and 39±14%, respectively (GOLD II-III). All patients 
performed physical activity regularly in the past. However, 
none of them had unstable cardiac disease or other co-
morbidities.
RCT The TG received 12 week of high intensity exercise such 
as ergometry at 60% of maximum work rate, treadmill 
training at 75% walking speed and also strength training at 
70% of 1RM. 
CG: 12 weeks of low intensity exercises including breathing 
exercises and calisthenics.





in HRV indices  occurred 
only after the high-







COPD: Diagnosis of COPD was based on a  %FEV1//FVC 
predicted of 45.8±10.4%. All patients were stable, free 
from exacerbations and had no serious co-morbidities. 
The patients were also ambulant with an average BMI 
of 22.9±3.6 kg/m2 . Those who use systemic drugs were 
excluded.
Non- RCT All patients received 12-week at 2 sessions/week outpatient-
based PR comprising education (self-management and 
breathing retraining). Exercise training consisted 40 
minutes of cycle ergometer training performed at the best 














COPD: Mild and moderate (GOLD II-III). The average %FEV1 
predicted of the patients was 43.6±18.1%. And the patients 
had only mild hypoxemia. Those with other co-morbidities 
were excluded. All patients were also allowed to continue 
their medications (beta agonist, anticholinergic and 
steroids). 
Non- RCT The participants underwent  8 weeks outpatient PR 
program comprising 30-40 minutes on a cycle ergometer 
for 3 time/week at 60%, which was progressively increased 









training is associated 
with a gain in 
spontaneous BRS in 






COPD: Patients were clinically stable. And had a %FEV1 
predicted of 45.7±18.7% (GOLD II-IV). All patients were 
ex-smokers and slightly overweight (BMI: 27.1±4.1 kg/
m2). The patients were allowed to continue their optimal 
medications. However, those with co-morbidities were 
excluded.
Non- RCT Patients received 36 sessions exercise-based 
cardiopulmonary rehabilitation program comprising of 
breathing control and relaxation techniques, clearance of 
secretions psychological support and exercise training of 
40 minutes daily between  60% to 80% of maximum work 
load at 3 times/week. 
HRR↑ Exercise-based 
rehabilitation modestly  
improves HRR in patient 
with COPD.





COPD:  Patients were clinically stable (moderate-to-
severe COPD). The %FEV1 predicted was approximately 
39% of  normal values. None of the patients had COPD 
exacerbations. The average BMI was 27.9±5 kg/m2. 
Moreover, those with severe chronic diseases, cancer and 
those who participated in rehabilitation programs < 12 
months prior to study were excluded. 
Non- RCT The patients received 8 weeks of interval training 
consisting on a cycle ergometer for 3 times/week for a 
duration of  40 minutes using a combination of 2-minute 
at high work rate (70–100% Wpeak) and 3-minute at 
(40–50% Wpeak).
*cycling was maintained at 60-70 rotations per minute.
HRR↑ Endurance training 
enhances HRR in 
patients with COPD. 
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Table 2   Table of evidence synthesis and study characteristics.
Reference Sample  Inclusion criteria/
characteristics
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exacerbations. The average BMI was 27.9±5 kg/m2. 
Moreover, those with severe chronic diseases, cancer and 
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Table 2   Continued.
Reference Sample  Inclusion criteria/
characteristics
Design Intervention Results Conclusion
Leite 
et al, 2015
16 COPD  COPD:  Patients were clinically stable (no exacerbation 
in the last 30 days) ex-smokers (> 1 year). Not performed 
any physical training program prior to the study, not on 
oxygen therapy.  No sever comorbidities. Participants were 
allocated to TG and CG, the data was analyzed for 10 and 
6, respectively.
Non-RCT 12-week aerobic training








Twelve weeks of aerobic 
training (continuous 










COPD: The patients were clinically stable (moderate-
to-severe). The %FEV1 predicted for the two groups was  
50±19% and 39±9%, respectively. 
None of the patients had COPD exacerbation at time 
of recruitment. Those on systemic medications, severe 
chronic and musculoskeletal  diseases were excluded.
Non- RCT Both patient groups received 12 weeks of exercise training 
on a calibrated ergo cycle for 30 minutes at 3 times/week. 
The exercise intensity was set at 80% of the maximal
power output (VO2).
*One group received irbesatan medication (drug) while the 









12-week aerobic exercise 
training program 
was not associated 
with significant 
enhancement of HRV 
parameters.
Ramponi 




COPD: The patients had a %FEV1 predicted was 
50±14%. The patients had moderate-to-severe (GOLD) 
airflow obstruction. Patients with a clinical history 
of concomitant cardiac heart failure, anemia and/or 
inability to perform a symptom-limited cycle ergometry 
cardiopulmonary test were excluded. The patients were 
allowed to take only regular medications. 
Non- RCT The patients received 9 weeks of PR of 3 hours per session 
at 3 times/week (minimum of 21 sessions) for a duration 
of 10-30 minutes of consecutive incremental exercise 
on a cycle ergometer at 70-80% of maximum load. The 
intervention consisted of strength training, education, 
nutritional, psychosocial counseling and exercise training.
HRR↑ The PR training 
program improved the 
cardio-
vascular response 
during exercise at 
submaximal exercise 







COPD: Patients were clinically stable with a %FEV1 
predicted of 42±13%. Patients had  no exacerbation and 
were not on steroid medications. Those with chronic 
comorbidities and those who participated in a previous PR 
or long term oxygen therapy were excluded. 
Non- RCT Two groups:8 weeks of cycle ergometry, 3 times/week for 
24 sessions:
 One group received interval training comprising; warm 
up at  30% of work rate; interval training of 40 minutes 
comprising 2 minutes of high work rate (Wpeak) at 
70–100%, with 3 minutes at moderate intensity (40–50%).
The other group received continuous training comprising 
warm-up (20%), exercise training at 60% work rate and a 
cool down for 3 minutes (20%).
*cycling was maintained at 60-70 rpm 
HRR↑ Both interval and 
continuous exercise 
training improved HRR 






COPD: The patients were clinically stable. And they had 
an average %FEV1 predicted of 37±20% (GOLD III-IV). The 
patients had a mean BMI of 25.8±6.7kg/m2. However, some 
patients with other co morbidities like hypertension were 
not excluded. Also, all patients were allowed to continue 
their medications. 
Non- RCT The patients received a 4 week rehabilitation program 
at 5 days/week. The program comprises; inspiratory and 
expiratory training exercises, cycle ergometry training 
of 20–35 minutes twice daily + occasional stair climbing 
exercises, treadmill workout for 10–25 minutes daily, 
electro stimulation of the quadriceps and muscle 
flexibility and strength training exercises for the upper 
extremities and thoracic muscles.













parameters of HRV were 
improved in patients 
with COPD after the 
rehabilitation program.
Notes: ↑= significantly increased, ↓= significantly decreased, (=) = no significant difference, ♂= Male, 
♀= female, yrs=years RCT=randomized control trial, , GOLD=global initiative for obstructive lung disease, 
HRR= heart rate recovery, HRV=heart rate variability, BRS, baroreceptor sensitivity, nu=normalized values;
%FEV1= percent forced expiratory volume in one second, RM=repetition maximum, PR= pulmonary rehabilitation, 
TG=training group, CG=control group, INT=Intervention, PA=physical activity LTOT=long time oxygen therapy.
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Table 2   Continued.
Reference Sample  Inclusion criteria/
characteristics
Design Intervention Results Conclusion
Leite 
et al, 2015
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intervention consisted of strength training, education, 
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predicted of 42±13%. Patients had  no exacerbation and 
were not on steroid medications. Those with chronic 
comorbidities and those who participated in a previous PR 
or long term oxygen therapy were excluded. 
Non- RCT Two groups:8 weeks of cycle ergometry, 3 times/week for 
24 sessions:
 One group received interval training comprising; warm 
up at  30% of work rate; interval training of 40 minutes 
comprising 2 minutes of high work rate (Wpeak) at 
70–100%, with 3 minutes at moderate intensity (40–50%).
The other group received continuous training comprising 
warm-up (20%), exercise training at 60% work rate and a 
cool down for 3 minutes (20%).
*cycling was maintained at 60-70 rpm 
HRR↑ Both interval and 
continuous exercise 
training improved HRR 






COPD: The patients were clinically stable. And they had 
an average %FEV1 predicted of 37±20% (GOLD III-IV). The 
patients had a mean BMI of 25.8±6.7kg/m2. However, some 
patients with other co morbidities like hypertension were 
not excluded. Also, all patients were allowed to continue 
their medications. 
Non- RCT The patients received a 4 week rehabilitation program 
at 5 days/week. The program comprises; inspiratory and 
expiratory training exercises, cycle ergometry training 
of 20–35 minutes twice daily + occasional stair climbing 
exercises, treadmill workout for 10–25 minutes daily, 
electro stimulation of the quadriceps and muscle 
flexibility and strength training exercises for the upper 
extremities and thoracic muscles.













parameters of HRV were 
improved in patients 
with COPD after the 
rehabilitation program.
Notes: ↑= significantly increased, ↓= significantly decreased, (=) = no significant difference, ♂= Male, 
♀= female, yrs=years RCT=randomized control trial, , GOLD=global initiative for obstructive lung disease, 
HRR= heart rate recovery, HRV=heart rate variability, BRS, baroreceptor sensitivity, nu=normalized values;
%FEV1= percent forced expiratory volume in one second, RM=repetition maximum, PR= pulmonary rehabilitation, 




The evidence synthesis for this review was conducted in accordance with the 
grading recommendations assessment, development, and evaluation (GRADE) guide- 
lines. For a clear assessment of evidence profiling, the results for each autonomic 
function outcome was analyzed only after a judgment had been made regarding 
the study design and the exercise training parameters utilized. Additionally, the 
exercise training intensity in each study was determined based on the information 
provided by the exercise and sports association (Australia) that categorized it into 
four categories; high, vigorous, moderate and light (26). 
Evidence grading was reached for RCT and non RCT (if applicable) studies separately. 
Non- RCT studies were only used for evidence grading in the absence of RCT studies. 
Results derived from RCT studies were initially ranked high quality (4 points) 
evidence, whereas those from Non- RCT studies were designated low quality (2 points) 
evidence level. Thereafter, evidence quality was scaled down using five assessment 
criteria: assessment of risk of bias (27); presence of publication bias, which was 
determined by assessing whether the sample size was representative of the 





Scale down if Scale up if
RCT High Risk of bias
     0 No serious limitation
     -1 Serious limitation
     -2 Very serious limitation
Large effect
     +1 large
     +2 very large
 Moderate Inconsistency
     0 No serious inconsistency
     -1 Serious inconsistency
     -2 Very serious inconsistencies
Dose response
      +1 Evidence of a gradient
Non RCT Low Imprecision
      0 No imprecision
     -1 Serious imprecision
     -2 Very serious imprecision
All plausible residual 
confounding
Very low Publication bias
      0 Unlikely 
     -1 Likely
     -2 Very likely
 +1 Would reduce a 
demonstrated effect 
+1 Would suggest a spurious 
effect if no effect was observed
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population or if signs of negative trends could be identified (28); presence of 
imprecision in the study results, which was determined by observing the margin 
of 95% confidence interval (CI) range around the mean difference and the effect 
sizes between the treatment and control groups (29); inconsistency in the different 
outcome results that could not be attributed to heterogeneity in population or 
end points (30) and the presence of indirectness determined through reported 
differences in population, intervention, outcomes and indirect comparisons, that 
could limit the generalizability of the results (31). Scaling up of evidence was 
conducted using three assessment criteria when there is a:  large effect, dose- 
response gradient and plausible confounders explaining the results were reported (32) 
(Table 3). The eventual cumulative points reached for each of the autonomic function 
outcomes per intervention based on the evidence quality levels were labeled as high 
(≥4 points), moderate (3 points), low (2 points) and very low (≤1 point), accordingly.
Results
Study selection 
As shown in Figure 1, a total of 127 hits were identified from database search. 
After 16 duplicates were removed, 111 articles remained. These articles were 
then screened based on the eligibility criteria (title and abstract), which resulted 
in the exclusion of 92 articles. One article was added manually. In total, the 
full-text of 18 articles were retrieved and evaluated based on the inclusion and 
exclusion criteria. Finally, 12 publications comprising three RCTs and nine non 
RCT studies were included in the review. 
Study characteristics
A total of 422 patients with COPD across twelve studies. Three autonomic function 
parameters were analyzed. The HRV was analyzed  in both time and frequency 
domain analyses (2, 5, 11, 22, 23, 33, 34). The BRS expressed in ms/mmHg was the 
outcome in one study (11), whereas the HRR (beats/minutes) was reported in four 
non RCT studies (12, 24, 35, 36). 
Evidence quality
As shown in Table 4, study limitations were mostly in the area of low sample sizes 
(22, 23, 37), and substantial drop out (30-50%) of participants at the point of final 
analysis (2, 5, 22, 23, 37). Three RCTs with methodological quality were used for 
grading the evidence for the HRV indices, while four non RCT studies were used to 





The exercise training in all the included studies had a frequency of at least three 
times/week and a duration of 4 to 12 weeks. Continuous exercise training was 
proposed in nine of the studies, interval training accounted for two studies and 
one study combine both interventions (38). Majority of the included studies utilized 
vigorous intensity for exercise training and each exercise session lasted between 
30 to 40 minutes. 
 Two RCT studies and one non RCT study used an intensity corresponding to 60 
- 75% of maximal speed/VO2 for a duration 30 minutes/session on a treadmill 
modality (2, 22). One RCT and one non RCT study combined both treadmill and 
cycle ergometer modalities with a combined intensity of 60-75% of maximal speed/
Table 4   Assessment of risk of bias in the studies used for evidence synthesis.





HRV Adequate Unclear, randomly assigned Unclear, it was not stated  
whether the caregiver, patients 
and data collectors were blinded
30% loss in control group. 
However, these were accounted 
for in the analyses
None detected.  
All autonomic 
function outcome 






HRV Adequate Through draws of shuffled, opaque,  
coded envelopes 
Patients were not blinded. 
However, the investigators 
(caregiver and data collector)  
were blinded.
40% loss in both treatment  
and control groups. However, 









Camillo et al, 
2011
HRV Adequate Using concealed envelop procedure Unclear, it was not stated  
whether the caregiver, patients 
and data collectors were blinded
30% loss in each of treatment  
and control groups. However, 
these were accounted for in  
the analyses
Unlikely Sample size  
adequate
Non RCTs Outcome Appropriate  
eligibility criteria
Flawed measurement  
in both exposure and outcome
Inadequate control of 
confounders





Unlikely all measurements were  
adequately described
Unlikely No loss at follow up N/A
Geogiopoulou 
et al, 2012
HRR Adequate,  
(but no control group)
Unlikely all measurements were  
adequately described
Unlikely 87% completed the testing N/A
Gimeno Santos 
et al, 2014
HRR Adequate  
(large sample size)
Unlikely, as HRR is a simple measurement. 
Moreover, this were adequately described
Unlikely, patients were also free 
from co morbidities
Likely, as a significant as about 





HRR Adequate,  
(but no control group)
Unlikely, as HRR is a simple measurement. 
Moreover, this were adequately described
Likely, 67% of the patients 
developed arterial hypertension 
and were administered 
medication during the course  
of the study
No loss at follow up N/A
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peak work rate as exercise training intervention (5, 34). Five studies reported using 
only cycle ergometer training. In two of these studies, cycle ergometer was used 
exclusively (11, 23). The remaining three studies combined cycle ergometer training 
with other pulmonary rehabilitation intervention such as, self-management, education, 
respiratory muscle strength training, peripheral muscle strength training, functional 
electrical stimulation, psychosocial support, nutritional counseling, and chest 
physiotherapy (3, 12, 36). The exercise intensities corresponded to an intensity of 
between  60% and 80% of VO2 max, except in one study (3) where participants 
voluntarily exercised at the highest level of intensity possible (60-100% of VO2 max).
Table 4   Assessment of risk of bias in the studies used for evidence synthesis.





HRV Adequate Unclear, randomly assigned Unclear, it was not stated  
whether the caregiver, patients 
and data collectors were blinded
30% loss in control group. 
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for in the analyses
None detected.  
All autonomic 
function outcome 






HRV Adequate Through draws of shuffled, opaque,  
coded envelopes 
Patients were not blinded. 
However, the investigators 
(caregiver and data collector)  
were blinded.
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Unlikely all measurements were  
adequately described
Unlikely 87% completed the testing N/A
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et al, 2014
HRR Adequate  
(large sample size)
Unlikely, as HRR is a simple measurement. 
Moreover, this were adequately described
Unlikely, patients were also free 
from co morbidities
Likely, as a significant as about 





HRR Adequate,  
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Unlikely, as HRR is a simple measurement. 
Moreover, this were adequately described
Likely, 67% of the patients 
developed arterial hypertension 
and were administered 
medication during the course  
of the study
No loss at follow up N/A
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Only two studies used interval training exercise exclusively (24, 35). Interestingly, 
both studies have similar exercise training parameters; duration (40 minutes), 
frequency (3 times/week), and length of intervention (8 weeks). Furthermore, both 
studies similar exercise intensities; two minutes of cycling of high work rate 
(70% to 100% of HRmax) combined with three minutes of  moderate work rate 
(40% to 50% of exercise capacity). 
Outcome Measures
The results from the majority of included studies revealed that exercise training 
had variable effects on HRV parameters of patients with COPD. Results from five 
studies  reported significant increases for time domain HRV analysis like RMSSD 
(2, 5, 22), SDNN (3, 5, 34), RMSM(2), SD1 (22), and SD2 (22). Similarly, results across 
four studies showed that exercise had no significant effect on some time domain 
HRV analysis including RMSSD (23, 34, 38), SDNN(22, 23, 38), AVNN (34), and 
pNN50 (23, 34) indices. Nevertheless, evidence synthesis of the RCT studies shows 
that exercise training leads to a significant increase in parameters of time domain 
HRV analyses (2, 5, 22).  
Table 5   GRADE evidence profile: different exercise training on AF in patients  
with COPD (quality assessment).
Outcome Subjects Risk of bias inconsistency indirectness imprecision Publication 
bias














No serious  
inconsistency 




Unlikely N/A N/A - 4 Significant improvements 










No serious  
inconsistency 




Unlikely N/A N/A - 4 No significant 
improvement were 
recorded in the frequency 
domain  HRV parameters 







N/A N/A No serious 
imprecision
Unlikely N/A N/A - 1 Evidence is limited 







Not serious Not serious Not serious Unlikely N/A +1b - 4 Two of the studies used 
interval training. 
High
Abbreviation: N/A= not applicable; a  a point reduced for presence of study limitations; b a dose response  
was demonstrated in the results of the outcome measure following aerobic exercise training.
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 Six studies investigated the effects of exercise training on frequency domain 
HRV parameters. The results from most of these studies indicated that exercise 
training had no significant effect on the frequency domain analyses of HRV such 
as LF (11, 23, 34, 38), HF (11, 23, 34), VLF (23),  LF(nu) (2, 5, 11, 34, 38), HF(nu) (2, 5, 11, 
34, 38), and  LF/HF (5, 11, 23, 34, 38). However, a few significant changes were 
reported. These included significant increases for HF(38), HF(nu) (3),  LF/HF(3), and TP(34) 
parameters, and significant decreases were reported for LF(nu) (3) and TP(11) values. 
Interestingly, evidence synthesis of the two RCT studies (2, 5) shows that exercise 
training does not significantly influence frequency domain HRV parameters. 
 Four non RCT studies reported on the effect of exercise training on HRR of patients 
with COPD (12, 24, 35, 36).  The results from these studies revealed the exercise 
training had a significant positive effect on the HRR indices (p<0.05). All four non 
RCT studies were used for evidence grading. In the end, a high quality evidence 
was found to support the influence of exercise training on HRR in patients with 
COPD. Lastly, one non RCT study reported the effect of cycle ergometer training 
on BRS values in patients with COPD. The results from this study also showed 
significant improvement in BRS values following exercise training (p<0.05).  
Table 5   GRADE evidence profile: different exercise training on AF in patients  
with COPD (quality assessment).
Outcome Subjects Risk of bias inconsistency indirectness imprecision Publication 
bias
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improvement were 
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domain  HRV parameters 







N/A N/A No serious 
imprecision
Unlikely N/A N/A - 1 Evidence is limited 







Not serious Not serious Not serious Unlikely N/A +1b - 4 Two of the studies used 
interval training. 
High
Abbreviation: N/A= not applicable; a  a point reduced for presence of study limitations; b a dose response  




Adverse events that can be attributed to exercise training were reported in 
32 patients (5.6%) in seven studies. These events included cardiac arrhythmias 
(24, 34), exacerbation of symptoms (2, 5, 36), arterial hypertension (12), atrial 
fibrillation (34), and non-specified abnormal cardiovascular responses (22). In the 
other four studies, no adverse events were reported (3, 11, 23, 35). 
Discussion
This systematic review evaluated the evidence for the effect of exercise training on 
autonomic function parameters in patients with COPD. Generally, the results 
indicated that exercise training has beneficial effects on only the time domain 
analyses of HRV and the HRR parameters. The results also indicated exercise 
training may have a significant effect on the BRS values in patients with COPD. 
More importantly, no evidence is in support of the effects of exercise training on 
the frequency domain analyses of HRV. 
 Exercise training interventions for patients with COPD are usually well 
structured.  This is obvious from the largely similar exercise training parameters 
recorded from the studies in this review. Nevertheless, to provide reliable evidence, 
the RCT studies formed the basis our evidence synthesis, and were given preference 
over results of non RCT studies. Each study was also appraised on its methodological 
strength before the results in it were extracted. For example, one originally 
designated RCT study by Marquis et al. (2008) (23), was considered to be non RCT in 
design because medication use was the outcome of interest, and all the participants 
received exercise training.    
 Heart rate variability is a major predictor of cardiovascular health with a 
significant clinical relevance (39, 40). The HRV is also an outcome of choice in 
studies focused on cardiovascular health and autonomic functioning. The significant 
changes that were reported in the studies for time domain parameters of HRV 
following exercise training was consistent in the studies used for evidence 
synthesis in our review (2, 5, 22).  Even though, the time domain HRV analysis 
represents important aspects of HRV markers with clinical benefits (41), these 
benefits appears to be limited because the frequency domain analysis, which 
provides a more robust index of heart rate function in across both sympathetic 
and parasympathetic branches was not significantly enhanced by exercise. The 
frequency domain analyses of HRV is also a more sensitive index for evaluating 
changes underlying the heart function rhythms compared to time domain 
analysis (39). Moreover, the frequency domain analyses has been recommended as 
the gold standard for short term measurements of HRV analyses (7). Hence, the 
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positive results reported for time domain analysis in this review maybe inadequate 
to arrive at a firm conclusion on the effect of exercise training on HRV.
 On the other hand, the results of this review showed substantial increases for 
HRR indices following both continuous and interval training. This finding is 
further corroborated by the results of previous studies that reported improvements 
in HRR in both healthy and diseased populations (42-44) following exercise. 
Clinically, the HRR is relevant because an immediate recovery of the heart rate 
after exercise signifies a function of vagal reactivation. Moreover, severely decreased 
vagal activity is known to be a risk factor for death. Interestingly, the exercise 
training intensity in the studies that reported on the HRR were also within the 
recommended guidelines for patients with chronic diseases(14, 45). Consequently, 
we assumed that there is sufficient evidence indicating that aerobic exercise 
training lasting for at six weeks at an intensity of between 60% to 80% of maximal 
work capacity has positive impact on the HRR in COPD. 
 This review also highlighted several benefits of exercise training for patients 
with COPD. For example, exercise training is known to improve muscle function, 
which is a strong determinant of autonomic function (4). Besides exercise training 
provides other benefits that may be directly linked to the overall wellbeing of 
patients (12, 46-48). Furthermore, the review has highlighted the need for the use 
of important cardiovascular markers as HRR for monitoring during exercise 
training intervention. Incidentally, the HRR can easily assessed by practitioners, 
and it does not require complex procedures (12, 24, 36).
 Our results must be viewed within the limitations of the review. Firstly, no 
study reported on the  effect of exercise training on autonomic function parameters 
like MSNA, chemoreflex sensitivity and sympathetic skin response indices, and 
only one non RCT study assessed the effect of exercise training on BRS (11). As a 
result, our conclusions are limited to HRV and HRR indices. Nevertheless, these 
indices captures a clinically relevant and significant areas of autonomic function 
that reflects the sympathovagal and cardiovascular health profile. Secondly, about 
half of the included studies recorded high drop-out rates among patients with COPD 
(2, 5, 22, 24, 36). Furthermore, a relatively low sample size (sparse data) were used 
on some of the included studies (3, 11, 23, 37). We assumed that most patients with 
COPD are elderly, and they may be uncooperative of intimidated by the prospects 
participating in exercise training programmes (49). Lastly, a few heterogeneity 
in clinical characteristics of patients with COPD, medication use and exercise 
training parameters were observed. For example, supplemental oxygen was 
administered to some participants (50-52). However, using only RCTs for evidence 
synthesis appears to have limited these concerns.
 Our review has shown that the HRR can be used for the determination of the 
heart’s capacity to adapt to induced stressors such as exercise training, and also 
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to evaluate the long term benefits of exercise-based interventions. At this stage, 
it is difficult to recommend whether the HRV can be effectively useful as physio- 
therapy treatment outcomes for prognostication and goal setting during COPD 
rehabilitation. Lastly, conducting this review using GRADE guidelines has provided 
an insight into the methodological inadequacies in the existing studies, as well as 
the paucity of data on this topic.
Conclusion 
Long-term exercise training with vigorous intensity provides beneficial effects 
on selected autonomic function indices in patients with COPD. Presently, only a 
limited number of high quality studies have reported on the effect of exercise 
training on autonomic function in COPD, indicating a significant gap in the 
literature. Therefore, future studies focusing on other relevant measures of 
autonomic function indices are still necessary. 
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“After climbing a great hill, one only finds that there are 







1.  Summary of main results
The aim of this dissertation was to provide a better understanding about the state 
of the autonomic nervous system (ANS) in chronic obstructive pulmonary disease 
(COPD) while focusing on both the existing literature and filling up well identified 
gaps in this area of expertise. The results described in the chapter 3, systematic 
review, revealed that a strong level of evidence supported the impairment of 
autonomic function in COPD patients expressed by time domain heart rate 
variability (HRV) analyses, baroreceptor sensitivity (BRS) and muscle sympathetic 
nerve activity (MSNA). This systematic review further identified physical activity 
level, muscle function and variation in time of day (circadian rhythm) as major 
influencing factors of the autonomic function in COPD. 
 Besides, two original studies were conducted to assess a possible dysautonomia 
among subjects with COPD. The results from the first study revealed that autonomic 
symptoms were present in all domains of the COMPASS-31 questionnaire in COPD 
(Chapter 4). These autonomic symptoms were slightly associated with mental 
health status, but not with severity and lung function outcomes in COPD patients. 
Furthermore, poor mental health status was found to be the most important 
predictor of autonomic symptoms. The aim of the second original study was to 
assess autonomic function through a standardized validated autonomic reactivity 
test (Chapter 5). The results of this study revealed a slightly impaired autonomic 
function among COPD subjects who were undergoing a pulmonary rehabilitation 
program, compared to their healthy counterparts. 
 The purpose of the third and final part was to examine non-pharmacological 
interventions for autonomic function in COPD through a systematic review. In the 
latter, there was a strong proof of concept supporting the acute positive effects of 
controlled breathing techniques and oxygen supplementation on the BRS of 
patients with COPD (Chapter 6). Similarly, a high-level of evidence was found to 
support the influence of aerobic exercise training on the autonomic function in 
COPD (Chapter 7). 
2.   Validation of the Dutch COMPASS-31 in a sub-group 
of patients with COPD
The COMPASS-31 is a validated, comprehensive instrument that is used to both 
evaluate autonomic symptoms (1-3) and effectively identify autonomic dysfunction 
in a wide variety of conditions (1, 2, 4-9). This instrument contains questions about 
both problems with the ANS and detection of psychosomatic indices.  As such, this 
self-report questionnaire is designed to provide an index for autonomic symptom 
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severity (3, 10). The questionnaire consists of 31 items, evaluating six domains of 
autonomic symptoms: orthostatic intolerance (4 items), secretomotor (3 items), 
vasomotor (4 items), gastrointestinal (12 items), urinary (3 items) and pupillomotor 
(5 items) complaints. The current COMPASS-31 is a shorter and simplified version, 
developed from an earlier 72-item COMPASS questionnaire, which was in turn 
derived from the original 169-item ASP questionnaire, developed by Suarez et al., 
in 1999 (3). Each domain of the COMPASS-31 is scored using a predetermined 
formula. The total scores are calculated by adding all six autonomic domains a 
weighted score with a possible maximum score of 100. Higher scores indicate more 
autonomic symptoms.
 Apart from the English version that has been validated in different diseases 
(4, 11, 12), an Italian, Spanish, Swedish, and Serbian/Croatian versions of the 
COMPASS-31 questionnaire are available (1, 4, 13, 14). In this study, a COMPASS-31, 
already translated into Dutch language (Appendix A) using the IQOLA project 
approach was used (15).  Thereafter, we aimed to validate and determine the cut-off 
score for screening of autonomic dysfunction in COPD on the Dutch COMPASS-31. 
For the validation of the COMPASS-31, the adrenergic and cardio vagal function 
were calculated as earlier explained (Chapter 2, sub-section 5.1, Table 5). Since 
sudomotor function data were not available for these subjects, the total CASS was 
not reported. However, specific adrenergic and cardiovagal functions were mainly 
utilized because resting HRV indices only provides information about sympathetic 
and vagal activity to the heart. Moreover, the COMPASS-31 assesses the autonomic 
contribution across many organs of the body. 
 Statistical analyses were conducted using the statistical package for social 
sciences (SPSS) version 24 (Inc., Chicago, IL). In general, all data were subjected to 
the Shapiro-Wilk’s test to check whether the variables were normally distributed 
or not. To determine the discriminative power of the Dutch COMPASS-31, a Man- 
Whitney U test was used for domain and total scores comparison between COPD 
patients with normal autonomic function and COPD patients with mild 
dysfunction. The internal validity (consistency) was assessed by Cronbach’s α value. 
For rating the level of internal consistency, a Cronbach score of between 0.50 and 
0.60 was considered poor, between 0.60 and 0.70 acceptable, between 0.70 and 0.90 
good, and higher than 0.90 was considered excellent. Spearman rho correlation 
coefficient between the COMPASS-31 scores and adrenergic/cardiovagal scores 
were performed to determine the criterion validity. Lastly, a receiver operating 
characteristic (ROC) analysis was tested on the adrenergic and cardiovagal 
function, HRV index (16) and the Valsalva index (17) in order to determine the best 
cut off for screening autonomic dysfunction in subjects with COPD.  
 The results of this study indicated that a majority (57.6%) of the COPD patients 
suffered from mild adrenergic dysfunction, while 8 (30.7%) patients had normal 
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function. For cardiovagal function, 57.6% of the COPD patients were normal, while 
38.5% reported mild dysfunction. Moderate and severe dysfunction were represented 
by very few patients. Consequently, discriminative power of the questionnaire was 
based upon the normal and mild dysfunction groups only (Table 1). 
The results of the discriminative power analyses of the COMPASS-31 indicated that 
all 6 domains and total scores of the Dutch COMPASS-31 were comparable across 
all domains, indicating a poor discriminative power for mild autonomic dysfunction 
in this COPD population (Table 1). The internal consistency (validity) of the Dutch 
COMPASS-31 in COPD was acceptable (Cronbach’s alpha, 0.669; 95%-CI, 0.424 - 
0.834, P= 0.001). For the criterion validity, all aspects of the Dutch COMPASS-31 in 
COPD did not significantly correlate with adrenergic and cardiovagal function 
tests (P> 0.05), as illustrated in Table 2.
 The results of this validation study indicated that the adrenergic, cardiovagal 
and Valsalva indices were not significant upon ROC analyses (p> 0.05). Hence, the 
HRV index was the only significant parameter to predict mild autonomic failure 
on the Dutch COMPASS-31 with an area under the curve of 0.825 (CI = 0.659- 0.991; 
P=0.027), as illustrated in Figure 1. A cut off point of 34.5 on the Dutch COMPASS-31 
was capable of screening for poor HRV index (with a sensitivity 60% and specificity 
of 85%).
Table 1   Discriminatory power of the Dutch COMPASS-31 questionnaire  





















Total score 23.1±14.96 15.1±13.98 12.86 23.0±22.83.237 16±13.45 19±16.06 33.61 .799
OI 13.7±13.04 4.5±8.67 0.00 14.0±19.8 .162 6.9±11.36 8.8±12.04 8.00 .666
Vasomotor 0.47±1.25 0.55±1.07 0.00 0.00 .731 .42±0.96 .25±0.79 3.32 .666
Secretomotor 3.6±3.14 3.9±3.26 6.3 2.1±2.96 .837 3.5±2.92 4.0±3.49 6.30 .625
GI 3.1±2.66 3.9±3.36 6.23 4.9±3.89 .535 3.2±2.17 3.65±2.58 13.35 .796
Urinary 0.95±1.35 0.96±1.1 0.00 0.56±0.79 .891 0.87±1.08 1.0±.1.22 0.00 .886
Pupillomotor 1.3±0.54 1.3±1.06 0.33 1.49±1.17 .945 1.1±.94 1.35±0.83 2.64 .508
Mann-Whitney U tests statistic of the COMPASS-31 between mild and normal COMPASS-31 scores P<0.05; 
OI, orthostatic intolerance; GI, gastrointestinal.
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To summarize, the Dutch COMPASS-31 has been found to have poor discriminative 
power and criterion validity for screening of mild autonomic dysfunction in this 
COPD population. However, the internal consistency was acceptable, and a cut off 
score to screen for poor HRV index was achievable. 




Total score -.100 .051






 *, significant at p< .05
Figure 1   The ROC curve indicating effectiveness of the Dutch COMPASS 31  




3.  Is autonomic function impaired in COPD? 
This part of the general discussion will focus on the autonomic function parameters 
that were found to be frequently reported in COPD, i.e. HRV analyses (time and 
frequency domains), BRS, MSNA and heart rate recovery (HRR). 
3.1  Heart rate variability
In our systematic review (Chapter  1), we reported  a general reduction in HRV 
among individuals with COPD (18). This is not surprising as HRV indices reflecting 
vagal modulation sympathetic tone are known to be affected in COPD (19). In 
addition, HRV is well known to be reduced in an elderly, inactive population as 
well as in a number of diseases (20). Therefore, it is not surprising that we found 
similar results in most of the chapters dealing with autonomic function in this 
dissertation (18, 21, 22). Furthermore, a reduced HRV may imply an increase in 
resting HR and/or a lowered cardiac parasympathetic nerve activity (cPNA) (23). In 
addition, patients with COPD have respiratory mechanical abnormalities 
(hyperinflation) that may contribute to the impairment of cardio dynamic 
responses and reduced heart rate kinetics (HRV) (24).
 The HRV is a reliable and robust outcome measure, capable of monitoring 
treatment prognosis in individuals with various disorders. In COPD, a reduced 
HRV could be the result of multi-systemic manifestations of the disease on several 
extra-pulmonary systems such as the cardiovascular system. Moreover, COPD is 
known to be associated with features that could have potential deleterious effects 
on the HRV such as hypoxemia, hyperventilation, anxiety and depression (25, 26). 
In chapter 5 of this dissertation, we have found that individuals with COPD had a 
significantly higher baseline heart rate (HR) compared to a healthy control 
population.  This higher baseline HR could be a possible explanation for the 
relatively lower HRV indices among subjects with COPD. 
 The HRV method is capable of reflecting both chronotropic and inotropic 
influences on the SA node in the heart (27). This HRV parameter, which is primarily 
a measure of sinus node cycle length (CL), is based on a physiological concept 
stating that ANS controls the pacemaker activity of the SA-node (28). Nevertheless, 
it is important to note that the HRV mainly assesses the end-organ response from 
the dual control of the periodic sympathovagal neural activity over the Sino-atrial 
(SA) node. Additionally, other factors have been documented to influence the value 
of the SA node including the sympatho-adrenal activity, mechanical/hemodynamic 
elements  and local reflexes that cannot be reflected by the HRV test (28). 
 Despite software advances for HRV analyses (18), a number of challenges keep 
on persisting. For example, a large number of reported HRV indices (Table 6) in the 
literature are very often contradictory (18). The frequency domain HRV analysis in 
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particular, shows variable results in COPD patients, suggesting a complex and 
heterogonous patient population (as described in the first section of the general 
introduction). Overall, from the results of the chapters in this dissertation, we can 
conclude that the HRV is reduced in COPD. This reduction can be interpreted as a 
reduced vagal activity or an increased sympathetic nerve activity. 
 In chapter 5 of this dissertation (29), we reported a number of HRV indices in 
COPD that have not been adequately reported earlier (30-32). Autonomic reactivity 
tests were also performed in a fairly homogenous subgroup of COPD, who were 
attending a pulmonary rehabilitation program. Surprisingly, our results seemed 
to indicate that resting HRV indices were largely comparable to autonomic 
reactivity tests. This result is in contrast with the findings of Scalvini et al., (1999), 
who reported that stable COPD patients without chronic respiratory insufficiency 
exhibit a quite normal HRV in the resting condition, and an abnormal response to 
autonomic reactivity tests (vagal and sympathetic stimuli) (33). We think that the 
differences in the physical activity status of the COPD population in both studies 
may explain the discrepancy in these results. 
3.2  Baroreflex receptor sensitivity
The short term regulation of the arterial blood pressure through the ANS 
principally involves the arterial baroreflex (34). Physiologically, the BRS plays a 
significant role in the maintenance of circulatory homeostasis by providing a 
continuous stream of information to the CNS via the stretch receptors, which 
results into either an increase or decrease in the discharge of vagal-cardio-inhibitory 
neurons or sympathetic neurons to the heart and blood vessels, respectively (35). 
The BRS is also subject to the cycle length of the SA-node (28). In chapters 3 and 5 
of this dissertation, we reported significant impairments in the values of the BRS 
in COPD (18, 29),  suggesting a possible underlying autonomic dysfunction in these 
patients. Moreover, the baroreflex system is known to be a strong predictor of 
COPD-comorbidities such as heart failure and arterial hypertension (36). 
 In general, the baroreflex system functions by either increasing or decreasing 
the HR and peripheral vascular resistance (sympathetic output to vessels) instigated 
by blood pressure changes (37). The BRS is also responsible for maintaining a stable 
blood pressure in the body during possible changes in body position. This stability 
in blood pressure is achieved either through the vagal part (adjusting the HR) or 
the sympathetic adrenergic part (adjusting the total peripheral resistance) (17). 
The results of poor BRS values are indicators to a possible future baroreflex failure, 
and can be an onset for chronic conditions such as autonomic failure and 
autonomic neuropathies. Due to the overall depression in the BRS index values, 
reported in multiple studies (18, 38, 39), there may be a need to screen COPD 
patients for autonomic imbalances during the course of initial assessment. 
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3.3  Muscle sympathetic nerve activity 
Efferent muscle sympathetic nerve activity (MSNA) has been used to assess the 
sympathetic activation in COPD (40). The MSNA test is highly reproducible, and it 
adequately reflects the short-term changes in the sympathetic outflow (activity) in 
the peripheral nerves. The acute hypoxemia, hypercapnia and apnea which is 
present in COPD pathology, will result in a stimulation of the arterial chemo-
receptors subsequently causing an increase of sympathetic outflow in the 
peripheral nerves (41, 42). Specifically, when peripheral chemoreceptor activation 
occurs, there is a release of exogenous adenosine, which is the chemical mediator 
leading to an increase in the MSNA. Peripheral chemoreceptor activation is also 
associated with increased cardiovascular parameters (blood pressure and heart 
rate) and hyperventilation (42, 43).  
 Even though we did not assess the MSNA in our original studies, we found 
evidence to support the significantly increased MSNA in patients with COPD by 
means of a systematic review (Chapter 3) (18).  Presently, we can conclude that 
MSNA is indeed increased in COPD.  Moreover, MSNA is associated with several 
sympathetic nervous system indicators such as increased cardiac and plasma 
norepinephrine and epinephrine levels (40, 44, 45). 
3.4  Heart rate recovery
The HRR is a cardiac marker for parasympathetic activity. Its reduction is a sign of 
impaired parasympathetic activity (46). The HRR is simple and easy to determine, 
and can be quickly used for assessing the autonomic function in exercising 
patients. The ability of the heart to recover from a stressful event like exercise 
training is subject to central command control. When exercise training is initiated, 
a concurrent sympathetic activation and parasympathetic withdrawal occurs 
continuously (47). The reverse mechanism occurs upon exercise cessation and is 
principally mediated by vagal reactivation (causing a rapid decrease in HR). 
A delayed HRR is thus indicative for abnormalities in the functioning of the 
nervous system.  
 Poor HRR has been reported to be an independent risk factor for predicting 
the occurrence and risk of mortality after cardiac diseases such as coronary artery 
disease, myocardial infarction and cardiac arrhythmia (48, 49). In chapter 7 of 
this dissertation, we revealed that aerobic exercise training was very effective 
in improving HRR in COPD. This means that HRR can serve as a tool for centers 
with limited resources to monitor treatment outcomes during exercise training 
intervention for individuals with COPD. 
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4.  Are autonomic symptoms prevalent in COPD?
To answer this research question, we assessed a profile of autonomic symptoms in 
COPD based on our hypotheses that individuals with COPD will have a higher 
prevalence of autonomic symptoms compared to their healthy counterparts. 
This hypothesis formed the core objective of Chapter 4 of this dissertation. In line 
with our expectations, autonomic symptoms were found to be more present in 
patients with COPD compared to a healthy control population. Additionally, COPD 
patients who had poorer health status reported higher autonomic symptoms. 
Specifically, the mental health status component from the SF-36 instrument was a 
found to be a significant predictor of total autonomic symptoms score, suggesting 
a possible impact of psychosocial issues in the autonomic function in COPD.
 Autonomic symptoms including orthostatic intolerance, upper gastrointestinal 
(GI) tract symptoms, bladder dysfunction, and secretomotor dysfunction are known 
to be associated with autonomic dysfunction in patients with postural orthostatic 
tachycardia syndrome (POTS) (50). In chapter 5, COPD patients also showed early 
signs of POTS. Hence, this discussion will focus on the 6 domains of autonomic 
symptoms that were reported in Chapter 4: orthostatic intolerance, secretomotor, 
vasomotor, gastrointestinal, urinary and pupillomotor.
4.1  Orthostatic intolerance
Symptoms of orthostatic intolerance were reported among COPD (Chapter 4) (51). 
This was mainly expected because COPD patients are known to  frequently have 
cerebral hypo-perfusion (52) (i.e.  a form of orthostatic stress that can be expressed 
as orthostatic symptoms (53)). Individuals with orthostatic intolerance usually 
express feelings of dizziness (of variable severity) and light headedness, which may 
lead to (pre) syncope (54). Orthostatic intolerance has been associated with common 
COPD features such as shortness of breath, reduced ventilatory capacity, hyper- 
capnia and lowered oxygen saturation (55). Physiologically, orthostatic intolerance 
is associated with norepinephrine transporter deficiency, especially when an 
individual changes from supine to an upright position (56). However, it is not yet 
clear whether the high rate of orthostatic symptoms is indicative of any underlying 
ANS deficits in patients with COPD. A head up tilt test study in a large cohort of 
subjects with COPD may be necessary to confirm this link. 
4.2  Secretomotor complaints
After orthostatic symptoms, secretomotor dysfunction complaints were the most 
prevalent autonomic symptoms in COPD (Chapter 4) (51). The COMPASS-31 delimits 
secretomotor symptoms to questions regarding impaired sweating and dryness of 
the eyes and mouth. Secretomotor disorders are characteristic for thermoregulatory 
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dysfunction such as heat tolerance, impaired body sweating, parasympathetic 
affectation, and dryness of the eyes and mouth (8). 
 Dryness of the mouth is common in the elderly, and is also associated with the 
use of many medications (57). A number of COPD medications, when ingested or 
inhaled, are known to have dryness of the mucus membranes as side effects. 
Therefore, it is difficult to state that these symptoms are solely caused by COPD 
pathology. This result may be explained by a recent study that concluded that 
autonomic symptoms are strongly associated with burden of co-morbid chronic 
diseases, and also associated with ANS-relevant medication use (58). In addition, 
the rapid and shallow breaths that is common in COPD, may also be a contributing 
factor to the secretomotor complaints reported in our study. 
4.3  Vasomotor problems
Vasomotor problems were identified to be slightly more present in COPD than 
their healthy counterparts. Vasomotor symptoms are associated with poor quality 
of life and are more prevalent in females and elderly (59). These symptoms can 
induce a loss in temperature control (especially in the extremities) or ‘night sweats’ 
and color changes in the hands and/or feet. All of these symptoms can be assessed 
by means of self-report. The ANS is also implicated in the control of vasomotor 
activity. For example, problems such as hypothermia and heat strokes are generally 
common in the elderly due to dysfunction in the sweat response and autonomic 
vasomotor (60). Therefore, it was not surprising that these vasomotor problems 
were reported in both COPD and healthy controls in our study (51). Loss of vaso- 
motor function is a potentially dangerous phenomenon and for that reason, it may 
be important to incorporate adequate means of identifying and treating vasomotor 
symptoms for eligible COPD patients (especially females and the elderly). 
4.4  Gastro intestinal problems
Gastrointestinal disorders form one of the six major common comorbidities in 
elderly patients (61, 62). Therefore, is was not surprising that gastrointestinal 
symptom(s) were recorded in both subjects with COPD and healthy controls in 
this study. However, COPD patients reported more gastrointestinal symptoms 
compared to both healthy controls in our study and previous scientific reports 
(63). Considering the lack of clear and specific age related explanations (60), it is 
not surprising that patients with chronic respiratory diseases have high 
prevalence ratios of gastro intestinal symptoms. Again, there is a close and 
complex anatomical and physiological relationship/interaction between the 
upper-airway tract and the esophagus, which has been linked to the high 
prevalence of  gastro- esophageal reflux disease (GERD) in COPD (64), and even 
asthmatic patients (65). These mechanisms may explain why we failed to find a 
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link between the presence of autonomic dysfunction and gastrointestinal symptoms 
in COPD. 
 Additionally, gastrointestinal symptoms are also known to affect QoL, and 
even contribute to mortality. The results in chapter 4 recorded a high (about >21% 
of COPD) use of gastrointestinal medications among the COPD patients (51). 
This finding implies that either there is a high prevalence of gastrointestinal 
problems or the use of COPD medications such as PDE4, corticosteroids or may 
have been responsible for these symptoms. Despite the high use of gastrointestinal 
medications, subjects with COPD still reported gastrointestinal symptoms, 
suggesting that these symptoms could have been under-estimated in these results. 
4.5  Bladder dysfunction symptoms
We also reported a higher prevalence of urinary tract complaints in COPD 
compared to age and gender matched controls. The ANS is one of the major systems 
controlling the optimal functioning of the urinary system via the micturition 
reflex (60). Therefore, it is very likely that autonomic dysfunction COPD extends to 
the higher centers responsible for various micturition (66). Patients with other 
forms of neurological and rheumatic disorders have been reported to suffer from 
urinary complaints as a result of unexplained autonomic affectation. This is 
particularly the case among patients with multiple sclerosis (67), Sjögren’s 
syndrome and systemic lupus erythematosus (68). In patients with Parkinson’s 
disease, urinary symptoms are also associated with problems in the higher centers 
(69). For now, we can assume a poor health status as a contributing factor to the 
susceptibility for bladder dysfunction symptoms in these COPD patients. 
4.6  Pupillomotor complaints
The pupillomotor domain of the COMPASS-31 question items measures the 
symptoms associated with problems with the neural control of the pupils in the 
eye. These questions specifically interrogated about focusing, blurred vision and 
photophobia (66). The significantly higher results reported in the COPD population 
suggest a possible neurological deficit. However, from the results of our studies, we 
cannot explain the link between these symptoms and autonomic function deficits. 
Presently, hypersensitivity to bright light and difficulty in focusing complaints 
have been linked to the use of ICS medication. Daily use of ICS medication, which 
are widely prescribed for COPD patients (70), has been associated with a number of 
adverse effects including ocular symptoms.   
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5.   What is the role of non-pharmacological interventions 
on the autonomic function in COPD?
Pulmonary rehabilitation remains an indispensable non-pharmacologic intervention 
in a significant proportion of patients with COPD (71). Nevertheless, pulmonary 
rehabilitation is still grossly underutilized worldwide due to both inadequate 
access to transportation and poor perception regarding the benefits of pulmonary 
rehabilitation and disease comorbidities like depression (72). In this section of the 
discussion, we focus on the effects of control breathing, oxygen supplementation 
and exercise training interventions on the autonomic function in COPD. 
5.1  Controlled breathing and oxygen supplementation
In COPD, exercise training (endurance or aerobic) is often limited due to ventilation, 
cardiorespiratory constraints and peripheral muscle weakness (73, 74). Therefore, 
alternative or supplementary interventions are administered in these patients. 
This study found that both oxygen supplementation and controlled breathing 
positively affected autonomic function variables in COPD. These beneficial effects 
of oxygen supplementation are induced by counteracting the hyper-adrenergic 
state which is associated with hypoxia in COPD. In addition, parasympathetic 
autonomic dysfunction has been associated with arterial oxygen tension (PaO2) 
in COPD (75), since reduced oxygen tension can cause structural and functional 
abnormalities in the peripheral nerves (76). Therefore, it is not surprising that oxygen 
supplementation had a positive influence on the autonomic function indices. 
 On the other hand, controlled breathing techniques such as slow breathing 
and pursed lip breathing influences the lung inflation reflex through the action of 
the pulmonary vagal afferent mediation, which alters the baroreflex. Controlled 
breathing increases both the tidal volume and attenuated sympatho-inhibitory 
effect of the lung inflation reflex (40). Controlled breathing is also associated with 
enhanced central inhibitory rhythms, and a reduction in the chemoreceptor 
activity, which can result in an attenuation of the autonomic function indices 
such as the baroreflex function (77, 78).
5.2  Exercise training
Chapter 7 indicated that exercise training positively influenced the autonomic 
function in COPD (22). This can be explained by the cardiovascular adjustments 
that take place in order to meet the metabolic (muscles) and thermoregulatory 
(skin) demands without compromising other structures (79). In general, when 
exercise training is initiated, the chemoreceptors/mechanoreceptors in the 
exercising skeletal muscles are activated. This activation leads to a withdrawal of 
the cardiac parasympathetic nerve activity (cPNA), resulting in an increased HR. 
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When exercise intensity remains above the aerobic threshold, arterial baro- 
receptors will reset as a consequence of both an increased concentration of the 
metabolites and sympatho-adrenergic activity. Also, an activation of the cardiac 
sympathetic nerve activity (cSNA) will take place, resulting in a preservation of the 
HR at maximal levels (Figure 2). 
 The cardiovascular autonomic control during exercise training is described as 
a process that involves an initial input (feed forward mechanism) from the higher 
brain centers (central command) into the medullary cardiovascular center, thereby 
resetting the arterial baroreflex to a higher operating point (27, 80). This process 
leads to a reduction in parasympathetic activity which subsequently leads to a 
rapid increase in HR (23). As exercise intensity increases, progressive baroreflex 
resetting (without concurrent change in sensitivity) and afferent muscle metabo-
receptors trigger a continuous cardiac parasympathetic withdrawal and sympathetic 
activation (via the excitatory afferents) (27). In the extremities (muscles), 
the production of oxygen free radicals following ischemic metabolism that occur 
during skeletal muscle contraction is also reported to contribute to the ANS 
adaptation during exercise (36).  The process of continuous activation of the 
cardiovascular center in the medulla during rhythmic exercise  by mechanical 
and chemical peripheral input  is called “exercise pressor reflex”




In the long run, exercise training has been associated with lowering resting HR 
and a reduction in the concentration of plasma catecholamine, norepinephrine 
and epinephrine (81-83). Moreover, muscle function is significantly correlated 
with autonomic function in COPD (84).  
6.   Issues associated with the assessment of  
autonomic function in COPD
During the course of this study, we identified a number of issues that can 
significantly affect the results of autonomic function testing in COPD. These issues 
include (i) variation in autonomic function testing protocol, (ii) heterogeneity and 
clinical differences among the individuals with COPD such as GOLD stage, 
medication use, demographic characteristics and physical activity level, and (iii) 
analysis and interpretation of the results.
6.1  Influence of the protocol used in reporting autonomic function
The earliest assessment of autonomic function in COPD mainly used invasive 
methods to determine whether there was an imbalance in the ANS function. 
Currently, a number of non-invasive assessment have been proposed. Hence, 
existing studies have relied on a variety of tests (85), depending on their objectives. 
In chapter 5 of this dissertation, we reported on the cardio-vagal indices following 
standardized autonomic reactivity tests comprising heart rate during deep 
breathing (HRDB), Valsalva maneuver (VM) (Figure 3) and passive tilting or head up 
tilt (HUT) (Figure 4). 
Figure 3   Subject with COPD performing VM test in supine position with  
the aid of a visual feedback.
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Other autonomic function parameters such as the BRS can be analyzed by means 
of either autoregressive spectral analysis or the alpha-angle method (40) or by 
intravenous injection of a pressor agent (e.g. phenylephrine) (86). Research 
performed in this dissertation (Chapter 5) showed different and novel BRS 
parameters for patients with COPD. 
 From the results of the studies in this dissertation, we also identified a number 
of autonomic function parameters that can be assessed for various purposes. 
The HRR and time domain HRV analyses offers simple and straight forward 
possibilities to interpret, and assess autonomic function in clinical practice. 
Additionally, due to continuous advancements in technology and technical devices, 
new noninvasive means for assessing the HRV are introduced. A good example of 
these novel techniques is the use of photo-plethysmography (an optical pulse 
sensor), which can be used to assess the HRV either during exercise surveillance or 
in a clinical setting (87, 88). This method may be utilized in subsequent studies to 
validate the results of the existing autonomic function studies. 
6.2   Effects of disease heterogeneity and clinical differences on  
the autonomic function in COPD
Since most COPD patients are elderly, it is expected that they already started to 
show or experience a decline in autonomic function. Therefore, it was important 
to interpret the results from our sample, with a majority of elderly COPD patients, 
Figure 4   A subject with COPD during HUT test with continuous ECG recording.
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with caution. In our chapters two and three, the control subjects also reported 
some autonomic symptoms and had a number of comparable autonomic function 
indices with COPD patients (51). Hence, we cannot completely rule out the effect of 
age in these results.   
 Studies have identified age and gender related differences to account for 
significant changes in autonomic function, even among healthy individuals. With 
advancing age, there is an increased basal and stimulated plasma noradrenaline 
concentration, adrenoceptor dysfunction and unresponsiveness to adrenergic 
agonists and antagonists agents (89). Increasing age is also associated with a 
reduction in maximal HR, an augmented resting HR and SBP and a decrease in 
beta adrenergic modulation. Age related changes are also reported to affect 
cardiovascular parameters like cardiac output (i.e. determinants such as preload, 
afterload, coronary flow and myocardial cell performance), peripheral vascular 
resistance and ejection fraction (90).
 A number of studies have reported gender differences in the ANS modulation. 
Specifically, the cardiopulmonary reflex inhibition of sympathetic nerve activity 
was found to be greater in females. Furthermore, females showed a decreased 
sensitivity to adrenergic nerve stimulation (but not to noradrenaline), attenuated 
stress-induced increases in plasma catecholamine (less sensitive and less responsive) 
and less sensitive pathways regulating the sympathetic nerve activity (91). 
Nevertheless, gender differences in autonomic function appear to be more 
pronounced among a younger population. Specifically, the influence of hormones 
(both estrogen and progesterone  having a vagal effect) has been associated with 
these differences (90). Based on these factors, we can presume that gender variation 
may not have significantly influenced the results presented in this dissertation. 
 Intrathoracic pressure swings is common in COPD (92), and has been associated 
with autonomic dysfunction and more specific with the activity of the sympathetic 
nerves due to airway obstruction.  COPD patients have a number of comorbidities 
as well such as coronary artery disease (CAD) and pulmonary arterial hypertension 
(PAH) that may affect autonomic function. CAD  is the most common cardiovascular 
morbidity in COPD, accounting for a significant proportion of CVD comorbidities 
in COPD (93), partly due to common risk factors (cigarette smoking, airborne 
pollution) (94, 95). Secondly, impaired autonomic function parameters such as 
increasing resting heart rate and orthostatic intolerance have been reported to 
predict both COPD and CAD, independent of one another (96-98). There may be a 
future need to compare the severity of autonomic function deficits among COPD 
patients with or without CAD co-morbidity in order to clearly answer these 
questions. Similarly, PAH has been associated with increased sympathetic nervous 
system (SNS) activation, decreased heart rate variability and presence of cardiac 
arrhythmias in COPD (99).
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Additionally, severe autonomic dysfunction and dysautonomia is frequently 
reported in patients with metabolic disorders such as diabetes mellitus, obesity 
and among severely malnourished individuals. Since these descriptions fit 
phenotypical description of most COPD patients (100), it is  likely that disease 
phenotype may be an important factor in the autonomic function in COPD (100).  
6.3  Influence of medication use on the autonomic function in COPD
Medication use remains an unavoidable confounder in the assessment of autonomic 
function in COPD. Even though the role of medication use in the impaired 
autonomic function in COPD has been frequently ruled out (101), a number of 
studies have assessed the autonomic function in COPD both with and without 
medication withdrawal (102, 103).  Of course, there are both ethical concerns and 
potential deleterious effects of COPD or vasoactive medication withdrawal in some 
COPD patients explaining why medications are not withdrawn in some studies.
 The major classes of drugs and how they can affect the two branches of the 
ANS (sympathetic and parasympathetic) is well established (104). Therefore, it is 
conceivable that the use of any of these drugs would have a significant influence 
on the autonomic function test results. These medications typically include the 
adrenergic (agonists and antagonists) and cholinergic drugs. Moreover, medications 
such as opiates, ACE inhibitors and beta-adrenergic blockers which are often used 
to frequently manage COPD comorbidities, are known for their autonomic 
properties (44, 105, 106). Other medications that could be administered to be used 
by COPD patients include macrolides and other broad-spectrum antibiotics. The 
use of a broad-spectrum macrolide  such as azithromycin have been reported to 
cause a prolongation of the QT interval, cardiac arrhythmias and even an increased 
risk of cardiac death (107, 108). Additionally, when assessing autonomic symptoms 
(COMPASS-31), there is a possibility that medication such as PDE4 inhibitors will 
cause gastrointestinal disturbances. 
 In order to assess the influence of beta blockers medication use on autonomic 
function in our COPD sample, an additional sensitivity analysis was performed. 
As such, 7 patients who reported to use beta adrenergic blockers, were excluded 
from the dataset. Afterwards, the analyses were repeated based on the remaining 
19 COPD patients versus controls. Interestingly, the results indicated that resting 
HRV results were still largely similar (means, standard deviation and P values). 
The results from these second analyses are presented in Table 4 below (refer to 
Chapter 5 Table 2 for the initial comparison analyses).    
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Table 4   Comparison of resting autonomic function parameters between  
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7.  Clinical implications 
The findings from our results have a number of clinical implications. Firstly, we 
have shown that a significant proportion of the COPD patients (7.7% to 76.9% 
respectively) suffer from impaired autonomic function indices (Table 5). These 
results largely suggest a persistent predominance of sympathetic activity among 
COPD patients who participated in our study. Since an imbalance (e.g. persistent 
sympathetic activation) in ANS functioning could lead to a number of consequences, 
these results imply the recommendation and importance of assessing autonomic 
function in COPD. A few examples of these consequences include sodium-sodium 
retention, rhythm disorders, hypertrophy of both the ventricles and arterial walls, 
coagulation and lymphadenopathy, which could lead to cardio- vascular events (109). 
Furthermore, autonomic imbalance can cause abnormal blood pressure and heart 
rate regulation, increased myocardial remodeling and impaired myocardial oxygen 
consumption, dysregulation of glucose concentrations in the blood, myocardial 
ischemia, lack of adaptation to stress situation, abnormal cardiovascular homeo- 
stasis and poor treatment prognosis (110-114).
 A decreased HRV index is a reflection of poor cardiac autonomic control, 
which represents a risk factor for future cardiovascular events even among healthy 
individuals (19). Specific HRV parameters that are often impaired in COPD such as 
the LF index and an increased LF/HF ratio represent a higher sympathetic tone 
possibly predicting severe cardiovascular disorders (115, 116). Hence, there may be 
a need to focus COPD treatment interventions to counteract sympathetic dominance 
in patients who fit to this description. It is important to keep in mind whatsoever, 
that a number of COPD features including systemic inflammation, hypoxia, 
oxidative stress, physical inactivity, and changes in the vascular connective tissue 
also contribute to the impairment of the ANS function (Figure 5) (117). One of the 
key outcomes of this dissertation is that  BRS index, which is an independent risk 
factor for mortality after cardiovascular events (118), was generally reduced in 
patients with COPD.  
 For the purpose of clinical practice, it is important to identify these COPD 
patients with impaired autonomic indices or autonomic dysfunction in an early 
stage to be able to monitor their disease prognosis and possibly prevent future 
cardiovascular events. These patients can be identified by an initial screening 
using the autonomic symptom profile questionnaires, after which simple tests 
such as the HRR and possibly HRV recording can be obtained among those with a 
higher number and intensity of autonomic symptoms based on the questionnaire. 
After these patients are identified, specific non-pharmacological interventions 
could be initiated. In this dissertation, it was reported that patients with COPD 
who were participating in pulmonary rehabilitation or maintenance programs 
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did not have severely diminished autonomic function quality. As such, this can be 
interpreted as evidence to support the current pulmonary rehabilitation guidelines 
in COPD as reported in chapter 1. However, a few COPD patients were found to 
have moderate/severe adrenergic and vagal dysfunction as presented in Table 1. 
For these patients we have proposed two case studies (Appendix B). Furthermore, 
as an alternative in case aerobic training could not be achieved, interval training, 
also provides a non-pharmacological option for modulating the autonomic function 
indices in COPD (Chapter 7). 
Table 5   Comparison of the selected autonomic function test variables of  
COPD patients in this research with established reference norms.
Variable Number and % of  
COPD patients with  
abnormal autonomic  
function values compared  
to normative value
Reference 
Time domain HRV analyses Nunan et al., 2010 (119)
      SDNN (ms) 15/26 (57.7%)
      RMSSD(ms) 16/26 (61.5%)
      Mean RR (ms) 9/26 (34.6%)
Frequency domain  
HRV analyses
Nunan et al., 2010 (119)
     LF (ms2) 14/26 (53.8%)
     HF (ms2) 10/26 (38.5%)
     LF (n.u.) 2/26 (7.7%)
      HF (n.u.) 4/26 (15.4%)
      LF/HF ratio 11/26 (42.3%)
Deep breathing
    HRDB (bpm)
         Normal
         Borderline




Novak et al., 2011 (120)
Valsalva maneuver 
    Valsalva index 
         Normal
         Abnormal
12/26 (46.2%)
14/26 (53.8%)
Schrezenmaier et al., 2007 (17)
Notes: SDNN, standard deviation of all normal R-R intervals; RMSSD, the root mean square of differences 
of successive RR intervals; LF, low frequency; HF, high frequency;  LF/HF, ratio of LF and HF frequency 




For now, exercise training appears to be a better and effective approach compared 
to oxygen supplementation in enhancing the autonomic function in COPD patients 
who have impaired autonomic function indices. Exercise training is known to 
enhance the ANS function by increasing the vagal modulation of the heart, as 
indicated by greater post exercise HRV and BRS values (121). Other benefits of 
exercise training include a cardiovascular adaption encompassing several neuro- 
muscular structures like the central command, baroreceptor reflex and the neural 
reflex feedback from the muscles. Additionally, fitness levels in both athletes and 
non-athletes are associated with vagal-HRV (122). 
 Even though the role of aerobic exercise training in modulating autonomic 
function in COPD is barely reported in literature, using three high quality RCT 
studies (22). Nevertheless, we have identified high evidence to support aerobic 
exercise training at an intensity of 60 - 80% of the maximal work range for 30-40 
minutes at a frequency of ≥3 times/week in order to be effective in enhancing HRV 
time domain analysis and HRR (Chapter 7). 
 Furthermore, we reported a strong association between skeletal muscle 
function and autonomic function for COPD patients in chapter 3. Skeletal muscles 
dysfunction in diaphragm and quadriceps muscles is common in COPD and 
associated with poor health status, health care utilization, exercise capacity and 
mortality (123, 124). Therefore, skeletal muscle function should be monitored in 
clinical COPD rehabilitation by physiotherapists as an indirect mean of 




ascertaining the possible state of the autonomic function. Typical interventions 
for muscle dysfunction may include exercise training, neuromuscular stimulation 
and resistance exercises. 
 The use of respiratory rehabilitation techniques in the context of pulmonary 
rehabilitation are equally important results in this dissertation. Specifically, the 
positive results recorded in the included studies in our review on the effect of 
controlled breathing (125, 126) and oxygen supplementation (21, 127, 128), remain 
a potential asset to exercise training in COPD patients  suffering from autonomic 
dysfunction during rehabilitation. Slow breathing in particular has been found to 
have a training effect on heart rate fluctuations (20). COPD patients who presented 
decreased autonomic function indices or autonomic dysfunction could be treated 
in the clinic using different combinations of respiratory rehabilitation techniques. 
For example, patients who are not able to perform endurance training could be 
administered controlled breathing. Also, improving physical activity status of 
these patients can offer a vital alternative intervention for autonomic dysfunction. 
 In conclusion, since COPD subjects have autonomic symptoms that could be 
linked to poor mental health status (4, 11, 12). And these results  suggest a possible 
psychosocial aspect manipulating the autonomic symptoms in COPD patients. 
Therefore, there may be a need to further assess and explore the need for possible 
psychological support or intervention for patients who report high autonomic 
symptoms.   
8.  Strengths and limitations
The first limitation of this research is that the obtained results in the original 
studies do not reflect all the COPD stages. For example, only moderate and severe 
COPD patients responded to our survey while no information was collected from 
patients with mild COPD (GOLD I). Similarly, in chapter 5 of this dissertation, only 
severe stage COPD patients (GOLD III-IV) who are clinically stable were included in 
the study. While this may not be the best approach to evaluate autonomic 
dysfunction in COPD, we tried to recruit a more homogenous sample. 
 Secondly, the etiology of autonomic dysfunction in different chronic disorders 
is multifactorial, and this includes ageing also. There is also a possibility that 
molecular/cellular changes such as inflammatory mediators, in many of these 
disorders can affect the results of autonomic function tests. Therefore, quantifying 
the actual impact of autonomic dysfunction and ascertaining a specific means of 
rehabilitation is difficult.
 Thirdly, a significant proportion of the study participants were males. 
Although the general prevalence of COPD is slightly more common in males than 
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in females [55 vs 45%] (129), the results of the original research in this dissertation 
were based on a higher male-female proportion as presented in chapter 4 (74% vs 
26%) and chapter 5 (88.5 vs 11.5%). Nevertheless, a one-on-one gender matching of 
the COPD patients with heathy control subjects was performed to provide a balance 
in the study results. Hence, the results have to be viewed within this perspective. 
 The fourth limitation is that a number of objective autonomic function 
screening tests such as the MSNA and sudomotor function were not assessed in 
this research due to practical issues. Also, it is possible that some of these tests 
could have provided more information, larger input and another perspective to 
our results as they examine other aspects of the ANS. Nonetheless, the inclusion of 
systematic reviews of existing research provided a reference to compare our 
results with existing results. Moreover, the MSNA, which reflects the rate of 
sympathetic discharge to the vascular bed of skeletal muscles (44), is an invasive 
test and may not be tolerated by all patients as stated earlier in this dissertation. 
The sudomotor test also requires a high level of expertise and the margin of error 
is high. At present,  the sudomotor test alone does not offer the gold standard any 
longer to measure sudomotor function (16), since the recent autonomic function 
test protocol, QASAT utilizes both QSART and small fibers (intra-epidermal sensory 
and sweat glands) densities from skin biopsies. Still, the results in this dissertation 
remains valid and reliable as we have reported on other important autonomic tests 
that can be used in simple practical situations. 
 The fifth limitation of this research is that we could not adequately validate 
the Dutch COMPASS-31 questionnaire for COPD patients in this research. The 
validation study was based on a relatively low sample of COPD patients who were 
recruited from an ongoing rehabilitation program (Chapter 5). The majority of 
these COPD patients had only mild adrenergic or cardiovagal dysfunction (General 
discussion, Table 1), partly due to the homogeneity of the study sample used in the 
laboratory study. For example, all COPD patients were clinically stable, and the 
majority suffered from stage III COPD based on the GOLD classification. Therefore, 
it was expected that the COMPASS-31 questionnaire was not able to discriminate 
and screen for autonomic dysfunction in this COPD population.  
 The sixth limitation is the relatively low sample sizes utilized in the laboratory 
study (chapter 5). Larger and adequately powered study designs are needed to 
confirm our results. An additional power analysis indicated that a larger sample 
comprising 44 to 77 subjects per group, is needed to achieve a conclusion on the 
question of autonomic function in COPD. Nevertheless, the results of this 
dissertation provide a current platform for future studies. 
 Lastly, since COPD remains a complex clinical syndrome that varies between 
individuals, comorbidities and other variables becomes an issue. As expected, a 
number of confounding factors that are known to influence the autonomic 
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function, could not be controlled. These variables include age, undiagnosed 
comorbidities, other sub-clinical disorders and use of medications such as beta-ad-
renergic blockers, sympathomimetic, inhaled corticosteroids. Despite these 
challenges, we believe our results are valid because we followed a validated 
autonomic function testing protocol (2011). Additionally, the sensitivity analyses 
performed after excluding patients who use beta blockers revealed that our results 
were not substantially influenced by these medications. However, similar 
sensitivity analyses could not have been performed for the COPD medications due 
to lack of statistical power to perform the analyses.     
 Notwithstanding these limitations, this work offers valuable insights. The use 
of three systematic reviews provides us with a high level of evidence for future 
clinical practice guide. More importantly, several autonomic function parameters 
that could be assessed and monitored as outcome measures during COPD 
rehabilitation have been highlighted in this research.
9.  Directions for future research
A large number of parameters are available to assess autonomic function and the 
integrity of the ANS in general. However, only the resting HRV and BRS indices, as 
well as adrenergic and cardio vagal function of patients with COPD were reported 
in this dissertation. Therefore, future studies in this area should focus on more 
recent autonomic function test protocols. The QASAT (Chapter 2, Tables 6, 7 & 8) 
and the MIBG provide two robust options for answering this question. Also, it will 
be interesting to consider whether the QASAT results will correlate with autonomic 
symptoms (in order to validate the COMPASS-31) and other COPD outcomes. 
 The results of this research showed a significantly higher prevalence of 
autonomic symptoms in COPD, which may suggest the presence of underlying ANS 
deficits. However, this link was not established in the present dissertation. Also, 
our attempt to validate the COMPASS-31 was not successful. Therefore, there is a 
need to identify a population of COPD patients who already have established 
autonomic imbalance or dysfunction (mild, moderate and severe) in order to 
validate this instrument in the future. One possibility would be to conduct a large 
questionnaire study (survey), and screen those who reported very high and low 
scores on the COMPASS-31 for further autonomic function testing.
 Going forward, future studies need to go beyond pilot observations in order to 
state some rigorous conclusions on this topic. Following a power analysis, 
conducted (presented above) to estimate the effect sizes of each outcome, we 
recommend that clinical trials should comprise, in each disease and control group, 
about 42 subjects for time domain HRV analyses, 77 subjects for nonlinear HRV 
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analyses, and 45 subjects for BRS indices.  Also, there is a need to use more robust 
assessment means to determine autonomic function, e.g. the QASAT and/or more 
reliable tests like MIBG.
 Additionally, future interventional studies could aim at reporting the effect of 
pulmonary rehabilitation in patients with COPD who have an established autonomic 
failure or dysautonomia. RCT designs should be used in these studies, and the 
assessment of autonomic function should be performed using comprehensive test 
protocols like the QASAT. Lastly, there is a need to also focus on the long-term 
effects (using follow up studies) of exercise training and other non-pharmacological 
interventions on the autonomic function in COPD. For example, an integrated 
pulmonary rehabilitation program comprising controlled breathing techniques, 
inspiratory muscle training, other forms of exercise training, physical activity 
participation and strength training could be tested in COPD populations. 
10.  General conclusion 
This dissertation formulated three research questions bothering around three 
main themes: (i) is autonomic function impaired in COPD? (ii) ‘are autonomic 
symptoms prevalent in COPD, and what are the contributing factors? and (iii) what is 
the role of non-pharmacological interventions for possible autonomic dysfunction in 
COPD? Therefore, the results of this dissertation are important for understanding 
the impact of COPD on the ANS integrity. 
 Presently, it can be concluded that there is evidence to support impairments 
of autonomic function indices in COPD. These indices include HRV in time domain, 
BRS and MSNA. More importantly, physical activity levels and muscle function 
were found to be the major factors that negatively contribute to the autonomic 
function indices in these patients. 
 The results of our research also indicated that a sub-population of COPD 
patients who are participating in a rehabilitation or maintenance program have 
autonomic function parameters that are largely similar with their healthy 
counterparts. The autonomic reactivity tests of sympathetic/vagal indices revealed 
even more parallel values between these patients and controls. Moreover, the vast 
majority of these COPD sub-population had normal or mild adrenergic and cardio- 
vagal dysfunction. This finding is suggesting that current pulmonary rehabilitation 
or maintenance programmes inadvertently provides beneficial influence on the 
autonomic health in COPD patients.
 For the question regarding autonomic symptoms, it was concluded that 
patients with COPD have a high prevalence of autonomic symptoms present across 
multiple domains compared to healthy individuals. Poor mental health status 
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considerably contributed to the rates of autonomic symptoms in these patients. 
Other COPD outcomes such as disease severity, fatigue levels, anxiety and depression 
status and demographic characteristics were not associated with total autonomic 
symptoms score in COPD. For now, the possible role medication use or unreported 
disease comorbidities is clearly identified. Presently the Dutch COMPASS-31 is 
capable of providing a profile of autonomic symptoms, as its validity and reliability 
for the overall COPD population was not ascertained at this moment. 
 Lastly, non-pharmacological interventions mainly aerobic exercise training, 
and oxygen supplementation, and possibly controlled breathing techniques offer 
important non-pharmacological options, with marginal beneficial effects, on the 
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31-item Dutch composite autonomic symptoms scale (COMPASS-31)
Domein hart en bloedvaten
1.   Hebt u zich in het voorbije jaar ooit flauw, duizelig of verdwaasd gevoeld,  
of hebt u moeite gehad met nadenken, kort na het rechtop komen uit zittende  
of liggende positie? 
 o Nee (ga naar vraag 5)
 o Ja 
2.   Hoe vaak hebt u deze gewaarwordingen of klachten bij het rechtop komen? 
Markeer slechts één alternatief. 
 o Zelden 
 o Af en toe 
 o Vaak 
 o Bijna altijd  
3.  Hoe ernstig zijn deze gewaarwordingen of klachten? 
 Markeer slechts één alternatief. 
 o Mild 
 o Matig 
 o Ernstig 
4.  Deze gewaarwordingen of klachten zijn in het voorbije jaar: 
 Markeer slechts één alternatief. 
 o Veel erger geworden 
 o een beetje erger geworden 
 o ongeveer gelijk gebleven 
 o een beetje verbeterd 
 o veel verbeterd 
 o volledig verdwenen 
5.  Hebt u in het voorbije jaar ooit opgemerkt dat de kleur van uw huid veranderde?  
Werd uw huid bijvoorbeeld rood, wit of paars?
 Markeer slechts een alternatief. 
 o Nee (ga naar vraag 8)
 o Ja 
6.   Welke delen van uw lichaam worden getroffen door deze kleurveranderingen?
 Kruis ALLE passend antwoorden aub.
 o Mijn handen 
 o Mijn voeten 
7.   Deze kleurveranderingen zijn: 
 Markeer slechts één alternatief. 
 o Veel erger aan het worden 
 o een beetje erger aan het worden 
 o ongeveer hetzelfde gebleven 
 o een beetje aan het verbeteren 
 o veel aan het verbeteren 




8.  Zijn er in de voorbije 5 jaar veranderingen opgetreden in uw algemeen zweetpatroon?  
 Markeer slechts één alternatief. 
 o Ik zweet veel meer dan vroeger 
 o Ik zweet een beetje meer dan vroeger 
 o Ik zweet een beetje minder dan vroeger 
 o Ik zweet veel minder dan vroeger 
 o Ik heb geen veranderingen gemerkt 
9.  Voelen uw ogen abnormaal droog aan? 
 o Nee 
 o Ja 
10.  Voelt uw mond abnormaal droog aan?       
 o Nee 
 o Ja 
11.  Hoe evolueert de klacht waarvan u langst last had? Deze klacht is.... 
 Markeer slechts één alternatief. 
 o veel erger aan het worden 
 o een beetje erger aan het worden 
 o ongeveer hetzelfde gebleven 
 o een beetje aan het verbeteren 
 o volledig verdwenen 
Spijsvertering
12.   Hebt u in het voorbije jaar verandering gemerkt in hoe snel u zich voldaan voelt bij  
een maaltijd?
 Markeer slechts één alternatief. 
 o Ik ben nu veel sneller voldaan dan vroeger 
 o Ik ben nu sneller voldaan dan vroeger 
 o Ik heb geen verandering gemerkt 
 o Ik ben nu minder snel voldaan dan vroeger 
 o Ik ben nu veel minder snel voldaan dan vroeger 
13.  Hebt u zich in het voorbije jaar na een maaltijd overmatig vol gevoeld of aanhoudend 
vol gevoeld (opgeblazen gevoel)? 
 Aanhoudend = gedurende een groot deel van de dag of langer 
 Markeer slechts één alternatief. 
 o Nooit 
 o Soms 
 o Vaak 
14.  Hebt u in het voorbije jaar gebraakt na een maaltijd? 
 Markeer slechts één alternatief. 
 o Nooit 
 o Soms 
 o Vaak 
15.  Hebt u in het voorbije jaar buikkrampen of koliekachtige buikpijn gehad?  
 Kolieken = hevige krampachtige buikpijn 
 Markeer slechts één alternatief. 
 o Nooit




16.   Hebt u in het voorbije jaar een periode van diarree gehad? 
 Markeer slechts één alternatief. 
 o Nee (Ga naar vraag 20) 
 o Ja
17.   Hoe vaak komt dit voor? 
 Markeer slechts één alternatief. 
 o Zelden 
 o Af en toe 
 o Vaak, hoeveel keer per maand? beschrijf hieronder 
 o Voortdurend 
Hoeveel keer per maand hebt u last van diarree?
___________________________________________
 
18.  Hoe ernstig zijn deze episodes van diarree? 
 Markeer slechts één alternatief. 
 o Mild 
 o Matig 
 o Ernstig 
19.  De periodes van diarree zijn:  ( Markeer slechts één alternatief.)
 o veel erger aan het worden 
 o een beetje erger aan het worden 
 o hetzelfde gebleven 
 o een beetje aan het verbeteren 
 o veel aan het verbeteren 
 o volledig verdwenen 
20.  Hebt u in het voorbije jaar last gehad van constipatie (moeilijke stoelgang, 
opstopping)? 
 o Nee (Ga naar vraag 24 ). 
 o Ja 
21.  Hoe vaak hebt u constipatie? 
 Markeer slechts één alternatief. 
 o Zelden 
 o Af en toe 
 o Vaak 
 o Voortdurend 
Hoeveel keer per maand hebt u last van constipatie? 
___________________________________________
 
22. Hoe ernstig zijn deze periodes van constipatie? 
 Markeer slechts één alternatief. 
 o Mild 
 o Matig 
 o Ernstig 
23.  Deze constipatie is: 
 Markeer slechts één alternatief. 
 o Veel erger aan het worden 
 o een beetje erger aan het worden 
 o hetzelfde gebleven 
 o een beetje aan het verbeteren 
 o veel aan het verbeteren 




24.   Hebt u in het voorbije jaar ooit last gehad van urineverlies of bent u in het voorbije 
jaar ooit de controle over uw blaas verloren? 
 Markeer slechts één alternatief. 
 o Nooit (Ga naar vraag 27 ) 
 o Af en toe  
 o Vaak  
 o Voortdurend 
25.  Had u in het voorbije jaar ooit moeite om te kunnen plassen? * 
 Markeer slechts één alternatief. 
 o Nooit
 o Af en toe 
 o Vaak 
 o Voortdurend 
26.   Had u in het voorbije jaar ooit moeite om uw blaas volledig te ledigen?
 Markeer slechts één alternatief. 
 o Nooit 
 o Af en toe 
 o Vaak 
 o Voortdurend 
Pupilref lex
27.   Hebt u het voorbije jaar last ondervonden van uw ogen van fel licht, als u geen 
zonnebril of donkere bril droeg?
 Markeer slechts één alternatief. 
 o Nooit (Ga naar SF-36 vragenlijst)
 o Af en toe 
 o Vaak
 o Voortdurend 
28.  Hoe ernstig is deze gevoeligheid voor fel licht? 
 Markeer slechts één alternatief. 
 o Mild 
 o Matig 
 o Ernstig 
29.   Hebt u in het voorbije jaar moeite gehad om uw ogen te focussen (scherp te stellen)? * 
 Markeer slechts één alternatief. 
 o Nooit (Ga naar SF-36 vragenlijst)
 o Af en toe 
 o Vaak
 o Voortdurend 
30.   Hoe ernstig is dit probleem? 
 Markeer slechts één alternatief. 
 o Mild 
 o Matig 
 o Ernstig 
31.   Deze hinderlijkste oogklacht is: 
 Markeer slechts één alternatief. 
 o veel erger aan het worden 
 o een beetje erger aan het worden 
 o hetzelfde gebleven 
 o een beetje aan het verbeteren 





Case 1: a 72-year-old man with moderate cardiovagal dysfunction
Patient RVH (race, Caucasian; occupation, retired; height, 163cm; weight, 81 
kilograms; BMI, 30.5 kg/m2) was diagnosed with COPD in 2010. RVH was actively 
smoking for several years before stopping in 2009. At the time of recruitment into 
the autonomic function study. He had a moderate stage COPD based on the global 
obstructive lung disease (GOLD) classification system. His lung function parameters are 
as follows: forced expiratory volume in first second (FEV1), 1.49 (60% of predicted); 
forced vital capacity (FVC), 2.29 (71% of predicted); and peak expiratory flow (PEF), 
5.46 (77% of predicted). RVH walked a distance of 370 meters (62% of predicted reference) 
during the six-minute walk test (6MWT). At the time of testing, his blood pressure 
and heart rate were 149/58 mmHg and 62 bpm, respectively. RVH was participating 
in a pulmonary rehabilitation program at the time of autonomic function testing. 
RVH reported using cardiovascular (Coruno® [molsidomine], Belsar plus® 
[olmesartan- hydrochlorothiazide]), cholesterol (Zocor® [simvastatin]), diabetes and 
gastro intestinal (Pantomed®  [pantoprazole], Asaflow® [acetylsalicylic acid]) medications. 
For COPD medication, He reported using long acting muscarinic antagonists 
(Spiriva® [tiotropium]) and a combination of inhaled corticosteroids and long acting 
beta agonists (ICS/LABA) (Seretide® (fluticasone propionate/salmeterol xinafoate).
 RVH reported a poor quality of life (mainly physical component), but anxiety 
and depression scores were fairly normal. He also reported no fatigue symptoms 
(using CIS), or dyspnea on the modified medical research council dyspnea scale 
(mMRC= 1/5). 
 The results of the autonomic symptoms score, from the COMPASS-31 questionnaire, 
revealed that RVH reported problems with all domains of the Dutch COMPASS-31 
version, with the exception of urinary tract complaints. Gastro intestinal symptoms 
were more intense, suggesting both parasympathetic (constipation) and sympathetic 
(diarrhea) nervous system problems. The total autonomic symptoms score was 
33.61 (out of 100). The autonomic function parameters for RVH are presented in 
Table 1 below. Lastly, Hiscardio-vagal dysfunction (moderate) level was determined 
based on the heart rate during deep breathing and valsalva maneuver (parameters) 
values. 
 Implication for rehabilitation experts: Based on the data presented above and 
in Table 1, pulmonary rehabilitation intervention for patient RVH should be 
slightly modified to also target the cardio-vagal dysfunction. Firstly, and more 
importantly, exercise training should be emphasized  This can be in the form of a 
combined exercise training program, since low 6MWD test can be caused by low 
aerobic capacity and/or low quadriceps strength. Aerobic exercise training session 
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should last between 30-40 minutes, at a frequency of ≥3 times/week. An intensity 
of 60-70% of peak work rate (Wpeak) should be maintained. Interval training 
program is also an option for RVH because of its huge impact on mitochondrial 
function in peripheral muscles. Interval training should be performed on a  cycle 
ergometer for 3 times/week for a duration of  40 minutes using a combination of 
2-minute at high work rate (70–100% Wpeak) and 3-minute low work rate at 
(40–50% Wpeak). Secondly, there is a need to carefully inspect the medication use of 
RVH. Since RVH used number of medications that have side effects that could have 
presented as autonomic symptoms reported in COMPASS-31, especially gastro 
intestinal symptoms. Specifically, the use of Spiriva® has been known to cause 
dryness of the mouth, constipation, upset stomach and vomiting. If possible these 
medications should be replaced by other agents. Thirdly, other non-pharmacological 
options aimed at stimulating the parasympathetic nerve activity should be 
incorporated in the management of RVH. One example can be the use of controlled 
breathing exercise such as deep breathing, based on the respiratory sinus arrhythmia 
(RSA) technique.
Case 2: a 72-year-old woman with severe adrenergic dysfunction
Patient IIR (race, Caucasian; occupation, retired; height, 159 cm; weight, 66 kilo- 
grams; BMI, 26.1 kg/m2) was diagnosed with COPD since 2004. IIR has a history of 
cigarette smoking which she quitted in 1997). Her blood pressure and heart rate on 
the test day was 200/90 mmHg and 65 bpm, respectively. IIR reported occasional 
alcohol consumption at the time of study testing. IIR has a severe staged (GOLD III) 
COPD, and was only able to walk 352 meters (67% predicted) during 6MWT. Her 
pulmonary function parameters are as follows: forced expiratory volume in first 
second (FEV1), 0.50 (27% of predicted); forced vital capacity (FVC), 2.11 (93% of 
predicted); and peak expiratory flow (PEF), 2.58 (47% of predicted). During the period 
of the study testing, IIR reported using cardiovascular (Belsar plus® [olmesartan- 
hydrochlorothiazide]), anti-rhinitis (Flixonase® [fluticasone]), anti-biotics (Augmentin® 
[amoxicillin/clavulanate]); and anti-inflammatory (Medrol® [methylprednisolone]) 
medications. For COPD medications, short acting muscarinic antagonists (Atrovent® 
[ipratropium]), long acting muscarinic antagonists (Spiriva® [tiotropium]) and a 
combination of inhaled corticosteroids and long acting beta agonists (Seretide® 
[fluticasone propionate/salmeterol xinafoate]), were used by IIR. Despite participating 
in an ongoing maintenance program (longclub), IIR was highly dyspneic (mMRC= 4/5). 
For other health outcomes, IIR reported having a moderately impaired quality of life 
(physical and mental) and also a moderate fatigue, anxiety and depression levels.
 IIR reported, by means of the Dutch COMPASS-31, a very intense orthostatic 
intolerance symptoms (peak), mild secretomotor, gastro intestinal, and urinary 
and pupillomotor complaints. Her total autonomic symptoms score at the time of 
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autonomic function testing was 39.2 points. Autonomic function parameters for 
RVH are also presented in Table 1 above. The adrenergic dysfunction for IIR was 
determined using the valsalva maneuver and tilt test values. 
 Implication for rehabilitation experts: Based on the data presented for IIR, she 
will likely benefit from a patient-tailored-education-program that specifically 
targets her orthostatic intolerance. Information which explains the underlying 
mechanisms for orthostatic symptoms need to be well explained in the form of 
Table 1   Autonomic function test results for patient RVH and IIR.
Autonomic function  indices Patient RVH Patient IIR
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education. IIR needs to know that these physical symptoms are relatively harmless, 
in order to reduce Her anxiety levels. Moreover, patient education has been shown 
to promote self-management. In the same vein, advice should be given to avoid 
large meals, alcohol consumption, prolonged mental activity, prolonged sitting 
and standing. Also, some instructions to deal with acute orthostatic intolerance 
symptoms can be provided. These include rapid ingestion of water (500 ml) and 
contraction of large muscle groups (especially the calf and quadriceps through 
squatting) in order to aide venous return. IIR can also benefit from an augmentation 
of cardiac vagal tone through an exercise training program (typically at 60 – 80% 
of maximum work rate). Endurance training has been shown to have beneficial 
effects on the cardiovascular regulation by four means: (i) increasing in blood 
volume, (ii) increase in muscle tone, (iii) decrease in cardiac sympathetic activity, 
and (iv) increase in vagal activity. Endurance exercises for IIR can be in form of 
cycling, hopping, stair climbing. The work rate for IIR should be gradually 
increased from 0 minutes to 20 minutes of aerobic exercise 3 times per week. 
Another possible intervention for IIR is tilt training (repeated orthostatic stress), 
which is thought to increase vascular tone. A typical tilt training session consists 
of standing upright for 30 minutes, once or twice daily. Furthermore, IIR should 
be thought techniques that reduces stress such as deep breathing exercises and 
mindfulness training in order to increase parasympathetic activity in favor of a 
better balance in the ANS. Several medication options could be explored to address 
the severe adrenergic dysfunction. The role of medications such as fludrocortisone 
(to increase blood volume), beta blockers, alpha-adrenergic (either alone or in 
combination with  fludrocortisone), either or both of serotonin reuptake inhibitors 
and norepinephrine reuptake inhibitors (to prevent neuro-cardiogenic syncope), 
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Summary
Chronic obstructive pulmonary disease (COPD) is a chronic and slowly progressive 
lung disease which results in more and more difficulty in breathing  as a result 
of an obstruction or narrowing of the airways. Abnormal functioning of the 
autonomic nervous system (ANS) is one of the most important systemic consequences 
of COPD. The ANS controls involuntary body functions such as the excretion of 
urine and sweat, heart rate, respiration, blood pressure and digestion. In general, 
the aim of this dissertation was to further improve our understanding about ANS 
deficits in COPD, and possible non-pharmacological interventions. Although previous 
studies have unanimously reported that autonomic function deficits are present 
in COPD, the assessment techniques used in these studies appear to be inadequate. 
Similarly, a number of studies have shown that non-pharmacological interventions 
could reverse the autonomic function deficits in COPD, however the evidence to 
support these claims is scanty. Therefore, this dissertation was based upon three 
key themes; (i) describing the evidence to support the link between autonomic 
function and COPD, (ii) assessment of possible dysautonomia in COPD, and (iii) 
non-pharmacological interventions for autonomic function modulation in COPD.
The organization of the present dissertation is based on seven chapters, divided in 
three parts: 
- In Part I, an extensive overview of COPD (Chapter 1) and the ANS (Chapter 2) was 
provided. The objective of this part was to present a detailed description of all 
relevant topics regarding COPD and ANS.  A secondary objective of this part was 
to introduce the link between COPD and the ANS by means of a systematic 
review, which assessed the evidence for autonomic dysfunction (and the 
influencing factors) in COPD (Chapter 3). 
- The second objective in this dissertation, presented in Part II,  was to assess 
dysautonomia in COPD with two distinct original studies. The first study focused 
on autonomic symptoms and its possible controlling variables, whereas the 
second original study concentrated on wide-ranging autonomic function 
parameters as well as cardiovagal reactivity in a subgroup of COPD. These studies 
are respectively presented as Chapters 4 and 5.
- Part III aimed to investigate the effects of selected non-pharmacological 
interventions on the autonomic function in COPD. This part included two 
systematic reviews evaluating current evidence of the latter: (i) the effect of 
respiratory rehabilitation techniques such as noninvasive ventilation (NIV), 
oxygen therapy and controlled breathing techniques on autonomic function in 
COPD (Chapter 6), and (ii) the influence of aerobic exercise training (AET) on the 
autonomic function modulation in COPD (Chapters 7).
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Part I of this dissertation, which is partly based on the results of a systematic 
review, showed that autonomic function parameters are more impaired in COPD 
than in healthy control subjects. The parameters that were reviewed included the 
time domain heart rate variability, baroreceptor sensitivity and muscle 
sympathetic nerve activity in COPD (strong evidence). Additionally, physical 
activity level, muscle function and day-night circadian rhythm were identified as 
influencing factors for the autonomic function in COPD (strong evidence). For 
other factors such as dyspnea, body composition, respiratory rate, pulmonary 
function outcomes, age, disease severity and quality of life, there was only weak to 
no evidence. These results demonstrate that autonomic function is compromised 
in patients with COPD, especially those with low physical activity status and 
impaired muscle function. 
 Because previous studies have reported autonomic function deficits in COPD, 
Part II of this dissertation included two original studies which aimed to further 
evaluate dysautonomia in COPD. The first study, which focused on autonomic 
symptoms in COPD, revealed higher rates of autonomic symptoms  in the patient 
population compared to healthy individuals. These symptoms were reported 
across the domains of orthostatic intolerance, secretomotor, vasomotor, gastroin-
testinal, urinary and pupillomotor symptoms, possibly indicating the presence of 
underlying ANS deficits. However, further analyses in a subgroup of COPD patients 
with mild autonomic dysfunction revealed that these autonomic symptoms were 
insufficient to screen for autonomic dysfunction. Also, medication use, age and 
participation in a rehabilitation programs were found to possibly confound the 
rates of autonomic symptoms. Nevertheless, mental health status was found to 
predict total autonomic symptoms score. This finding further highlights the 
importance of the psychological aspect in COPD.
 The findings from the second study revealed that the resting autonomic 
function were only slightly reduced in a subgroup of COPD, who were recruited 
from a pulmonary rehabilitation program. From these results, two conclusions 
could be drawn: (i) the persistence of mild ANS deficits in COPD, and (ii) a possible 
amelioration of autonomic dysfunction among COPD patients in pulmonary 
rehabilitation. Furthermore, the adrenergic and cardio-vagal autonomic function 
tests showed similar results for both the COPD population and heathy controls, 
thereby indicating that none of these tests may have additional advantages 
compared to the resting autonomic function tests. 
 To appraise evidence in support of non-pharmacological aspects to autonomic 
function modulation in COPD, two separate systematic reviews were conducted. 
The first systematic review indicated that a moderate to strong level of evidence 
supports the effect of oxygen supplementation and slow breathing techniques in 
increasing baroreceptor sensitivity. These results demonstrate that these 
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techniques could serve as potential treatment options or adjuncts in COPD 
rehabilitation. The second systematic review revealed that a high level of evidence 
supports the role of aerobic exercise training programs in enhancing time-domain 
HRV analyses and heart rate recovery (HRR) parameters in COPD. However, most of 
these results are based on a low number of randomized control trials. In addition, 
there was only a limited number of studies reporting on autonomic function 
parameters (resting heart rate variability and baroreceptor sensitivity) were. 
Hence, future assessment studies are necessary.
 Due to the large number of available parameters for the assessment of 
autonomic function, future studies should focus on reporting homogenous 
subgroups of COPD that have not been included in the existing literature. Also, 
future interventional studies with both sufficient power and high quality designs 
are needed to reveal the effect of other non-pharmacological approaches on 
autonomic dysfunction in COPD. It would be interesting to see the effect of 
interventions like inspiratory muscle training, partitioning exercises, physical 
activity participation and strength training. 
 To conclude, the research in this dissertation has provided evidence to show 
that several ANS parameters are impaired in COPD. Autonomic symptoms are 
also present across several domains (body systems) in COPD. Medication use and 
other patient characteristics such as age muscle function and physical activity 
levels largely influenced autonomic function in these patients. Last but not least, 
non-pharmacological interventions such as aerobic exercise training and oxygen 
therapy have demonstrated a capability to enhance the autonomic function indices 
in COPD.  
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Nederlandse samenvatting
Chronisch obstructieve longlijden (Engels afkorting, COPD) is een chronisch en 
langzaam progressieve longaandoening die net zoals astma, ontstaat ten gevolge 
van een obstructie of vernauwing van de luchtwegen. Hierdoor wordt het ademen 
steeds moeilijker. COPD heeft verschillende systemische consequenties. Het 
autonome zenuwstelsel (AZS) is het systeem dat onze onvrijwillige lichaamsfunc-
ties controleert zoals het afscheiden van urine en zweet, de hartslag, de 
ademhaling, de bloeddruk en de spijsvertering. Het algemene doel van deze thesis 
is het verder uitdiepen van de kennis omtrent het functioneren van het AZS bij 
patiënten met COPD. Vroegere studies hebben reeds uitgebreid gerapporteerd dat 
de autonome functie bij deze patiënten een dysbalans vertoond tot effectief faalt 
in COPD, maar het bepalen en karakteriseren van de defecten is nooit uitgebreid 
gebeurd. Bovendien is het interessant om na te gaan in welke mate niet-farmacol-
ogische interventies het autonome functie falen in COPD kan verhelpen. Dit doc-
toraatsproefschrift is gebaseerd op drie belangrijke thema’s;  (i) autonoom functie 
falen in COPD aan de hand van een systematisch literatuuronderzoek en het 
bevragen van specifieke autonome klachten in deze populatie; (ii) onderzoek naar 
dysautonomie in een zeer specifieke subgroep van patiënten met COPD, en (iii) ni-
et-farmacologische interventies voor autonome functies in COPD aan de hand van 
een systematisch literatuuronderzoek.
De inhoud van deze thesis bestaat uit zeven hoofdstukken verdeeld over drie delen: 
- In Deel I van dit werk, wordt een uitgebreid overzicht van COPD (Hoofdstuk 1) 
en het AZS (Hoofdstuk 2) gegeven. Het doel van dit deel is om in detail alle 
relevante informatie over deze onderwerpen te beschrijven alsook om de 
evidentie te onderzoeken over het voorkomen van autonome dysbalans/
dysfunctie (en zijn beïnvloedende factoren) in COPD (Hoofdstuk 3). 
- Het tweede doel van deze thesis, dat wordt voorgesteld in Deel II,  onderzoekt 
dysautonomie in COPD. Dit heeft geleid tot twee originele studies.  De eerste 
studie behandelt autonome symptomen in COPD en welke factoren hier een 
belangrijke correlatie mee vertonen, terwijl de tweede studie een rapport omvat 
over  de autonome functie in rust en in stress (cardiovasculaire reactiviteit) in 
een subgroep van COPD. Beide studies worden voorgesteld in Hoofdstuk 4 en 5, 
respectievelijk.
- Deel III heeft tot doel om het effect van geselecteerde niet-farmacologische 
interventies na te gaan op de autonome functies in COPD. Dit deel omvat twee 
systematische reviews die de huidige evidentie evalueren binnen studies die; (i) 
het effect van respiratoire revalidatietechnieken zoals niet-invasieve ventilatie 
(NIV), zuurstoftherapie en gecontroleerde ademhalingstechnieken onderzoeken 
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op de autonome functies in COPD (Hoofdstuk 6), en (ii) de invloed van een aerobe 
training (Engelse afkorting AET) op de autonome functie modulatie in COPD 
(Hoofdstuk 7).
Deel I dat gedeeltelijk op de resultaten van een systematische review is gebaseerd, 
toont aan de autonome functie aangetast is bij patiënten met COPD wanneer ze 
worden vergeleken met gezonde individuen. Deze onderzochte parameters 
omvatten de time domain heart rate variability (HRV), baroreceptor sensitiviteit (BRS) 
en de musculaire sympathetische zenuwactiviteit (Engelse afkorting MSNA) in 
COPD (bescheiden evidentie). Fysieke activiteit, spierfunctie en dag-nacht circadische 
ritmes werden geïdentificeerd als beïnvloedende factoren voor de autonome 
functie in COPD (bescheiden evidentie). Voor andere factoren zoals ademnood, 
 lichaamssamenstelling, longfunctie, leeftijd, ziektestatus en levenskwaliteit, 
was de evidentie niet bestaande, gelimiteerd of conflicterend. 
 Omdat de aantasting van de autonome functie reeds beschreven is in de vorige 
studies, bevat Deel II van deze verhandeling twee originele studies die een verdere 
evaluatie omvatten  van dysautonomie in COPD. De eerste studie, die als doel had 
om autonome symptomen in COPD in kaart te brengen resulteerde in de bevinding 
dat, vergeleken met gezonde individuen, de COPD patiënten een hoger aantal 
autonome symptomen vertoonden, met name orthostatische intolerantie, secreto - 
motor, vasomotor, gastro-intestinale, urinaire en pupillomotor symptomen. 
Deze resultaten tonen aan dat COPD patiënten symptomen vertonen die indicatief 
zijn voor het onderliggende AZS falen. Deze autonome symptomen correleerden 
ook met de gezondheidstoestand, waarbij vooral de mentale toestand een goede 
voorspeller bleek te zijn van deze symptomen. Dit doet vermoeden dat psychosociale 
interventies mee moeten genomen worden in de behandeling van dysautonomie 
in COPD. 
 De bevindingen van de tweede studie toonden aan dat de rust-autonome 
functie verminderd was in een COPD cohort die een longrevalidatieprogramma 
doorliepen. Dit resultaat is misschien indicatief voor een persistent AZS falen in 
COPD. De cardio-vagale autonome reactiviteitstesten gaven geen bijkomende 
informatie, benevens de resultaten van de Tilt-test. Dit kan een indicatie zijn van 
vroege signalen van een mogelijke orthostatische hypotensie en posturele 
tachycardie syndroom (POTS).  
 In deel III werd ingegaan op mogelijke niet-farmacologische interventies om 
autonoom falen te verbeteren. Een systematische review gaf een gematigd en sterk 
niveau van evidentie aan voor een verhoogde baroreflex sensitiviteit (BRS) als gevolg 
van zuurstofsupplementatie respectievelijk specifieke ademhalingstechnieken. 
Deze resultaten demonstreren dat deze technieken potentie bevatten als 
behandeling tijdens COPD revalidatie. Een laatste systematische review toonde 
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een hoge mate van evidentie voor een verhoogde time-domain HRV analyse en 
een hartslag herstel als gevolg van een aerobe trainingsinterventie in COPD. 
Echter, de meeste van deze resultaten waren gebaseerd op lage aantallen RCTs, met 
een gelimiteerd aantal gerapporteerde autonome functieparameters waardoor 
verder studies noodzakelijk blijven.
 Door het grote aantal mogelijke parameters bij het onderzoek naar autonome 
functies zullen toekomstige studies zich moeten toespitsen op het rapporteren 
van homogene subgroepen bij COPD patiënten die niet zijn opgenomen in de 
bestaande literatuur. Bovendien, zouden toekomstige interventies de effecten van 
niet-farmacologische technieken op de autonome functies in COPD moeten onder- 
zoeken. Hierbij is aandacht voor inspiratoire spierkrachttraining en algemene 
krachttraining noodzakelijk.
 Tot besluit, deze thesis geeft een bewijs voor de aanwezigheid van ANS falen 
in COPD. Dit autonome functie falen kon gecorreleerd worden aan het fysieke 
 activiteitsniveau en met spierfuncties van de patiënten. Zoals verwacht, autonome 
symptomen zijn wijdverbreid in deze patiënten, en vooral bij deze met een lage 
mentale gezondheid. Tenslotte, niet-farmacologische interventies zoals aerobe 
training en zuurstoftherapie zorgen voor een potentiële mogelijkheid om AZS 
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